NIH | National Cancer Institute | NCI Wiki  

As of

NCI has published 664 Standard CDEs. These were created through a process of review and harmonization by the NCI content owners.These are recommended for use when developing new case report forms or studies.

To search for content, use the web browsers "Find" feature.

Click CDE ID link to visit the entry's NCI CDE Browser page.
Listed in by primary topic.

 

Primary TopicCDE Public IdCRF Question TextData ElementDefinitionValid Values (hover to see Value Meaning)
Access2003586v6RouteAccess Route of Administration Text CodeA text code or name to represent an access route for the administration of agents or substances.Transmucosal | Intraventricular | Intravesical | Urethral | Intrauterine | Oral and IV | Otic | ENDOTR | Interstl | Unknown | ID | IV | IVI | CIV | IA | SC | IT | IP | IH | IHI | PO | RT | PR | Transdermal | Sublingual | IM | NASAL | SWSP | SWSW | TOP | NG | Inhalatn | G Tube | Oph Each | Oph Left | Oph Rt | INTUM | Vaginal
Address2341940v1Derived Address Street/Thoroughfare Line1 TextDerived Address Street/Thoroughfare Line 1 TextA component of an address that specifies a location by formatted concatenation of street/thoroughfare address components as described by a derivation rule. 
Address2341946v1Derived Address Street/Thoroughfare Supplemental TextDerived Address Street/Thoroughfare Supplemental TextA component of an address that specifies a location by formatted concatenation of supplemental address components as described by a derivation rule. 
Address2405440v1Address RegionAddress Region IdentifierA component of an address that specifies a location by identification of a specified district, territory, or extended spatial location. 
Address2405442v1Address County/Parish Subdivision NameAddress County/Parish Sub Division NameA component of an address that specifies a location by identification of a sub-part of a governmental administrative subdivision. 
Address2179603v2StateAddress State/Province NameA component of an address that specifies a location by identification of a principal administrative unit of a country.US Minor Outlying Islands | Utah | Virginia | Veracruz-Llave | Virgin Islands of the US | Vermont | Washington | Wisconsin | West Virginia | Wyoming | Yukon Territory | Yucatan | Zacatecas | Mexico | Texas | Kentucky | Louisiana | Massachusetts | Manitoba | Maryland | Maine | Marshall Islands | Michigan | Michoacan de Ocampo | Minnesota | Missouri | Morelos | Northern Mariana Islands | Mississippi | Montana | Nayarit | New Brunswick | North Carolina | North Dakota | Nebraska | Newfoundland | New Hampshire | New Jersey | Nuevo Leon | New Mexico | Nova Scotia | Northwest Territories | Nunavut | Nevada | New York | Oaxaca | Kansas | Ohio | Oklahoma | Ontario | Oregon | Pennsylvania | Prince Edward Island | Quebec | Puerto Rico | Puebla | Palau | Queretaro de Arteaga | Quintana Roo | Rhode Island | South Carolina | South Dakota | Sinaloa | Saskatchewan | San Luis Potosi | Sonora | Tabasco | Tamaulipas | Tlaxcala | Tennessee | Alberta | Aguascalientes | American Samoa | British Columbia | Baja California | Baja California Sur | Campeche | Chihuahua | Chiapas | Colorado | Coahuila de Zaragoza | Colima | District of Columbia | Distrito Federal | Durango | Florida | Micronesia | Georgia | Guerrero | Guanajuato | Guam | Hildalgo | Hawaii | Iowa | Idaho | Illinois | Indiana | Jalisco | Alabama | Alaska | Arizona | Arkansas | California | Connecticut | Delaware | Delaware | Connecticut | California | Arkansas | Arizona | Alaska | Alabama | Aguascalientes | Baja California | Baja California Sur | Campeche | Chiapas | Chihuahua | Coahuila de Zaragoza | Colima | Distrito Federal | Durango | Guanajuato | Guerrero | Hidalgo | Jalisco | Michoacan de Ocampo | Morelos | Nayarit | Nuevo Leon | Oaxaca | Puebla | Queretaro de Arteaga | Quintana Roo | San Luis Potosi | Sinaloa | Sonora | Tabasco | Tamaulipas | Tlaxcala | US Minor Outlying Islands | Veracruz-Llave | Zacatecas
Address2179606v2ZIP CodeAddress Postal Code IdentifierThe string of characters used to identify the five-digit Zone Improvement Plan (ZIP) code and the four-digit extension code (if available) that represents the geographic segment that is a subunit of the ZIPcode, assigned by the U.S. Postal Service to a geographic location to facilitate mail delivery; or the postal zone specific to the country, other than the U.S., where the mail is delivered. 
Address2405166v1Address Dependent Street/Thoroughfare NameAddress Dependent Street/Thoroughfare NameA component of an address that specifies a location by identification of a related road or public highway. 
Address2179601v1CityAddress City NameA component of an address that specifies a location by identification of a city, town, or village. 
Address2341883v1Address Street/Thoroughfare NameAddress Street/Thoroughfare NameA component of an address that specifies a location by identification of a related road or public highway. 
Address2405150v1Address Floor/PremisesAddress Floor/Premises Text IdentifierA component of an address that specifies a location by identification of the story or level of a building. 
Address2341893v1Address Street Pre DirectionalAddress Street Pre Directional TypeA component of an address that specifies a location by identification of directional text occurring before the street/thoroughfare name.N | E | S | W
Address2341930v1Address Department/Division Name TextAddress Department/Division Name TextA component of an address that specifies a location by identification of a specialized division of a large organization. 
Address2341863v1Address/Street NumberAddress Street/Thoroughfare NumberA component of an address that specifies a location by identification of an assigned numeral or string of numerals on a street/thoroughfare. 
Address2405444v1Address Double Dependent LocalityAddress Double Dependent Locality NameA component of address that specifies a locality or minor thoroughfare the address for which must be specified in relationship to a more major one. 
Address2405174v1Address Street/Thoroughfare NameAddress Street/Thoroughfare Section NameA component of an address that specifies a location by identification of a distinct area of road or public highway. 
Address2179604v1CountryAddress Country NameA component of an address that specifies a location by identification of a country.Canada | Mexico | United States of America
Address2405161v1Address DoorAddress Door Text IdentifierA component of an address that specifies a location by identification of an entrance way into a building. 
Address2405187v1Address TowerAddress Tower Text IdentifierA component of an address that specifies a location by identification of a vertical building, often in a complex of buildings. 
Address2341957v1Indicator/Designator NumberAddress Secondary Unit Indicator/Designator NumberA component of an address that specifies a location by identification of an additional subdivision of the primary address by number. 
Address2341900v1Address Street Post DirectionalAddress Street Post Directional TypeA component of an address that specifies a location by identification of directional text occurring after the street/thoroughfare name.NE | SE | NW | SW
Address2405434v1Address VillageAddress Village IdentifierA component of an address that specifies a location by identification of a small group of dwellings in a rural area. 
Address2405430v1Address SectorAddress Industrial Zone IdentifierA component of an address that specifies a location by identification of an area where products are manufactured. 
Address2405421v1Address BlocksAddress Blocks Text IdentifierA component of an address that specifies a location by identification of a city area that is commonly rectangular and surrounded by streets. 
Address2405182v1Additional Geographic Place, Name, ServiceAddress Additional Identifier TextA component of address where additional attributes of an address are represented through the use of text. The additional attributes may include name, service, or geographical place. 
Address2345409v1Address County/Parish NameAddress County/Parish NameA component of an address that specifies a location by identification of a governmental administrative subdivision. 
Address2341934v1Address Post Office Box NumberAddress Post Office Box NumberA component of an address that specifies a location by identification of a delivery box at a postal facility. 
Address2341932v1Address Mail Stop CodeAddress Mail Stop CodeA component of an address that specifies a location by identification of an internal delivery code assigned by the addressee. 
Address2405176v1Address Street/Thoroughfare Extension NameAddress Street/Thoroughfare Extension NameA component of an address that specifies a location by identification of an expanded part of road or public highway. 
Address2341926v1Address Entity NameAddress Entity Name TextA component of an address that specifies a location by identification of a specific person, corporation, organization, building or similar unit. 
Address2341948v1Street TypeAddress Street/Thoroughfare TypeA component of an address that specifies a location by identification of a street/thoroughfare by type. 
Address2405436v1Address PrefectureAddress Prefecture IdentifierA component of an address that specifies a location by identification of a district administered or governed by a prefect. 
Address2341954v1Secondary Unit Indicator/DesignatorAddress Secondary Unit Indicator/Designator TypeA component of an address that specifies a location by identification of an additional subdivision of the primary address by type.BLDG | FL | STE | RM | DEPT | APT
Address2345411v1Address Locality NameAddress Locality NameA component of an address that specifies a location by identification of a local name for a particular neighborhood, place, or district. 
Address2405446v1Address Island NameAddress Island NameA component of an address that specifies a location by identification of an land mass surrounded by water. 
Address2405428v1Address SectorAddress Sector Text IdentifierA component of an address that specifies a location by identification of a part or division. 
Address2345415v1Address Quarter NameAddress Quarter NameA component of an address that specifies a location by identification of a place of residence, especially the buildings or barracks. 
Address2405432v1Address FarmAddress Farm IdentifierA component of an address that specifies a location by identification of a area of agricultural activities. 
Address2345413v1Address District NameAddress District NameA component of an address that specifies a location by identification of an administrative division and/or a locality marked off by a distinguishing feature. 
Address2341928v1Address Entity NumberAddress Entity NumberA component of an address that specifies a location by identification of a specific person, corporation, organization, building or similar unit. 
Address2405438v1Address CantonAddress Canton IdentifierA component of an address that specifies a location by identification of a small territorial division of a country. 
Address2405159v1Address StaircaseAddress Staircase Entity Text IdentifierA component of address that specifies a location by identification of a flight or series of flights of steps. 
Adenosarcoma3447306v1Clinical N StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the uterine adenosarcoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Adenosarcoma3447309v1Pathologic M StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the uterine adenosarcoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Adenosarcoma3447307v1Pathologic N StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the uterine adenosarcoma based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Adenosarcoma3447305v1Pathologic T StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary uterine adenosarcoma based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T1a | T1b | T1c | T2 | T2a | T2b | T3 | T3a | T3b | T4 | TX
Adenosarcoma3447304v1Clinical T StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary uterine adenosarcoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T1a | T1b | T1c | T2 | T2a | T2b | T3 | T3a | T3b | T4 | TX
Adenosarcoma3447310v1Disease StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for uterine adenosarcoma.Stage unknown | I | IA | IB | IC | II | IIIA | IIIB | IIIC | IVA | IVB
Adenosarcoma3447308v1Clinical M StageUterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the uterine adenosarcoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Administration2003322v4FrequencyAdministration Schedule Term NameThe frequency schedule used for administration of agents.3 times/week | bid | Biw | q3h | q4h | q6h | q8h | qam | qd | qhs | qid | qod | qwk | tid | Tiw | q3wk | q1h | q12h | q2d | q2h | q2wk | ac | pc | q3d | 2 times/week | qd x3 | qd x4 | x4 | x3 | x2 | x1 | qmonth | qd x5 | PRN
Administration2004139v3Stop TimeStop TimeThe stop time for the administration of an intervention. 
Adrenal Cortex Carcinoma4983472v1Clinical N StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the adrenal cortical cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Adrenal Cortex Carcinoma4983476v1Pathologic M StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the adrenal cortical cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Adrenal Cortex Carcinoma4983477v1Disease StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for adrenal cortical cancer.I | II | III | IV | Stage unknown
Adrenal Cortex Carcinoma4983474v1Pathologic T StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary adrenal cortical cancer based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | TX
Adrenal Cortex Carcinoma4983475v1Pathologic N StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the adrenal cortical cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Adrenal Cortex Carcinoma4983473v1Clinical M StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the adrenal cortical cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Adrenal Cortex Carcinoma4983471v1Clinical T StageAdrenal Cortical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary adrenal cortical cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | TX
Adverse Event2201348v1Other Attribution, SpecifyAdverse Event Suspected Other Attribution Text NameText to describe suspected "Other" attribution of an adverse event. 
Adverse Event2746280v1Pre-existing AE?Adverse Event Pre-Existing IndicatorThe question that asks whether the Adverse Event existed prior to the reporting period.Yes | No
Adverse Event2746301v1AE Resolved TimeAdverse Event Resolution TimeThe time of day when the adverse event was resolved. 
Adverse Event2183619v1Expected? (Yes/No)Adverse Event Expected IndicatorText indicator to represent anticipation that an unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure may occur.Yes | No
Adverse Event2744993v1AE Start DateAdverse Event Onset DateThe date on which the adverse event was first evident.Unknown
Adverse Event2008418v1Adverse Event Condition PatternAdverse Event Condition PatternTime pattern by which Adverse Event occurs1 | 2 | 3
Adverse Event2746517v1Participant Status/OutcomeAdverse Event Outcome TypeThe final status of the participant related to the adverse event.Fatal | Not Recovered/Not Resolved | Recovered/Resolved | Unknown | Recovering/Resolving | Recovered/Resolved with Sequelae
Adverse Event2006851v4Reporting Period End DateAdverse Event Final Assessment Datethe last date on which a clinical examination is conducted to identify unfavorable or unintended signs, symptoms or diseases associated with use of a medical product or procedure. 
Adverse Event2179892v2To what is the AE attributed?Adverse Event Cancer Treatment Related Typethe description a of a treatment modality or patient disease to which a reported adverse event may be related.Device | Concomitant medication | Combined modality | Endocrine Therapy | Chemotherapy | Immunotherapy | Radiation therapy | Surgery | Investigational agent | Biological Therapy | Other | Disease
Adverse Event2944515v1Adverse Event GradeAdverse Event Severity GradeNumeric representation of the intensity/severity of an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite).0 | 1 | 2 | 3 | 5 | 4
Adverse Event2744943v1AE Evaluation Period Start DateAdverse Event Begin Assessment DateThe start date of the assessment period. 
Adverse Event3133353v1MedDRA AE Code (CTCAE v4.0)Common Terminology Criteria for Adverse Events Version 4.0 Mapped Low Level Term MedDRA CodeA MedDRA code number mapped to a CTCAE v4.0 low level system organ class - other, specify term.10056519 | 10065775 | 10053662 | 10060929 | 10000521 | 10051592 | 10069339 | 10001598 | 10001675 | 10001723 | 10055226 | 10065721 | 10065722 | 10002167 | 10002176 | 10002180 | 10002218 | 10002544 | 10061640 | 10002899 | 10061589 | 10003012 | 10003011 | 10003162 | 10065744 | 10003586 | 10003658 | 10003673 | 10003674 | 10061664 | 10066480 | 10003988 | 10051341 | 10050458 | 10004665 | 10061695 | 10065802 | 10005047 | 10063575 | 10048994 | 10005332 | 10005452 | 10005561 | 10005778 | 10005901 | 10061017 | 10048580 | 10006179 | 10006259 | 10006298 | 10006437 | 10055078 | 10006440 | 10063524 | 10065746 | 10006504 | 10006556 | 10048677 | 10065906 | 10007515 | 10007810 | 10065747 | 10065761 | 10065784 | 10008164 | 10008330 | 10008481 | 10008496 | 10008661 | 10064848 | 10009845 | 10009995 | 10009998 | 10010000 | 10010001 | 10010004 | 10010006 | 10010250 | 10010276 | 10010742 | 10010783 | 10061788 | 10048492 | 10011268 | 10065765 | 10011368 | 10063057 | 10052015 | 10011912 | 10011914 | 10057066 | 10012205 | 10012260 | 10012318 | 10061103 | 10064687 | 10013774 | 10013828 | 10055242 | 10065752 | 10013830 | 10013832 | 10050094 | 10014020 | 10014217 | 10014222 | 10050068 | 10058720 | 10014326 | 10050528 | 10014383 | 10014594 | 10014621 | 10014678 | 10058838 | 10062570 | 10061461 | 10065961 | 10065851 | 10015384 | 10058804 | 10065727 | 10015387 | 10015388 | 10055472 | 10015448 | 10015451 | 10015453 | 10065837 | 10065785 | 10015829 | 10015832 | 10015929 | 10015958 | 10061145 | 10051272 | 10061457 | 10016059 | 10065788 | 10065789 | 10065790 | 10065791 | 10016241 | 10016288 | 10016296 | 10061149 | 10054382 | 10016479 | 10054746 | 10016596 | 10065799 | 10016750 | 10016757 | 10016791 | 10017577 | 10017631 | 10062632 | 10059446 | 10017636 | 10017638 | 10017639 | 10065893 | 10065713 | 10017789 | 10051886 | 10017815 | 10061970 | 10066874 | 10065879 | 10017877 | 10017999 | 10065712 | 10062572 | 10018146 | 10056910 | 10018286 | 10061185 | 10052426 | 10018746 | 10018748 | 10018761 | 10018784 | 10019077 | 10065779 | 10019279 | 10055599 | 10019515 | 10060640 | 10019678 | 10056522 | 10019692 | 10019799 | 10020100 | 10020407 | 10061212 | 10065728 | 10055287 | 10065730 | 10021305 | 10021307 | 10021309 | 10021918 | 10051792 | 10064774 | 10022095 | 10022161 | 10022213 | 10065849 | 10022356 | 10022402 | 10059095 | 10059094 | 10049468 | 10055291 | 10022763 | 10065826 | 10065831 | 10065843 | 10065844 | 10065834 | 10065825 | 10065842 | 10055298 | 10065827 | 10065829 | 10065830 | 10065841 | 10065845 | 10065840 | 10065832 | 10065846 | 10065847 | 10065828 | 10065848 | 10022992 | 10023030 | 10065836 | 10065719 | 10055300 | 10065732 | 10023174 | 10023176 | 10023177 | 10023215 | 10023216 | 10065796 | 10065800 | 10048706 | 10065803 | 10023424 | 10061261 | 10065891 | 10023838 | 10065786 | 10065759 | 10065735 | 10065880 | 10059639 | 10023862 | 10062667 | 10048293 | 10024421 | 10065755 | 10024561 | 10062466 | 10051746 | 10061229 | 10050823 | 10065773 | 10025182 | 10025256 | 10025258 | 10056356 | 10057483 | 10027175 | 10065838 | 10061532 | 10027786 | 10027787 | 10028041 | 10065764 | 10028130 | 10028154 | 10065780 | 10065776 | 10065794 | 10065795 | 10065895 | 10065783 | 10028533 | 10028691 | 10061304 | 10049281 | 10062283 | 10028735 | 10054482 | 10028836 | 10065781 | 10029366 | 10029404 | 10065823 | 10062501 | 10029957 | 10053661 | 10056388 | 10061322 | 10065720 | 10054520 | 10030980 | 10031009 | 10064658 | 10033072 | 10033078 | 10065763 | 10055005 | 10033279 | 10033314 | 10033425 | 10033474 | 10054524 | 10051741 | 10050457 | 10065703 | 10062646 | 10049192 | 10033626 | 10058096 | 10069138 | 10034040 | 10064026 | 10058674 | 10034263 | 10065793 | 10061912 | 10034310 | 10034405 | 10053565 | 10061339 | 10034536 | 10054541 | 10051472 | 10034578 | 10065766 | 10057262 | 10065704 | 10056238 | 10065705 | 10034825 | 10055315 | 10065881 | 10065706 | 10050028 | 10034844 | 10056627 | 10055319 | 10061351 | 10036206 | 10036402 | 10055322 | 10056745 | 10058084 | 10036595 | 10036601 | 10036790 | 10065745 | 10065822 | 10050662 | 10055325 | 10055026 | 10036968 | 10037375 | 10065873 | 10061541 | 10063636 | 10037767 | 10037847 | 10037868 | 10037888 | 10065894 | 10038062 | 10038064 | 10063190 | 10065709 | 10065707 | 10038072 | 10038073 | 10038079 | 10038080 | 10038130 | 10038385 | 10038419 | 10038463 | 10038695 | 10038897 | 10038901 | 10038981 | 10063761 | 10059827 | 10058597 | 10056681 | 10039411 | 10039413 | 10049120 | 10061510 | 10062156 | 10039757 | 10040139 | 10040639 | 10062244 | 10040747 | 10040799 | 10040865 | 10040868 | 10051837 | 10040872 | 10040947 | 10040975 | 10065892 | 10065710 | 10041101 | 10041103 | 10062263 | 10065771 | 10041133 | 10062255 | 10065777 | 10065778 | 10041367 | 10065897 | 10065762 | 10065805 | 10041569 | 10041633 | 10062112 | 10065898 | 10042033 | 10064505 | 10042112 | 10042127 | 10042435 | 10042458 | 10042464 | 10065798 | 10042554 | 10042604 | 10043306 | 10055347 | 10043345 | 10043648 | 10044030 | 10044031 | 10048762 | 10044223 | 10065787 | 10062548 | 10065900 | 10044291 | 10050816 | 10065749 | 10044391 | 10049737 | 10061389 | 10060890 | 10045152 | 10045158 | 10065738 | 10045542 | 10055356 | 10046300 | 10065814 | 10065815 | 10052298 | 10065368 | 10046571 | 10061574 | 10062225 | 10046628 | 10059895 | 10065882 | 10065883 | 10065748 | 10065885 | 10065886 | 10065811 | 10046789 | 10062233 | 10065928 | 10046809 | 10046810 | 10065887 | 10046901 | 10046904 | 10065813 | 10046912 | 10046914 | 10046916 | 10065817 | 10046937 | 10065818 | 10053496 | 10061403 | 10065888 | 10062169 | 10047166 | 10047228 | 10047290 | 10047302 | 10047386 | 10054692 | 10047580 | 10047681 | 10065772 | 10047848 | 10047896 | 10049182 | 10048015 | 10053692 | 10048031 | 10048049 | 10036774 | 10000081 | 10038748 | 10021041 | 10028606 | 10034835 | 10002272 | 10044565 | 10042772 | 10042244 | 10041416 | 10041349 | 10039906 | 10061928 | 10036653 | 10029864 | 10027198 | 10020765 | 10013911 | 10044684 | 10039722 | 10021038 | 10020680 | 10020670 | 10001680 | 10000486 | 10047900 | 10040102 | 10048038 | 10044302 | 10040753 | 10040047 | 10040400 | 10038743 | 10037234 | 10046543 | 10046539 | 10037032 | 10046593 | 10046555 | 10038921 | 10037400 | 10037383 | 10035759 | 10002972 | 10003883 | 10037549 | 10034966 | 10021013 | 10020864 | 10020642 | 10020112 | 10047924 | 10042241 | 10041232 | 10034879 | 10035623 | 10000060 | 10000636 | 10001367 | 10001409 | 10001497 | 10001540 | 10001551 | 10001718 | 10001760 | 10001949 | 10002156 | 10002646 | 10002652 | 10002855 | 10002953 | 10003074 | 10003239 | 10003246 | 10003445 | 10003481 | 10003504 | 10003591 | 10003598 | 10003662 | 10005265 | 10005364 | 10005886 | 10006002 | 10006482 | 10006634 | 10007196 | 10007612 | 10007613 | 10007739 | 10007839 | 10008417 | 10008531 | 10008612 | 10009887 | 10010300 | 10010741 | 10010774 | 10011224 | 10011655 | 10012174 | 10012218 | 10012373 | 10012378 | 10012727 | 10013442 | 10013573 | 10013781 | 10013786 | 10013836 | 10013887 | 10013934 | 10013941 | 10013946 | 10013950 | 10013951 | 10013963 | 10014625 | 10014801 | 10014893 | 10015090 | 10015218 | 10015277 | 10015461 | 10015533 | 10015688 | 10016173 | 10016256 | 10016558 | 10016766 | 10016778 | 10016825 | 10016987 | 10017076 | 10017822 | 10017853 | 10018043 | 10018304 | 10018801 | 10019150 | 10019211 | 10019245 | 10019428 | 10019450 | 10019489 | 10019491 | 10019611 | 10019663 | 10019705 | 10020039 | 10020201 | 10020508 | 10020587 | 10020639 | 10020647 | 10020705 | 10020772 | 10020850 | 10020870 | 10020907 | 10020943 | 10020949 | 10021005 | 10021018 | 10021028 | 10021059 | 10021097 | 10021113 | 10021114 | 10021143 | 10021328 | 10022437 | 10022998 | 10023332 | 10023509 | 10023874 | 10023891 | 10024264 | 10024378 | 10024382 | 10024419 | 10024574 | 10024842 | 10025233 | 10025476 | 10025482 | 10026749 | 10027199 | 10027308 | 10027313 | 10028411 | 10028524 | 10028596 | 10028653 | 10028813 | 10029223 | 10029883 | 10030300 | 10031282 | 10033371 | 10033557 | 10033645 | 10033703 | 10033987 | 10034016 | 10034474 | 10034484 | 10034580 | 10034620 | 10034719 | 10034960 | 10035528 | 10035598 | 10035742 | 10036200 | 10037087 | 10038848 | 10038923 | 10040741 | 10040752 | 10043189 | 10043565 | 10043882 | 10044055 | 10045271 | 10046735 | 10046851 | 10046947 | 10047115 | 10047281 | 10047340 | 10047488 | 10047656 | 10047700 | 10048642 | 10051228 | 10053481 | 10060602 | 10062315 | 10062872 | 10065417 | 10065973 | 10069501 | 10042569 | 10010331 | 10007541 | 10005329 | 10013993 | 10014698 | 10015919 | 10017947 | 10018065 | 10019805 | 10021428 | 10021881 | 10022117 | 10022891 | 10027433 | 10028395 | 10029104 | 10029205 | 10036585 | 10037175 | 10038359 | 10038604 | 10038738 | 10040785 | 10041244 | 10042613 | 10047065
Adverse Event3125302v1.1Adverse Event Term (v4.0)Common Terminology Criteria for Adverse Events Version 4.0 Low Level Term NameText that represents the Common Terminology Criteria for Adverse Events low level term name for an adverse event.Vasculitis | Vascular disorders - Other, Specify | Surgical and medical procedures - Other, Specify | Social circumstances - Other, Specify | Skin and subcutaneous tissue disorders - Other, Specify | Respiratory, thoracic and mediastinal disorders - Other, Specify | Reproductive system and breast disorders - Other, Specify | Renal and urinary disorders - Other, Specify | Psychiatric disorders - Other, Specify | Pregnancy, puerperium and perinatal conditions - Other, Specify | Nervous system disorders - Other, Specify | Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, Specify | Musculoskeletal and connective tissue disorders - Other, Specify | Metabolism and nutrition disorders - Other, Specify | Investigations - Other, Specify | Injury, poisoning and procedural complications - Other, Specify | Infections and infestations - Other, Specify | Immune system disorders - Other, Specify | Hepatobiliary disorders - Other, Specify | General disorders and administration site conditions - Other, Specify | Gastrointestinal disorders - Other, Specify | Eye disorders - Other, Specify | Endocrine disorders - Other, Specify | Ear and labyrinth disorders - Other, Specify | Congenital, familial and genetic disorders - Other, Specify | Cardiac disorders - Other, Specify | Blood and lymphatic system disorders - Other, Specify | Bone marrow hypocellular | Febrile neutropenia | Hemolytic uremic syndrome | Lymph node pain | Spleen disorder | Thrombotic thrombocytopenic purpura | Acute coronary syndrome | Aortic valve disease | Asystole | Atrial fibrillation | Atrioventricular block complete | Atrioventricular block first degree | Cardiac arrest | Chest pain - cardiac | Conduction disorder | Constrictive pericarditis | Heart failure | Left ventricular systolic dysfunction | Mitral valve disease | Mobitz (type) II atrioventricular block | Mobitz type I | Paroxysmal atrial tachycardia | Pericardial tamponade | Pulmonary valve disease | Right ventricular dysfunction | Sick sinus syndrome | Supraventricular tachycardia | Tricuspid valve disease | Ventricular fibrillation | Ventricular tachycardia | Wolff-Parkinson-White syndrome | Delayed puberty | Growth accelerated | Precocious puberty | Ear pain | External ear inflammation | External ear pain | Middle ear inflammation | Vestibular disorder | Corneal ulcer | Dry eye | Extraocular muscle paresis | Eye pain | Eyelid function disorder | Flashing lights | Night blindness | Optic nerve disorder | Retinal tear | Retinal vascular disorder | Scleral disorder | Watering eyes | Abdominal distension | Anal hemorrhage | Anal mucositis | Anal necrosis | Anal pain | Anal stenosis | Anal ulcer | Cecal hemorrhage | Colonic fistula | Colonic hemorrhage | Colonic obstruction | Colonic perforation | Colonic stenosis | Colonic ulcer | Dental caries | Duodenal fistula | Duodenal hemorrhage | Duodenal obstruction | Duodenal perforation | Duodenal stenosis | Enterovesical fistula | Esophageal fistula | Esophageal hemorrhage | Esophageal necrosis | Esophageal obstruction | Esophageal pain | Esophageal perforation | Esophageal stenosis | Esophageal ulcer | Esophageal varices hemorrhage | Fecal incontinence | Gastric fistula | Gastric hemorrhage | Gastric necrosis | Gastric perforation | Gastric stenosis | Gastroesophageal reflux disease | Gastrointestinal fistula | Gastrointestinal pain | Gingival pain | Hemorrhoidal hemorrhage | Ileal fistula | Ileal hemorrhage | Ileal obstruction | Ileal perforation | Ileal stenosis | Ileal ulcer | Intra-abdominal hemorrhage | Jejunal fistula | Jejunal hemorrhage | Jejunal obstruction | Jejunal perforation | Jejunal stenosis | Jejunal ulcer | Lip pain | Lower gastrointestinal hemorrhage | Mucositis oral | Obstruction gastric | Oral cavity fistula | Oral dysesthesia | Oral hemorrhage | Oral pain | Pancreatic duct stenosis | Pancreatic fistula | Pancreatic hemorrhage | Pancreatic necrosis | Periodontal disease | Peritoneal necrosis | Rectal fistula | Rectal hemorrhage | Rectal mucositis | Rectal necrosis | Rectal obstruction | Rectal pain | Rectal perforation | Rectal stenosis | Rectal ulcer | Retroperitoneal hemorrhage | Salivary duct inflammation | Salivary gland fistula | Small intestinal mucositis | Small intestinal obstruction | Small intestinal perforation | Small intestinal stenosis | Small intestine ulcer | Stomach pain | Tooth development disorder | Tooth discoloration | Upper gastrointestinal hemorrhage | Death neonatal | Death NOS | Edema face | Edema limbs | Edema trunk | Facial pain | Flu like symptoms | Gait disturbance | Infusion related reaction | Infusion site extravasation | Injection site reaction | Localized edema | Multi-organ failure | Neck edema | Non-cardiac chest pain | Sudden death NOS | Bile duct stenosis | Biliary fistula | Gallbladder fistula | Gallbladder necrosis | Gallbladder obstruction | Gallbladder pain | Gallbladder perforation | Hepatic hemorrhage | Hepatic necrosis | Perforation bile duct | Portal vein thrombosis | Anaphylaxis | Autoimmune disorder | Cytokine release syndrome | Abdominal infection | Anorectal infection | Appendicitis | Appendicitis perforated | Arteritis infective | Biliary tract infection | Bladder infection | Bone infection | Breast infection | Bronchial infection | Catheter related infection | Cecal infection | Cervicitis infection | Conjunctivitis infective | Corneal infection | Cranial nerve infection | Device related infection | Duodenal infection | Encephalitis infection | Encephalomyelitis infection | Endocarditis infective | Enterocolitis infectious | Esophageal infection | Eye infection | Gallbladder infection | Gum infection | Hepatic infection | Hepatitis viral | Infective myositis | Joint infection | Kidney infection | Lip infection | Lung infection | Lymph gland infection | Mediastinal infection | Mucosal infection | Nail infection | Otitis externa | Otitis media | Ovarian infection | Pancreas infection | Papulopustular rash | Pelvic infection | Penile infection | Periorbital infection | Peripheral nerve infection | Peritoneal infection | Phlebitis infective | Pleural infection | Prostate infection | Rash pustular | Rhinitis infective | Salivary gland infection | Scrotal infection | Skin infection | Small intestine infection | Soft tissue infection | Splenic infection | Stoma site infection | Tooth infection | Upper respiratory infection | Urethral infection | Urinary tract infection | Uterine infection | Vaginal infection | Vulval infection | Abdominal soft tissue necrosis | Avascular necrosis | Back pain | Buttock pain | Chest wall pain | Fibrosis deep connective tissue | Flank pain | Generalized muscle weakness | Growth suppression | Head soft tissue necrosis | Joint effusion | Joint range of motion decreased | Joint range of motion decreased cervical spine | Joint range of motion decreased lumbar spine | Muscle weakness left-sided | Muscle weakness lower limb | Muscle weakness right-sided | Muscle weakness trunk | Muscle weakness upper limb | Musculoskeletal deformity | Neck pain | Neck soft tissue necrosis | Osteonecrosis of jaw | Pain in extremity | Pelvic soft tissue necrosis | Soft tissue necrosis lower limb | Soft tissue necrosis upper limb | Superficial soft tissue fibrosis | Unequal limb length | Alcohol intolerance | Glucose intolerance | Tumor lysis syndrome | Alkaline phosphatase increased | Blood antidiuretic hormone abnormal | Blood corticotrophin decreased | Blood gonadotrophin abnormal | Blood prolactin abnormal | Carbon monoxide diffusing capacity decreased | Cholesterol high | CPK increased | Creatinine increased | Ejection fraction decreased | Electrocardiogram QT corrected interval prolonged | Fibrinogen decreased | GGT increased | Growth hormone abnormal | Hemoglobin increased | INR increased | Lymphocyte count decreased | Lymphocyte count increased | Neutrophil count decreased | Pancreatic enzymes decreased | Serum amylase increased | Urine output decreased | Vital capacity abnormal | Weight gain | White blood cell decreased | Ankle fracture | Aortic injury | Arterial injury | Biliary anastomotic leak | Bladder anastomotic leak | Bruising | Dermatitis radiation | Esophageal anastomotic leak | Fallopian tube anastomotic leak | Fallopian tube perforation | Gastric anastomotic leak | Gastrointestinal anastomotic leak | Gastrointestinal stoma necrosis | Hip fracture | Injury to carotid artery | Injury to inferior vena cava | Injury to jugular vein | Injury to superior vena cava | Intestinal stoma leak | Intestinal stoma obstruction | Intestinal stoma site bleeding | Intraoperative arterial injury | Intraoperative breast injury | Intraoperative cardiac injury | Intraoperative ear injury | Intraoperative endocrine injury | Intraoperative gastrointestinal injury | Intraoperative head and neck injury | Intraoperative hemorrhage | Intraoperative hepatobiliary injury | Intraoperative musculoskeletal injury | Intraoperative neurological injury | Intraoperative ocular injury | Intraoperative renal injury | Intraoperative reproductive tract injury | Intraoperative respiratory injury | Intraoperative skin injury | Intraoperative splenic injury | Intraoperative urinary injury | Intraoperative venous injury | Kidney anastomotic leak | Large intestinal anastomotic leak | Pancreatic anastomotic leak | Pharyngeal anastomotic leak | Postoperative hemorrhage | Postoperative thoracic procedure complication | Prolapse of intestinal stoma | Prolapse of urostomy | Radiation recall reaction (dermatologic) | Rectal anastomotic leak | Small intestinal anastomotic leak | Spermatic cord anastomotic leak | Spinal fracture | Stenosis of gastrointestinal stoma | Stomal ulcer | Tracheal hemorrhage | Tracheal obstruction | Tracheostomy site bleeding | Ureteric anastomotic leak | Urethral anastomotic leak | Urostomy leak | Urostomy obstruction | Urostomy site bleeding | Urostomy stenosis | Uterine anastomotic leak | Uterine perforation | Vaginal anastomotic leak | Vas deferens anastomotic leak | Vascular access complication | Venous injury | Wound complication | Wound dehiscence | Wrist fracture | Acute kidney injury | Bladder perforation | Bladder spasm | Chronic kidney disease | Cystitis noninfective | Renal calculi | Renal colic | Renal hemorrhage | Urinary fistula | Urinary tract obstruction | Urinary tract pain | Urine discoloration | Delayed orgasm | Delusions | Hallucinations | Libido increased | Suicidal ideation | Suicide attempt | Fetal death | Fetal growth retardation | Premature delivery | Unintended pregnancy | Abducens nerve disorder | Accessory nerve disorder | Acoustic nerve disorder NOS | Central nervous system necrosis | Cerebrospinal fluid leakage | Cognitive disturbance | Concentration impairment | Edema cerebral | Extrapyramidal disorder | Facial muscle weakness | Facial nerve disorder | Glossopharyngeal nerve disorder | Hypoglossal nerve disorder | Intracranial hemorrhage | Ischemia cerebrovascular | IVth nerve disorder | Memory impairment | Movements involuntary | Oculomotor nerve disorder | Olfactory nerve disorder | Phantom pain | Pyramidal tract syndrome | Recurrent laryngeal nerve palsy | Reversible posterior leukoencephalopathy syndrome | Sinus pain | Transient ischemic attacks | Trigeminal nerve disorder | Vagus nerve disorder | Vasovagal reaction | Leukemia secondary to oncology chemotherapy | Myelodysplastic syndrome | Treatment related secondary malignancy | Tumor pain | Breast atrophy | Breast pain | Ejaculation disorder | Erectile dysfunction | Fallopian tube obstruction | Fallopian tube stenosis | Female genital tract fistula | Feminization acquired | Genital edema | Irregular menstruation | Lactation disorder | Nipple deformity | Ovarian hemorrhage | Ovarian rupture | Ovulation pain | Pelvic floor muscle weakness | Pelvic pain | Penile pain | Perineal pain | Premature menopause | Prostatic hemorrhage | Prostatic obstruction | Prostatic pain | Scrotal pain | Spermatic cord hemorrhage | Spermatic cord obstruction | Testicular disorder | Testicular hemorrhage | Testicular pain | Uterine fistula | Uterine hemorrhage | Uterine obstruction | Uterine pain | Vaginal discharge | Vaginal dryness | Vaginal fistula | Vaginal hemorrhage | Vaginal inflammation | Vaginal obstruction | Vaginal pain | Vaginal perforation | Vaginal stricture | Allergic rhinitis | Bronchial fistula | Bronchial obstruction | Bronchial stricture | Bronchopulmonary hemorrhage | Laryngeal edema | Laryngeal fistula | Laryngeal hemorrhage | Laryngeal inflammation | Laryngeal mucositis | Laryngeal obstruction | Laryngeal stenosis | Laryngopharyngeal dysesthesia | Mediastinal hemorrhage | Nasal congestion | Pharyngeal fistula | Pharyngeal hemorrhage | Pharyngeal mucositis | Pharyngeal necrosis | Pharyngeal stenosis | Pharyngolaryngeal pain | Pleural hemorrhage | Postnasal drip | Productive cough | Pulmonary edema | Pulmonary fistula | Respiratory failure | Sinus disorder | Sleep apnea | Sore throat | Tracheal fistula | Tracheal mucositis | Tracheal stenosis | Voice alteration | Body odor | Bullous dermatitis | Fat atrophy | Nail discoloration | Nail loss | Nail ridging | Pain of skin | Palmar-plantar erythrodysesthesia syndrome | Periorbital edema | Rash acneiform | Rash maculo-papular | Scalp pain | Skin atrophy | Skin hyperpigmentation | Skin hypopigmentation | Skin induration | Skin ulceration | Stevens-Johnson syndrome | Toxic epidermal necrolysis | Hot flashes | Lymph leakage | Peripheral ischemia | Superficial thrombophlebitis | Superior vena cava syndrome | Visceral arterial ischemia | Allergic reaction | Alopecia | Amnesia | Anal fistula | Abdominal pain | Acidosis | Activated partial thromboplastin time prolonged | Adrenal insufficiency | Adult respiratory distress syndrome | Agitation | Akathisia | Alanine aminotransferase increased | Alkalosis | Iron overload | Anemia | Anorexia | Anorgasmia | Anxiety | Aphonia | Apnea | Arachnoiditis | Arthralgia | Arthritis | Ascites | Aspartate aminotransferase increased | Aspiration | Ataxia | Atelectasis | Atrial flutter | Azoospermia | Bloating | Blood bilirubin increased | Blurred vision | Bone pain | Bronchospasm | Burn | Capillary leak syndrome | Cardiac troponin I increased | Cardiac troponin T increased | Cataract | CD4 lymphocytes decreased | Cheilitis | Chills | Cholecystitis | Colitis | Confusion | Conjunctivitis | Constipation | Cough | Cushingoid | Dehydration | Delirium | Depressed level of consciousness | Depression | Diarrhea | Disseminated intravascular coagulation | Dizziness | Dry mouth | Dry skin | Duodenal ulcer | Dysarthria | Dysgeusia | Dysmenorrhea | Dyspareunia | Dyspepsia | Dysphagia | Dysphasia | Dyspnea | Encephalopathy | Endophthalmitis | Enterocolitis | Epistaxis | Erythema multiforme | Erythroderma | Esophagitis | Euphoria | Exostosis | Fall | Fatigue | Fever | Flatulence | Floaters | Flushing | Forced expiratory volume decreased | Fracture | Gastric ulcer | Gastritis | Gastroparesis | Glaucoma | Gynecomastia | Haptoglobin decreased | Headache | Hearing impaired | Hematoma | Hematuria | Hemoglobinuria | Hemolysis | Hemorrhoids | Hepatic failure | Hepatic pain | Hiccups | Hirsutism | Hoarseness | Hydrocephalus | Hypercalcemia | Hyperglycemia | Hyperhidrosis | Hyperkalemia | Hypermagnesemia | Hypernatremia | Hyperparathyroidism | Hypersomnia | Hypertension | Hyperthyroidism | Hypertrichosis | Hypertriglyceridemia | Hyperuricemia | Hypoalbuminemia | Hypocalcemia | Hypoglycemia | Hypohidrosis | Hypokalemia | Hypomagnesemia | Hyponatremia | Hypoparathyroidism | Hypophosphatemia | Hypotension | Hypothermia | Hypothyroidism | Hypoxia | Ileus | Insomnia | Irritability | Keratitis | Kyphosis | Laryngitis | Laryngospasm | Lethargy | Leukocytosis | Leukoencephalopathy | Libido decreased | Lipase increased | Lordosis | Lymphedema | Malabsorption | Malaise | Mania | Meningismus | Meningitis | Menopause | Menorrhagia | Myalgia | Myelitis | Myocardial infarction | Myocarditis | Myositis | Nausea | Neuralgia | Nystagmus | Obesity | Oligospermia | Osteoporosis | Pain | Palpitations | Pancreatitis | Papilledema | Paresthesia | Paronychia | Pericardial effusion | Pericarditis | Peripheral motor neuropathy | Peripheral sensory neuropathy | Personality change | Pharyngitis | Phlebitis | Photophobia | Photosensitivity | Platelet count decreased | Pleural effusion | Pleuritic pain | Pneumonitis | Pneumothorax | Portal hypertension | Presyncope | Proctitis | Proteinuria | Pruritus | Psychosis | Pulmonary fibrosis | Pulmonary hypertension | Purpura | Restlessness | Restrictive cardiomyopathy | Retinal detachment | Retinoic acid syndrome | Retinopathy | Scoliosis | Seizure | Sepsis | Seroma | Serum sickness | Sinus bradycardia | Sinus tachycardia | Sinusitis | Sneezing | Somnolence | Spasticity | Stridor | Stroke | Syncope | Telangiectasia | Thromboembolic event | Tinnitus | Toothache | Tracheitis | Tremor | Trismus | Typhlitis | Urinary frequency | Urinary incontinence | Urinary retention | Urinary urgency | Urticaria | Uveitis | Vaginismus | Ventricular arrhythmia | Vertigo | Virilization | Vitreous hemorrhage | Vomiting | Weight loss | Wheezing | Wound infection | Lymphocele | Chylothorax | Bronchopleural fistula | Hematosalpinx | Radiculitis | Lipohypertrophy | Dysesthesia | Brachial plexopathy
Adverse Event2746311v1AE Ongoing?Adverse Event Ongoing Event IndicatorThe flag used to indicate whether the adverse event has resolved or not.Yes | No
Adverse Event2188132v1Describe 'Other' Adverse EventAdverse Event Verbatim Term TextThe text that describes the adverse event word for word as described by the participant. 
Adverse Event2179615v1Did event reappear after study agent was reintroduced?Adverse Event Reappearance IndicatorThe name that indicates whether an adverse event problem reappeared after reintroduction of a agent.Yes | No | N/A
Adverse Event2179971v1Were adverse events assessed during most recent periodAdverse Event Most Recent Assessment Ind-3the yes/no/unknown indicator used to determine whether Adverse Events were identified during the reporting period.No | Yes | Unknown
Adverse Event2538246v1MedDRA AE Code (CTCAE v3.0)MedDRA Adverse Event CodeNumeric MedDRA code (with some CTEP codes) to represent any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). 
Adverse Event2585234v1Event Onset TimeAdverse Event Onset TimeThe time of the first observation of the adverse event. 
Agent2003870v4IndicationConcomitant Agent Concomitant Intervention or Procedure ReasonThe reason for administration of a concomitant (nonstudy) agent or measure. This is not the pharmacologic classification of an agent (antibiotic, analgesic, etc.), but the reason for its administration to the patient. [Manually-curated]Apheresis | Birth Control | Confusion | Rash | Weight Gain | Dyspepsia | Dysuria | Hiatal hernia | Erythema | Diabetes | Hemorrhage | Headache | Vomiting | Depression | Dermatitis | Chronic Obstructive Pulmonary Disease (COPD) | Antipsychotic | Anti-angina | Anesthesia | Allergic Reaction | Adrenal Suppression | Acidity | Accelerate Hematopoietic Recovery | Anemia | Anticoagulation | Anxiety | Appetite | Arthralgia | Attention Deficit Disorder | Benign Prostatic Hyperplasia | Bipolar Disorder | Bronchospasm | Cardiac | Cellulitis | Conjunctivitis | HIV | CNS Disease | Dyspnea | Earache | Electrolyte Imbalance | Engraftment | Esophagitis | Gastric Ulcer | Gastritis | Gastroesophageal Reflux Disease | Glaucoma | Gout | Granulocytopenia | Flu Symptoms | Hiccoughs | Hemorrhoids | Hand Foot Syndrome (HFS) | GVHD Therapy | GVHD Prophylaxis | Erectile Dysfunction | Epiphora (Watery Eyes) | Empirical Coverage | Contrast Study | Congestion | Complicating Disease or Condition | CMV Therapy | Bursitis | Bony Disease | Bloating | Blepharitis (Eyelid Inflammation) | Malignancy | Hormonal Manipulation | Hepatic Lab abnormality | Heparin Reversal | Hemolytic Urem Syndrome | Gastrointestinal distress | GI Decontamination | Fluid Retention | Fluid Overload | Fever w/Low WBC | Eye Redness | Extrapyramidal | Local Anesthesia | Line Patency | Line Occlusion | Leg cramps | Nail Changes | Mouth Sores | Metabolic Imbalance | Menopausal symptoms | Malignant Hyperthermia | Macular degeneration | Nausea and vomiting | Nasal Symptom | Narcolepsy | Neuropathy | Neutropenia | Dry Skin | Hot Flashes | Hypercalcemia | Hypercholesterolemia | Hyperglycemia | Hyperkalemia | Hyperlipidemia | Hyperparathyroidism | Keratitis sicca (Dry Eyes) | Itching | Induce Sedation | Hyperthyroidism | Hypoalbuminemia | Hypocalcemia | Hypokalemia | Hypomagnesemia | Hypophosphatemia | Infection | Injection Site Reaction | Insomnia | Lactose Intolerance | Mucositis | Muscle Spasm | Partial Thromboplastin Time (PTT) Prolongation | Palliation | Parkinson's Disease | Pharyngitis | Petechiae | Periodontal Disease | Xerosis | Venous Thrombosis | Vasodilitation (Flush) | Vascular Access | Vaginal Dryness | Urinary | Tremors | Stomach Cramps | Rigors | Restlessness | Restless Leg Syndrome | Respiratory Distress/Dyspnea | Replacement | Renal/Urinary | Rectal Bleeding | Pulmonary Embolus | Preprocedure/Diagnostic Testing | Prechemotherapy | PostTreatment | PreTreatment | Post Traumatic Stress Disorder | Port Occlusion | Pneumonitis | Pleural Effusion | Prophylaxis | Pruritus | Pseudogout | Rhinorrhea | Seizures | Sinusitis | Skin Irritation | Sleep | Sleep Apnea | Smoking Cessation | Supplement | Thrombus | Thrush | Urticaria | Vitamins | Weight Loss | Xerostomia | Hyperuricemia | Wheezing | Uveitis | Pancreatic insufficiency | Immunosuppression | Anorexia | Somnolence | Myasthenia Gravis | Allergy | Asthma | Reflux | Renal Failure | Myalgia | Stomatitis | Hypotension | Alopecia | Epistaxis | Cough | Constipation | Hypothyroidism | Dehydration | Hypoxia | Flatulence | Nausea | Rhinitis | Attention Deficit Hyperactivity Disorder (ADHD) | Osteoporosis | Edema | Psoriasis | Nutrition | Pain | Mood | Ascites | Dysphagia | Fatigue | Arthritis | Fever | Thrombocytopenia | Airway Protection | Mental Status Changes | Pulmonary Edema | Respiratory Failure | Phlebitis | Indigestion | Vertigo | Diarrhea | Bronchitis | Arrhythmia | Hypertension | Inflammation | Scabies
Agent2006399v4Date Agent AdministeredAgent Administered Datethe date an agent was administered. 
Agent2971977v1SupplierAgent Supplier NameText identification of the business or organization is supplying an agent. 
Agent2179777v2MedicationConcomitant Agent NameThe name that describes the concomitant medication. 
Agent2867247v1Agent CodeAgent NCI Enterprise Vocabulary Services CodeThe NCI's Enterprise Vocabulary (EVS) identification number. 
Agent2179618v1FormulationAgent Formulation Descriptive TextThe text that describes the formulation of the agent used in the study.Sachet | Caplet | Capsule | Capsule/Liquid-filled | Capsule/Micronized Powder | Cartridge | Cream | Depot | Device | Liquid | Lotion | Ointment | Powder | Tablet | Patch | Injection
Agent62589v6Route of AdministrationAgent Administration Typethe method of delivery by which a medication, drug or agent is administered to a patient.Bolus injection | Infusion | IM | IV | Ocular | PO | oral | transdermal/topical | injection/implant | vaginal | nasal | Inhaled | Intramuscular | Subcutaneous | Other | Pill
Agent62592v3Study Treatment Identification NumberAgent Lot Identifier Numberthe manufacturer's batch or lot ID number assigned to the drug or other agent for the dose administered to the patient. 
Agent2867515v1Dispense DateAgent Provided DateThe date the agent was given to the participant. 
Agent10v4Agent NameAgent NameA text name for an Agent. An agent is a distinct substance or ingredient or compound/product/mixture thereof, contained in drugs, biologics, foods, and devices that act to produce a specific effect (commonly health related). This can include radiopharmaceutical, nutritional, complimentary and alternative medicine (CAM), molecular components of devices (i.e. silicon in implants) and nano-technologic agents but does not include whole devices (implants), or procedures (i.e. surgeries). Individual agents included in a treatment regimen or therapy is included in this definition, however, whole regimen names or other broad classification of therapies (i.e. "CHOP", "chemotherapy", etc), are not. 
Agent2871611v1Date Study Agent ReturnedStudy Agent Returned DateThe date the remaining agent was returned by the participant. 
Agent62590v3Total # of Courses ReceivedAgent Course Countthe total number of cycles administered to the patient. 
Agent Administration2871633v1Total Volume Administered to ParticipantAgent Administration Drug Vehicle Total Volume NumberA volume of a carrier or inert medium used as a solvent in which a medicinally active agent is formulated and/or administered to the participant. 
Agent Administration2789683v1UnitAgent Administration Potency Unit of Measure Unified Code for Units of Measure CodeA code system intended to include all units of measures being contemporarily used in international science, engineering, and business. Its purpose is to facilitate unambiguous electronic communication of quantities together with their units.h | [oz_av] | ng | ug | mol | mg/mL | 10^7{Cells}/kg | kU/L | [iU]/L | [iU] | L/min | mg/kg | mg/dL | mg/24.h | meq/L | meq/dL | meq/24.h | meq | 10^6 | 10^6{pfu} | m[iU]/m2 | m[iU] | ng/mL | {No Scre} | {Unknown} | U/m2 | 10^3 | mg/h | ug/h | meq/h | [RAD] | [gal_us] | {Seed} | {Unit} | 10^9{Cells}/kg | {Wafer} | J | mg/m2/h | [iU]/mg | U/g | ug/m2 | {Bottle} | 10^5{Cells}/kg | 10^6{Cells}/kg | {AUC} | {IV Bag} | mg/{inhalation} | [iU]/mg{alpha-Tocopherol} | [iU]{Vitamin A} | {RAE} | {RE} | {Session} | {Patch} | mL/h | mg/wk | {Measure} | kU/kg | keV | J/cm2 | [iU]/kg | {Inhalation} | g/m2 | eq | [drp] | {Dose} | {Course} | {Course} | {Cells} | {Capsule} | {Caplet} | u | {Application} | 10^9{pfu} | 10^8{pfu} | 10^7{pfu} | mg/m2 | ug/kg | ug/cm2 | uCi | M[RAD] | 10^6eV | mL/kg | [psi] | {pfu} | {packet} | osm | nm{light} | ng/L | ng/kg | mU | mosm | 10^6{VP} | MU | {VP} | U/kg | {Troche} | {TCID50} | [tsp_us] | {tbl} | [tbs_us] | {Suppository} | {Spray} | {puff} | % | {YU} | mg/m2/wk | mg/m2/24.h | ug/kg/24.h | ug/m2/h | mg/kg/d | g/d | ug/kg/wk | g/wk | kg | pg | uL | % | g | min | umol | cGy | Ci | dL | Gy | Hz | kHz | kPa | kU | L | mCi | MHz | mL | mmol | mV | nCi | nmol | Pa | mg | s | u[IU]/mL
Animal2638253v1Lab animal body surface areaLaboratory Animal Body Surface Area ValueThe calculated numerical quantity relating height to weight that represents a measure of the 2-dimensional extent of the body surface of a living being housed in a place used for the conduct of scientific research. 
Animal2222451v1Animal Sex PhenotypeAnimal Sex Phenotype Text TypeText designations that identify sex; particulary a type of animal. Sex is described as the assemblage of physical properties or qualities by which male is distinguished from female. [Explanatory Comment 1: Identification is based upon observation/phenotype.] [Explanatory Comment 2: Phenotype is the outward appearance of the animal. It is the product of interactions between genes and between the genotype and the environment.] [Explanatory Comment 3: An animal is a living, sentient organism that has membranous cell walls, requires oxygen and organic foods, and is capable of voluntary movement, as distinguished from a plant or mineral.]Unknown | Unspecified | Hermaphrodite | Intersex | Male Phenotype | Female Phenotype | Male-to-Female Transsexual Animal | Female-to-Male Transsexual Animal
Assessment2182832v1Specify Reason for NoncomplianceNoncompliant Reason TextThe text that describes the reason the participant was noncompliant. 
B-Symptoms2902402v1Are B symptoms present?Lymphoma B-Symptoms Medical Record Documented IndicatorText term to signify whether lymphoma B-symptoms are present as noted in the patient's medical record.No | Unknown | Yes | Not Applicable
Begin2004095v3Start TimeStart TimeThe start time for the administration of an intervention, using a 24-hour clock time. 
Blood63954v3Estimated Blood Loss (cc)Total Estimate Blood Loss Amounta numeric value for the total estimated amount of blood lost (EBL) by the patient during the procedure. 
Blood Pressure2004289v1Systolic BPSystolic Blood Pressure ValueThe pressure of the blood against the artery walls during systole (the contraction phase). 
Blood Pressure2004291v1Diastolic BPDiastolic Blood Pressure ValueThe pressure of the blood against the artery walls during diastole (the relaxation phase). 
Blood Transfusion2685525v1Blood transfusionBlood Transfusion Timepoint Administered Typethe specific point blood or blood products were administered into a blood vessel.During or after evaluation | Since exposure but prior to evaluation | Intraoperative | Within 30 days post-operative | Preoperative
Blood Transfusion2182866v1UnitsTransfuse Blood Component UnitsNumber of units of blood component transfused into a recipient. 
Blood Transfusion2182863v2Transfusion ComponentBlood Component Transfusion Text NameName of blood components administered to recipients or donors.FFP | No Blood Products | Albumin | Packed RBC, Irradiated and Leukoreduced | Platelets, Irradiated and Leukoreduced | Manipulated Lymphocytes | Packed RBC | Packed RBC, Irradiated | Packed RBC, Leukopoor | Packed RBC, Leukoreduced | Packed RBC, Autologous | Packed RBC, Autologous, Irradiated | Packed RBC, Autologous, Leukoreduced | WBC | Platelets, Irradiated | Platelets, HLA Match | Platelets, Leukoreduced | Cryoprecipitate | Whole Blood | WBC, Irradiated | Platelet
Body2002895v4Body SystemBody System TypeText term to identify a Review of Systems (ROS) component that consists of one or all members of an organ system, and/or additional medical questions.Psychiatric | Vulvovaginal | HEMATOLOGIC | NEUROLOGIC | H/E/E/N/T | NECK | RESPIRATORY | CARDIOVASCULAR | GASTROINTESTINAL | GENITALIA | BREASTS | PELVIS | ABDOMEN | DERMATOLOGIC | HEMATOPOIETIC/LYMPH | ENDOCRINE/METABOLIC | URINARY | OTHER | Chest | MUSCULOSKELETAL | Rectal | PSYCHOLOGIC | IMMUNE | Hepatic | Spleen | Pulmonary | Renal | Reproductive History | Constitutional | Extremities | Integumentary/Hair | Peripheral Vascular | Transfusion History | Central Nervous System | Appearance | Genitourinary | Allergy/Drug Sensitivity | Endocrine | Body as a Whole | Substance abuse/Dependency
Body2182671v1Other (Body) System/Site TextOther Body System/Site TextThe text that describes the other specific organ system or body site. 
Carcinoma2902390v1St. Jude StagePediatric Lymphoid Cancer St. Jude StageCategorization of pediatric patients with lymphoid cancer using the St. Jude system, which was designed to accommodate the noncontiguous nature of disease spread, predominant extranodal involvement, and involvement of the central nervous system and bone marrow that characterize the pediatric non-Hodgkins lymphomas.IV | III | II | I
Case Report Form3008890v1CRF Version DateCase Report Form Version DateThe released or published date of the specific version of a case report form. 
Case Report Form3008880v1Total Number of Pages in CRFCase Report Form Total Page NumberThe complete number of pages of the case report form document. 
Case Report Form3008875v1CRF Page #Case Report Form Page NumberThe specific page number being referenced in the case report form document. 
Case Report Form2003745v5Date CompletedForm Completion DateThe date on which a data capture form (CRF or case report form) was completed. 
Case Report Form3008897v1Review DateCase Report Form Review DateThe date on which the case report form was evaluated. 
Case Report Form3008888v1CRF Version #Case Report Form Version NumberThe number that represents the sequence of copies different from others of the same type of a case report form. 
Case Report Form3008882v1CRF IdentifierCase Report Form IdentifierThe unique alphanumeric string used to identify, name, or characterize the nature, properties, or contents of the case report form. 
Case Report Form3009034v1CRF NameCase Report Form NameThe words that uniquely describe the case report form title. 
Change3286567v1Person Amending FormCase Report Form Change Person NameName of a person who amended data on a case report form (CRF). 
Checklist2960683v1Checklist Version DateEligibility Determination Checklist Version DateThe date of the version of the Eligibility Checklist that was used in determining eligibility. 
Chemotherapy62676v3Total Number of Prior Chemotherapy RegimensPrior Chemotherapy Regimen Numberthe number of chemotherapy regimens the patient has previously received. 
Chronic Myelogenous Leukemia, BCR-ABL1 Positive2902396v1CML PhaseCML Disease Phase CategoryCategorization/classification of patients with chronic myelogenous leukemia or CML, the most common chronic myeloproliferative disorder finding by well-defined periods of disease increased activity or indolence.Chronic phase | Accelerated phase | Blastic phase
Clinical Study2182613v1Off Study Other, SpecifyOff Study Reason TextThe text that describes the reason the participant went off study. 
Clinical Study3608v4Stratification Factors (protocol specific)Study Stratification Textselected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol. 
Clinical Study2003605v3Off Study DateOff Study DateThe date when the patient/participant is removed from the protocol, i.e., is not being followed and will not be retreated. 
Clinical Study2453215v1Off Study ReasonOff-Treatment Study Follow-Up Codethe coded reason or cause for a patient to end the follow-up visit schedule specified by the protocol.(CDUS Exchange)01 | 02 | 03 | 04 | 05 | 98
Clinical Study Protocol2746459v1Study IdentifierProtocol Clinical Study Identifier NumberThe numeric or alphanumeric identification assigned to the study. 
Clinical Trial2184691v1Screen Completion DateScreen DateDate of an evaluation or assessment of an individual's eligibility to enter a clinical trial. 
Clinical Trial2960860v1If not, which screening criteria not met?Clinical Trial Screening Ineligibility Reason TextThe free text description of the specific criteria that were not met from the eligibility checklist. 
Clinical Trial2960675v1Does the participant meet all screening criteria?Clinical Trial Screening IndicatorText response that indicates whether the participant satisfies all of the screening criteria.No | Yes
Collection2004004v3Sample Collection DateSample Collection DateThe date when the sample (specimen) was collected. 
Colorectal Neuroendocrine Neoplasm4986357v1Pathologic M StageColon or Rectum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the colon or rectum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Colorectal Neuroendocrine Neoplasm4986354v1Clinical M StageColon or Rectum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the colon or rectum neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Colorectal Neuroendocrine Neoplasm4986356v1Pathologic N StageColon or Rectum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the colon or rectum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Colorectal Neuroendocrine Neoplasm4986355v1Pathologic T StageColon or Rectum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary colon or rectum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T1b | T1a | T0 | T1 | T2 | T3 | T4 | TX
Colorectal Neuroendocrine Neoplasm4986352v1Clinical T StageColon or Rectum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary colon or rectum neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T1b | T1a | T0 | T1 | T2 | T3 | T4 | TX
Colorectal Neuroendocrine Neoplasm4986353v1Clinical N StageColon or Rectum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the colon or rectum neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Comment2956253v1Comments DateComment Created DateThe date on which the general notes were entered. 
Common Terminology Criteria for Adverse Events1285v3AE AttributionCTC Adverse Event Attribution ScaleRelation of the causality between the treatment modality and the specific adverse event.Definite | Possible | Probable | Unlikely | Unrelated
Common Terminology Criteria for Adverse Events323v3Adverse Event Name (v3.0)Common Toxicity Criteria Adverse Event Term Typethe medical description of the adverse event using NCI CTC terminology.Allergic reaction/hypersensitivity (including drug fever) | Bone marrow cellularity | Acute vascular leak syndrome | Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae) | Alkaline phosphatase | Bladder spasms | Adult respiratory distress syndrome (ARDS) | Cataract | Acidosis (metabolic or respiratory) | DIC (disseminated intravascular coagulation) | Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) | CD4 count | Creatinine | Arachnoiditis/meningismus/radiculitis | Alkalosis (metabolic or respiratory) | Anorexia | Apnea | Feminization of male | Bruising (in absence of grade 3 or 4 thrombocytopenia) | Fibrinogen | Autoimmune reaction | Gynecomastia | Carbon monoxide diffusion capacity (DL(co)) | Ataxia (incoordination) | Amylase | Ascites (non-malignant) | Palpitations | Haptoglobin | Serum sickness | Glaucoma | CNS cerebrovascular ischemia | Myositis (inflammation/damage of muscle) | Colitis | Hot flashes/flushes | Cough | Dry skin | Hemoglobin | Hemoglobinuria | Dyspnea (shortness of breath) | Keratitis (corneal inflammation/corneal ulceration) | CPK (creatine phosphokinase) | Constipation | Sweating (diaphoresis) | Cardiac troponin I (cTnI) | Vasculitis | Irregular menses (change from baseline) | Masculinization of female | Flushing | Weight gain | Cardiac troponin T (cTnT) | Osteonecrosis (avascular necrosis) | Dehydration | Libido | Hiccoughs (hiccups, singultus) | Vision-blurred vision | Confusion | Liver dysfunction/failure (clinical) | Leukocytes (total WBC) | Hypoxia | Portal vein flow | Weight loss | Hypertension | Hypotension | Proteinuria | Pleural effusion (non-malignant) | Vision-flashing lights/floaters | Nail changes | Vasovagal episode | Tumor flare | Vaginal dryness | Renal failure | Petechiae/purpura (hemorrhage/bleeding into skin or mucosa) | Lymphopenia | Myocarditis | Tumor lysis syndrome | Pneumonitis/pulmonary infiltrates | Vision-photophobia | Photosensitivity | Pneumothorax | Neutrophils/granulocytes (ANC/AGC) | Urinary frequency/urgency | Extrapyramidal/involuntary movement/restlessness | Peripheral arterial ischemia | Platelets | Insomnia | Irritability (children <3 years of age) | Rash/desquamation | Vaginitis (not due to infection) | Visceral arterial ischemia (non-myocardial) | Urticaria (hives, welts, wheals) | Flatulence | Lipase | Nystagmus | Personality/behavioral | Nausea | Pyramidal tract dysfunction (e.g., increased tone, hyperreflexia, positive Babinski, decreased fine motor coordination) | Pancreatitis | Speech impairment (e.g., dysphasia or aphasia) | Proctitis | Syncope (fainting) | Tremor | Vomiting | Allergy/Immunology-Other (Specify) | Auditory/Ear-Other (Specify) | Blood/Bone Marrow-Other (Specify) | Cardiac Arrhythmia-Other (Specify) | Cardiac General-Other (Specify) | Coagulation-Other (Specify) | Constitutional Symptoms-Other (Specify) | Dermatology/Skin-Other (Specify) | Endocrine-Other (Specify) | Gastrointestinal-Other (Specify) | Hemorrhage/Bleeding-Other (Specify) | Hepatobiliary/Pancreas-Other (Specify) | Infection-Other (Specify) | Lymphatics-Other (Specify) | Metabolic/Laboratory-Other (Specify) | Musculoskeletal/Soft Tissue-Other (Specify) | Neurology-Other (Specify) | Ocular/Visual-Other (Specify) | Pain-Other (Specify) | Pulmonary/Upper Respiratory-Other (Specify) | Renal/Genitourinary-Other (Specify) | Secondary Malignancy-possibly related to cancer treatment (Specify) | Sexual/Reproductive Function-Other (Specify) | Syndromes-Other (Specify) | Growth and Development-Other (Specify) | Intra-operative Injury-Other (Specify) | Vascular-Other (Specify) | Pain - Abdomen NOS | Hair loss/Alopecia (scalp or body) | Pain - Joint | Arthritis (non-septic) | Bicarbonate, serum-low | Bilirubin (hyperbilirubinemia) | Pain - Bone | Hemorrhage, CNS | Left ventricular systolic dysfunction | Infection with unknown ANC - Catheter-related | Pain - Chest/thorax NOS | Cognitive disturbance | Conduction abnormality/Atrioventricular heart block - Asystole | Ocular surface disease | Psychosis (hallucinations/delusions) | Somnolence/depressed level of consciousness | Diarrhea | Dizziness | Dry eye syndrome | Ulcer, GI - Duodenum | Pain - Uterus | Heartburn/dyspepsia | Esophagitis | Dysphagia (difficulty swallowing) | Pain - Urethra | Pain - External ear | Edema: limb | Hemorrhage, pulmonary/upper respiratory - Nose | Erectile dysfunction | Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) | Otitis, external ear (non-infectious) | FEV(1) | Fatigue (asthenia, lethargy, malaise) | Fistula, GU - Vagina | Fistula, GI - Esophagus | Fistula, GI - Duodenum | Fistula, GI - Anus | GGT (gamma-glutamyl transpeptidase) | Ulcer, GI - Stomach | Gastritis (including bile reflux gastritis) | Rash: hand-foot skin reaction | Adrenal insufficiency | Pain - Head/headache | Hemorrhage, GI - Stomach | Hemorrhage, GU - Urinary NOS | Hemorrhage, pulmonary/upper respiratory - Respiratory tract NOS | Hemorrhage/bleeding associated with surgery, intra-operative or post-operative | Pain - Liver | Calcium, serum-high (hypercalcemia) | Potassium, serum-high (hyperkalemia) | Magnesium, serum-high (hypermagnesemia) | Sodium, serum-high (hypernatremia) | Triglyceride, serum-high (hypertriglyceridemia) | Uric acid, serum-high (hyperuricemia) | Albumin, serum-low (hypoalbuminemia) | Calcium, serum-low (hypocalcemia) | Glucose, serum-low (hypoglycemia) | Potassium, serum-low (hypokalemia) | Magnesium, serum-low (hypomagnesemia) | Sodium, serum-low (hyponatremia) | Phosphate, serum-low (hypophosphatemia) | Thyroid function, low (hypothyroidism) | Glucose, serum-high (hyperglycemia) | Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation) | Incontinence, urinary | Infection with unknown ANC - Lymphatic | Infection with normal ANC or Grade 1 or 2 neutrophils - Lymphatic | Injection site reaction/extravasation changes | Leukoencephalopathy (radiolographic findings) | Infertility/sterility | Hemorrhage, GI - Abdomen NOS | Memory impairment | Otitis, middle ear (non-infectious) | Mood alteration - anxiety | Mood alteration - depression | Mood alteration - euphoria | Dry mouth/salivary gland (xerostomia) | Mucositis/stomatitis (functional/symptomatic) - Esophagus | Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized | Pain - Muscle | Neuropathy: cranial - CN II Vision | Neuropathy: motor | Neuropathy: sensory | Intra-operative injury - Vein NOS | Intra-operative injury - Bladder | PTT (Partial thromboplastin time) | Pain - Pelvis | Pericardial effusion (non-malignant) | Phlebitis (including superficial thrombosis) | Hyperpigmentation | Pain - Pleura | Prolonged QTc interval | INR (International Normalized Ratio of prothrombin time) | Pruritus/itching | Hemorrhage, GI - Rectum | Taste alteration (dysgeusia) | Watery eye (epiphora, tearing) | Thrombosis/thrombus/embolism | Pain - Tumor pain | Typhlitis (cecal inflammation) | Obstruction, GU - Ureter | Urinary retention (including neurogenic bladder) | Hemorrhage, GU - Vagina | Ophthalmoplegia/diplopia (double vision) | Night blindness (nyctalopia) | Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis) | Infection with unknown ANC - Wound | Wound complication, non-infectious | Alcohol intolerance syndrome (antabuse-like syndrome) | Bone growth: femoral head; slipped capital femoral epiphysis | Bone growth: limb length discrepancy | Bone growth: spine kyphosis/lordosis | Bone: spine-scoliosis | Brachial plexopathy | Death not associated with CTCAE term - Multi-organ failure | Death not associated with CTCAE term - Sudden death | Dental: dentures or prosthesis | Dental: periodontal disease | Dental: teeth | Fistula, GI - Ileum | Fistula, GI - Jejunum | Fistula, GI - Oral cavity | Fistula, GI - Pancreas | Fistula, GI - Rectum | Infection with normal ANC or Grade 1 or 2 neutrophils - Cervix | Infection with normal ANC or Grade 1 or 2 neutrophils - Colon | Infection with normal ANC or Grade 1 or 2 neutrophils - Conjunctiva | Infection with normal ANC or Grade 1 or 2 neutrophils - Cornea | Infection with normal ANC or Grade 1 or 2 neutrophils - Dental-tooth | Infection with normal ANC or Grade 1 or 2 neutrophils - Duodenum | Infection with normal ANC or Grade 1 or 2 neutrophils - Esophagus | Infection with normal ANC or Grade 1 or 2 neutrophils - External ear (otitis externa) | Infection with normal ANC or Grade 1 or 2 neutrophils - Eye NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Fallopian tube | Breast function/lactation | Breast nipple/areolar deformity | Breast volume/hypoplasia | Bronchospasm, wheezing | Burn | Chylothorax | CNS necrosis/cystic progression | Colitis, infectious (e.g., Clostridium difficile) | Conduction abnormality/Atrioventricular heart block - AV block-first degree | Conduction abnormality/Atrioventricular heart block - Wolff-Parkinson-White syndrome | Cystitis | Cytokine release syndrome/acute infusion reaction | Death not associated with CTCAE term - Death NOS | Death not associated with CTCAE term - Disease progression NOS | Fibrosis-deep connective tissue | Fistula, GI - Abdomen NOS | Fistula, GI - Biliary tree | Fistula, GI - Colon/cecum/appendix | Fistula, GI - Gallbladder | Fistula, pulmonary/upper respiratory - Larynx | Fistula, pulmonary/upper respiratory - Lung | Fistula, pulmonary/upper respiratory - Oral cavity | Fistula, pulmonary/upper respiratory - Pharynx | Fistula, pulmonary/upper respiratory - Pleura | Hemorrhage, pulmonary/upper respiratory - Larynx | Hemorrhage, pulmonary/upper respiratory - Lung | Hemorrhage, pulmonary/upper respiratory - Mediastinum | Hemorrhage, pulmonary/upper respiratory - Pharynx | Hemorrhage, pulmonary/upper respiratory - Pleura | Infection with normal ANC or Grade 1 or 2 neutrophils - Brain (encephalitis, infectious) | Infection with normal ANC or Grade 1 or 2 neutrophils - Brain + Spinal cord (encephalomyelitis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Bronchus | Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related | Infection with normal ANC or Grade 1 or 2 neutrophils - Cecum | Infection with normal ANC or Grade 1 or 2 neutrophils - Gallbladder (cholecystitis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Heart (endocarditis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Ileum | Infection with normal ANC or Grade 1 or 2 neutrophils - Jejunum | Infection with normal ANC or Grade 1 or 2 neutrophils - Joint | Infection with normal ANC or Grade 1 or 2 neutrophils - Kidney | Infection with normal ANC or Grade 1 or 2 neutrophils - Larynx | Infection with normal ANC or Grade 1 or 2 neutrophils - Lens | Infection with normal ANC or Grade 1 or 2 neutrophils - Lip/perioral | Cardiopulmonary arrest, cause unknown (non-fatal) | Cervical spine-range of motion | Cholecystitis | Chyle or lymph leakage | Conduction abnormality/Atrioventricular heart block - AV block-second degree Mobitz Type II | Conduction abnormality/Atrioventricular heart block - AV block-third degree (complete AV block) | Conduction abnormality/Atrioventricular heart block - Conduction abnormality NOS | Conduction abnormality/Atrioventricular heart block - Sick sinus syndrome | Conduction abnormality/Atrioventricular heart block - Stokes-Adams syndrome | Exostosis | Extremity-lower (gait/walking) | Extremity-upper (function) | Eyelid dysfunction | Fibrosis-cosmesis | Fistula, GU - Kidney | Fistula, GU - Ureter | Fistula, GU - Urethra | Fistula, GU - Uterus | Fistula, pulmonary/upper respiratory - Bronchus | Hemorrhage, GI - Cecum/appendix | Hemorrhage, GI - Colon | Hemorrhage, GI - Duodenum | Hemorrhage, GI - Esophagus | Hemorrhage, GI - Ileum | Hemorrhage, GU - Retroperitoneum | Hemorrhage, GU - Spermatic cord | Hemorrhage, GU - Stoma | Hemorrhage, GU - Testes | Hemorrhage, GU - Ureter | Aspiration | Atelectasis | Atrophy, skin | Atrophy, subcutaneous fat | Bone age (alteration in bone age) | Dental: teeth development | Dermal change lymphedema, phlebolymphedema | Distention/bloating, abdominal | Edema, larynx | Edema: head and neck | Hemorrhage, GI - Peritoneal cavity | Hemorrhage, GI - Stoma | Hemorrhage, GI - Upper GI NOS | Hemorrhage, GI - Varices (esophageal) | Hemorrhage, GI - Varices (rectal) | Hemorrhage, GU - Bladder | Hemorrhage, GU - Fallopian tube | Hemorrhage, GU - Kidney | Hemorrhage, GU - Ovary | Hemorrhage, GU - Prostate | Hemorrhage, GU - Urethra | Hemorrhage, GU - Uterus | Hemorrhage, GU - Vas deferens | Hemorrhage, pulmonary/upper respiratory - Bronchopulmonary NOS | Hemorrhage, pulmonary/upper respiratory - Bronchus | Infection with normal ANC or Grade 1 or 2 neutrophils - Nose | Infection with normal ANC or Grade 1 or 2 neutrophils - Oral cavity-gums (gingivitis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Pancreas | Infection with normal ANC or Grade 1 or 2 neutrophils - Paranasal | Infection with normal ANC or Grade 1 or 2 neutrophils - Pelvis NOS | Hemorrhage, pulmonary/upper respiratory - Stoma | Hemorrhage, pulmonary/upper respiratory - Trachea | Hemorrhoids | Hydrocephalus | Hypopigmentation | Infection with normal ANC or Grade 1 or 2 neutrophils - Appendix | Infection with normal ANC or Grade 1 or 2 neutrophils - Artery | Infection with normal ANC or Grade 1 or 2 neutrophils - Biliary tree | Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) | Infection with normal ANC or Grade 1 or 2 neutrophils - Bone (osteomyelitis) | Hypothermia | Incontinence, anal | Induration/fibrosis (skin and subcutaneous tissue) | Infection with normal ANC or Grade 1 or 2 neutrophils - Abdomen NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Anal/perianal | Edema: trunk/genital | Edema: viscera | Ejaculatory dysfunction | Encephalopathy | Enteritis (inflammation of the small bowel) | Hearing: patients with/without baseline audiogram and enrolled in a monitoring program | Hearing: patients without baseline audiogram and not enrolled in a monitoring program | Hematoma | Hemorrhage, GI - Biliary tree | Hemorrhage, GI - Anus | Infection with normal ANC or Grade 1 or 2 neutrophils - Prostate | Infection with normal ANC or Grade 1 or 2 neutrophils - Rectum | Infection with normal ANC or Grade 1 or 2 neutrophils - Salivary gland | Infection with normal ANC or Grade 1 or 2 neutrophils - Scrotum | Infection with normal ANC or Grade 1 or 2 neutrophils - Sinus | Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Small bowel NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Soft tissue NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Spinal cord (myelitis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Spleen | Fistula, GI - Salivary gland | Fistula, GI - Small bowel NOS | Fistula, GI - Stomach | Fistula, GU - Bladder | Fistula, GU - Genital tract-female | Infection with normal ANC or Grade 1 or 2 neutrophils - Mucosa | Infection with normal ANC or Grade 1 or 2 neutrophils - Muscle (infection myositis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Neck NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Nerve-cranial | Infection with normal ANC or Grade 1 or 2 neutrophils - Nerve-peripheral | Fistula, pulmonary/upper respiratory - Trachea | Flu-like syndrome | Fracture | Glomerular filtration rate | Growth velocity (reduction in growth velocity) | Infection with normal ANC or Grade 1 or 2 neutrophils - Penis | Infection with normal ANC or Grade 1 or 2 neutrophils - Peristomal | Infection with normal ANC or Grade 1 or 2 neutrophils - Peritoneal cavity | Infection with normal ANC or Grade 1 or 2 neutrophils - Pharynx | Infection with normal ANC or Grade 1 or 2 neutrophils - Pleura (empyema) | Hemorrhage, GI - Jejunum | Hemorrhage, GI - Liver | Hemorrhage, GI - Lower GI NOS | Hemorrhage, GI - Oral cavity | Hemorrhage, GI - Pancreas | Infection with normal ANC or Grade 1 or 2 neutrophils - Liver | Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia) | Infection with normal ANC or Grade 1 or 2 neutrophils - Mediastinum NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Meninges (meningitis) | Infection with normal ANC or Grade 1 or 2 neutrophils - Middle ear (otitis media) | Infection with normal ANC or Grade 1 or 2 neutrophils - Stomach | Infection with normal ANC or Grade 1 or 2 neutrophils - Trachea | Infection with normal ANC or Grade 1 or 2 neutrophils - Ungual (nails) | Infection with normal ANC or Grade 1 or 2 neutrophils - Upper aerodigestive NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Upper airway NOS | Infection with unknown ANC - Lung (pneumonia) | Infection with unknown ANC - Mediastinum NOS | Infection with unknown ANC - Meninges (meningitis) | Infection with unknown ANC - Middle ear (otitis media) | Infection with unknown ANC - Mucosa | Infection with unknown ANC - Muscle (infection myositis) | Infection with unknown ANC - Neck NOS | Infection with unknown ANC - Nerve-cranial | Infection with unknown ANC - Nerve-peripheral | Infection with unknown ANC - Nose | Intra-operative injury - Nasal cavity | Intra-operative injury - Nasopharynx | Intra-operative injury - Neck NOS | Intra-operative injury - Nose | Intra-operative injury - Oral | Intra-operative injury - Sinus | Intra-operative injury - Skin | Intra-operative injury - Small bowel NOS | Intra-operative injury - Soft tissue NOS | Intra-operative injury - Spinal cord | Infection with normal ANC or Grade 1 or 2 neutrophils - Ureter | Infection with normal ANC or Grade 1 or 2 neutrophils - Urethra | Infection with normal ANC or Grade 1 or 2 neutrophils - Urinary tract NOS | Infection with normal ANC or Grade 1 or 2 neutrophils - Uterus | Infection with normal ANC or Grade 1 or 2 neutrophils - Vagina | Infection with unknown ANC - Gallbladder (cholecystitis) | Infection with unknown ANC - Heart (endocarditis) | Infection with unknown ANC - Ileum | Infection with unknown ANC - Jejunum | Infection with unknown ANC - Joint | Intra-operative injury - Artery-extremity (lower) | Intra-operative injury - Artery-extremity (upper) | Intra-operative injury - Artery-hepatic | Intra-operative injury - Artery-major visceral artery | Intra-operative injury - Artery-pulmonary | Infection with normal ANC or Grade 1 or 2 neutrophils - Vein | Infection with normal ANC or Grade 1 or 2 neutrophils - Vulva | Infection with normal ANC or Grade 1 or 2 neutrophils - Wound | Infection with unknown ANC - Abdomen NOS | Infection with unknown ANC - Anal/perianal | Infection with unknown ANC - Brain (encephalitis, infectious) | Infection with unknown ANC - Brain + Spinal cord (encephalomyelitis) | Infection with unknown ANC - Bronchus | Infection with unknown ANC - Cecum | Infection with unknown ANC - Cervix | Infection with unknown ANC - Oral cavity-gums (gingivitis) | Infection with unknown ANC - Pancreas | Infection with unknown ANC - Paranasal | Infection with unknown ANC - Pelvis NOS | Infection with unknown ANC - Penis | Infection with unknown ANC - Urethra | Infection with unknown ANC - Urinary tract NOS | Infection with unknown ANC - Uterus | Infection with unknown ANC - Vagina | Infection with unknown ANC - Vein | Intra-operative injury - Sacral plexus | Intra-operative injury - Salivary duct | Intra-operative injury - Salivary gland | Intra-operative injury - Sciatic | Intra-operative injury - Scrotum | Intra-operative injury - Spleen | Intra-operative injury - Stoma (GI) | Intra-operative injury - Stomach | Intra-operative injury - Teeth | Intra-operative injury - Tendon | Intra-operative injury - Trachea | Intra-operative injury - Upper aerodigestive NOS | Intra-operative injury - Upper airway NOS | Intra-operative injury - Ureter | Intra-operative injury - Urethra | Infection with unknown ANC - Appendix | Infection with unknown ANC - Artery | Infection with unknown ANC - Biliary tree | Infection with unknown ANC - Bladder (urinary) | Infection with unknown ANC - Bone (osteomyelitis) | Infection with unknown ANC - Small bowel NOS | Infection with unknown ANC - Soft tissue NOS | Infection with unknown ANC - Spinal cord (myelitis) | Infection with unknown ANC - Spleen | Infection with unknown ANC - Stomach | Intra-operative injury - Cornea | Intra-operative injury - Cranial nerve or branch NOS | Intra-operative injury - Duodenum | Intra-operative injury - Esophagus | Intra-operative injury - Extremity-lower | Intra-operative injury - Gingiva | Intra-operative injury - Heart | Intra-operative injury - Ileum | Intra-operative injury - Inner ear | Intra-operative injury - Jejunum | Infection with unknown ANC - Colon | Infection with unknown ANC - Conjunctiva | Infection with unknown ANC - Cornea | Infection with unknown ANC - Dental-tooth | Infection with unknown ANC - Duodenum | Infection with unknown ANC - Peristomal | Infection with unknown ANC - Peritoneal cavity | Infection with unknown ANC - Pharynx | Infection with unknown ANC - Pleura (empyema) | Infection with unknown ANC - Prostate | Infection with unknown ANC - Vulva | Intra-operative injury - Abdomen NOS | Intra-operative injury - Adrenal gland | Intra-operative injury - Anal sphincter | Intra-operative injury - Anus | Intra-operative injury - Cartilage | Intra-operative injury - Cecum | Intra-operative injury - Cervix | Intra-operative injury - CN I (olfactory) | Intra-operative injury - CN II (optic) | Intra-operative injury - Joint | Intra-operative injury - Kidney | Intra-operative injury - Larynx | Intra-operative injury - Lens | Intra-operative injury - Ligament | Intra-operative injury - Lingual | Intra-operative injury - Lip/perioral area | Intra-operative injury - Liver | Intra-operative injury - Lung | Intra-operative injury - Lung thoracic | Intra-operative injury - Testis | Intra-operative injury - Thoracic duct | Intra-operative injury - Thoracodorsal | Intra-operative injury - Thyroid | Intra-operative injury - Tongue | Infection with unknown ANC - Esophagus | Infection with unknown ANC - External ear (otitis externa) | Infection with unknown ANC - Eye NOS | Infection with unknown ANC - Fallopian tube | Infection with unknown ANC - Foreign body (e.g., graft, implant, prosthesis, stent) | Intra-operative injury - Peripheral motor NOS | Intra-operative injury - Peripheral sensory NOS | Intra-operative injury - Peritoneal cavity | Intra-operative injury - Pharynx | Intra-operative injury - Pituitary | Infection with unknown ANC - Kidney | Infection with unknown ANC - Larynx | Infection with unknown ANC - Lens | Infection with unknown ANC - Lip/perioral | Infection with unknown ANC - Liver | Intra-operative injury - Mediastinum | Intra-operative injury - Meninges | Intra-operative injury - Middle ear | Intra-operative injury - Muscle | Intra-operative injury - Nails | Intra-operative injury - Urinary conduit | Intra-operative injury - Urinary tract NOS | Intra-operative injury - Uterus | Intra-operative injury - Vagina | Intra-operative injury - Vein-extremity (lower) | Infection with unknown ANC - Rectum | Infection with unknown ANC - Salivary gland | Infection with unknown ANC - Scrotum | Infection with unknown ANC - Sinus | Infection with unknown ANC - Skin (cellulitis) | Intra-operative injury - Extremity-upper | Intra-operative injury - Eye NOS | Intra-operative injury - Face NOS | Intra-operative injury - Fallopian tube | Intra-operative injury - Gallbladder | Intra-operative injury - Pleura | Intra-operative injury - Prostate | Intra-operative injury - Rectum | Intra-operative injury - Recurrent laryngeal | Intra-operative injury - Retina | Infection with unknown ANC - Trachea | Infection with unknown ANC - Ungual (nails) | Infection with unknown ANC - Upper aerodigestive NOS | Infection with unknown ANC - Upper airway NOS | Infection with unknown ANC - Ureter | Intra-operative injury - Appendix | Intra-operative injury - Artery NOS | Intra-operative injury - Artery-aorta | Intra-operative injury - Artery-carotid | Intra-operative injury - Artery-cerebral | Intra-operative injury - Biliary tree-common bile duct | Intra-operative injury - Biliary tree-common hepatic duct | Intra-operative injury - Biliary tree-left hepatic duct | Intra-operative injury - Biliary tree-right hepatic duct | Intra-operative injury - Bone | Intra-operative injury - Brachial plexus | Intra-operative injury - Brain | Intra-operative injury - Breast | Intra-operative injury - Bronchus | Intra-operative injury - CN III (oculomotor) | Intra-operative injury - CN IV (trochlear) | Intra-operative injury - CN IX (glossopharyngeal) motor pharynx | Intra-operative injury - CN IX (glossopharyngeal) sensory ear-pharynx-tongue | Intra-operative injury - CN V (trigeminal) motor | Intra-operative injury - CN V (trigeminal) sensory | Intra-operative injury - CN VI (abducens) | Intra-operative injury - CN VII (facial) motor-face | Intra-operative injury - CN VII (facial) sensory-taste | Intra-operative injury - CN VIII (vestibulocochlear) | Intra-operative injury - CN X (vagus) | Intra-operative injury - CN XI (spinal accessory) | Intra-operative injury - CN XII (hypoglossal) | Intra-operative injury - Colon | Intra-operative injury - Conjunctiva | Intra-operative injury - Oral cavity NOS | Intra-operative injury - Outer ear NOS | Intra-operative injury - Outer ear-pinna | Intra-operative injury - Ovary | Intra-operative injury - Pancreas | Intra-operative injury - Pancreatic duct | Intra-operative injury - Parathyroid | Intra-operative injury - Parotid gland | Intra-operative injury - Pelvis NOS | Intra-operative injury - Penis | Mucositis/stomatitis (clinical exam) - Larynx | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (clinical exam) - Rectum | Mucositis/stomatitis (clinical exam) - Small bowel | Mucositis/stomatitis (clinical exam) - Stomach | Mucositis/stomatitis (functional/symptomatic) - Pharynx | Mucositis/stomatitis (functional/symptomatic) - Rectum | Mucositis/stomatitis (functional/symptomatic) - Small bowel | Mucositis/stomatitis (functional/symptomatic) - Stomach | Mucositis/stomatitis (functional/symptomatic) - Trachea | Obstruction, GU - Bladder | Obstruction, GU - Fallopian tube | Obstruction, GU - Prostate | Obstruction, GU - Spermatic cord | Obstruction, GU - Stoma | Pain - Oral-gums | Pain - Ovulatory | Pain - Pain NOS | Pain - Penis | Pain - Pericardium | Pain - Scrotum | Pain - Sinus | Pain - Skin | Pain - Stomach | Pain - Testicle | Muscle weakness, generalized or specific area (not due to neuropathy) - Extraocular | Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-lower | Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-upper | Muscle weakness, generalized or specific area (not due to neuropathy) - Facial | Muscle weakness, generalized or specific area (not due to neuropathy) - Left-sided | Opportunistic infection associated with >=Grade 2 lymphopenia | Optic disc edema | Orgasmic dysfunction | Osteoporosis | Pain - Anus | Pain - Perineum | Pain - Peritoneum | Pain - Phantom (pain associated with missing limb) | Pain - Prostate | Pain - Scalp | Necrosis, GI - Jejunum | Necrosis, GI - Oral | Necrosis, GI - Pancreas | Necrosis, GI - Peritoneal cavity | Necrosis, GI - Pharynx | Obstruction, GI - Colon | Obstruction, GI - Duodenum | Obstruction, GI - Esophagus | Obstruction, GI - Gallbladder | Obstruction, GI - Ileum | Pain - Face | Pain - Gallbladder | Pain - Intestine | Pain - Kidney | Pain - Larynx | Intra-operative injury - Vein-extremity (upper) | Intra-operative injury - Vein-hepatic | Intra-operative injury - Vein-inferior vena cava | Intra-operative injury - Vein-jugular | Intra-operative injury - Vein-major visceral vein | Obstruction, GI - Jejunum | Obstruction, GI - Rectum | Obstruction, GI - Small bowel NOS | Obstruction, GI - Stoma | Obstruction, GI - Stomach | Intra-operative injury - Vein-portal vein | Intra-operative injury - Vein-pulmonary | Intra-operative injury - Vein-superior vena cava | Intra-operative injury - Vulva | Iron overload | Leak (including anastomotic), GI - Large bowel | Leak (including anastomotic), GI - Leak NOS | Leak (including anastomotic), GI - Pancreas | Leak (including anastomotic), GI - Pharynx | Leak (including anastomotic), GI - Rectum | Leak (including anastomotic), GI - Small bowel | Leak (including anastomotic), GI - Stoma | Leak (including anastomotic), GI - Stomach | Local complication - device/prosthesis-related | Lumbar spine-range of motion | Lymphedema-related fibrosis | Lymphocele | Malabsorption | Mental status | Mood alteration - agitation | Mucositis/stomatitis (clinical exam) - Anus | Mucositis/stomatitis (clinical exam) - Esophagus | Mucositis/stomatitis (clinical exam) - Large bowel | Myelitis | Myelodysplasia | Nasal cavity/paranasal sinus reactions | Necrosis, GI - Anus | Necrosis, GI - Colon/cecum/appendix | Necrosis, GI - Rectum | Necrosis, GI - Small bowel NOS | Necrosis, GI - Stoma | Necrosis, GI - Stomach | Neuroendocrine: ACTH deficiency | Pain - Lip | Pain - Lymph node | Pain - Middle ear | Pain - Neck | Pain - Oral cavity | Joint-effusion | Joint-function | Laryngeal nerve dysfunction | Leak (including anastomotic), GI - Biliary tree | Leak (including anastomotic), GI - Esophagus | Mucositis/stomatitis (clinical exam) - Trachea | Mucositis/stomatitis (functional/symptomatic) - Anus | Mucositis/stomatitis (functional/symptomatic) - Large bowel | Mucositis/stomatitis (functional/symptomatic) - Larynx | Mucositis/stomatitis (functional/symptomatic) - Oral cavity | Obstruction, GU - Testes | Obstruction, GU - Urethra | Obstruction, GU - Uterus | Obstruction, GU - Vagina | Obstruction, GU - Vas deferens | Leak (including anastomotic), GU - Kidney | Leak (including anastomotic), GU - Spermatic cord | Leak (including anastomotic), GU - Stoma | Leak (including anastomotic), GU - Ureter | Leak (including anastomotic), GU - Urethra | Muscle weakness, generalized or specific area (not due to neuropathy) - Ocular | Muscle weakness, generalized or specific area (not due to neuropathy) - Pelvic | Muscle weakness, generalized or specific area (not due to neuropathy) - Right-sided | Muscle weakness, generalized or specific area (not due to neuropathy) - Trunk | Muscular/skeletal hypoplasia | Neuroendocrine: gonadotropin secretion abnormality | Neuroendocrine: growth hormone secretion abnormality | Neuroendocrine: prolactin hormone secretion abnormality | Neuropathy: cranial - CN III Pupil, upper eyelid, extra ocular movements | Neuropathy: cranial - CN IV Downward, inward movement of eye | Neuropathy: cranial - CN V Motor-jaw muscles; Sensory-facial | Neuropathy: cranial - CN VI Lateral deviation of eye | Neuropathy: cranial - CN VII Motor-face; Sensory-taste | Neuropathy: cranial - CN VIII Hearing and balance | Neuropathy: cranial - CN X Motor-palate; pharynx, larynx | Neuropathy: cranial - CN XI Motor-sternomastoid and trapezius | Neuropathy: cranial - CN XII Motor-tongue | Obesity | Obstruction, GI - Cecum | Leak (including anastomotic), GU - Uterus | Leak (including anastomotic), GU - Vagina | Leak (including anastomotic), GU - Vas deferens | Leak, cerebrospinal fluid (CSF) | Left ventricular diastolic dysfunction | Necrosis, GI - Duodenum | Necrosis, GI - Esophagus | Necrosis, GI - Gallbladder | Necrosis, GI - Hepatic | Necrosis, GI - Ileum | Pain - Back | Pain - Bladder | Pain - Breast | Pain - Buttock | Pain - Cardiac/heart | Pain - Chest wall | Pain - Dental/teeth/peridontal | Pain - Esophagus | Pain - Extremity-limb | Pain - Eye | Obstruction/stenosis of airway - Bronchus | Obstruction/stenosis of airway - Larynx | Obstruction/stenosis of airway - Pharynx | Obstruction/stenosis of airway - Trachea | Odor (patient odor) | Valvular heart disease | Ventricular arrhythmia - Idioventricular rhythm | Ventricular arrhythmia - PVCs | Ventricular arrhythmia - Torsade de pointes | Ventricular arrhythmia - Trigeminy | Vessel injury-vein - Extremity-upper | Vessel injury-vein - IVC | Vessel injury-vein - Jugular | Vessel injury-vein - Other NOS | Vessel injury-vein - SVC | Ventricular arrhythmia - Ventricular fibrillation | Ventricular arrhythmia - Ventricular flutter | Ventricular arrhythmia - Ventricular tachycardia | Vessel injury-artery - Aorta | Vessel injury-artery - Carotid | Vessel injury-vein - Viscera | Viral hepatitis | Vital capacity | Vitreous hemorrhage | Pain - Throat/pharynx/larynx | Pain - Vagina | Pancreas, exocrine enzyme deficiency | Pancreatic endocrine: glucose intolerance | Parathyroid function, low (hypoparathyroidism) | Perforation, GI - Appendix | Perforation, GI - Biliary tree | Perforation, GI - Cecum | Perforation, GI - Colon | Perforation, GI - Duodenum | Perforation, GI - Esophagus | Perforation, GI - Gallbladder | Perforation, GI - Ileum | Perforation, GI - Jejunum | Perforation, GI - Rectum | Skin breakdown/decubitus ulcer | Soft tissue necrosis - Abdomen | Soft tissue necrosis - Extremity-lower | Soft tissue necrosis - Extremity-upper | Soft tissue necrosis - Head | Stricture/stenosis (including anastomotic), GU - Ureter | Stricture/stenosis (including anastomotic), GU - Urethra | Stricture/stenosis (including anastomotic), GU - Uterus | Stricture/stenosis (including anastomotic), GU - Vagina | Stricture/stenosis (including anastomotic), GU - Vas deferens | Perforation, GI - Small bowel NOS | Perforation, GI - Stomach | Perforation, GU - Bladder | Perforation, GU - Fallopian tube | Perforation, GU - Kidney | Stricture/stenosis (including anastomotic), GI - Rectum | Stricture/stenosis (including anastomotic), GI - Small bowel NOS | Stricture/stenosis (including anastomotic), GI - Stoma | Stricture/stenosis (including anastomotic), GI - Stomach | Perforation, GU - Ovary | Perforation, GU - Prostate | Perforation, GU - Spermatic cord | Perforation, GU - Stoma | Perforation, GU - Testes | Soft tissue necrosis - Neck | Soft tissue necrosis - Pelvic | Soft tissue necrosis - Thorax | Splenic function | Striae | Stricture/stenosis (including anastomotic), GI - Esophagus | Stricture/stenosis (including anastomotic), GI - Ileum | Stricture/stenosis (including anastomotic), GI - Jejunum | Stricture/stenosis (including anastomotic), GI - Pancreas/pancreatic duct | Stricture/stenosis (including anastomotic), GI - Pharynx | Perforation, GU - Ureter | Perforation, GU - Urethra | Perforation, GU - Uterus | Perforation, GU - Vagina | Perforation, GU - Vas deferens | Supraventricular and nodal arrhythmia - Atrial flutter | Supraventricular and nodal arrhythmia - Atrial tachycardia/paroxysmal atrial tachycardia | Supraventricular and nodal arrhythmia - Nodal/junctional | Supraventricular and nodal arrhythmia - Sinus arrhythmia | Supraventricular and nodal arrhythmia - Supraventricular tachycardia | Telangiectasia | Thrombosis/embolism (vascular access-related) | Thyroid function, high (hyperthyroidism, thyrotoxicosis) | Tinnitus | Pericarditis | Phlebolymphatic cording | Phrenic nerve dysfunction | Prolapse of stoma, GI | Prolapse of stoma, GU | Prolonged chest tube drainage or air leak after pulmonary resection | Prolonged intubation after pulmonary resection (>24 hrs after surgery) | Proptosis/enophthalmos | Puberty (delayed) | Puberty (precocious) | Pulmonary hypertension | Rash: acne/acneiform | Restrictive cardiomyopathy | Retinal detachment | Retinoic acid syndrome | Retinopathy | Right ventricular dysfunction (cor pulmonale) | Scleral necrosis/melt | Seroma | Short stature | Stricture/stenosis (including anastomotic), GI - Anus | Stricture/stenosis (including anastomotic), GI - Biliary tree | Stricture/stenosis (including anastomotic), GI - Cecum | Stricture/stenosis (including anastomotic), GI - Colon | Stricture/stenosis (including anastomotic), GI - Duodenum | Stricture/stenosis (including anastomotic), GU - Fallopian tube | Stricture/stenosis (including anastomotic), GU - Prostate | Stricture/stenosis (including anastomotic), GU - Spermatic cord | Stricture/stenosis (including anastomotic), GU - Stoma | Stricture/stenosis (including anastomotic), GU - Testes | Trismus (difficulty, restriction or pain when opening mouth) | Ulcer, GI - Anus | Ulcer, GI - Cecum | Ulcer, GI - Colon | Ulcer, GI - Esophagus | Vessel injury-artery - Extremity-lower | Vessel injury-artery - Extremity-upper | Vessel injury-artery - Other NOS | Vessel injury-artery - Visceral | Vessel injury-vein - Extremity-lower | Ulcer, GI - Ileum | Ulcer, GI - Jejunum | Ulcer, GI - Rectum | Ulcer, GI - Small bowel NOS | Ulcer, GI - Stoma | Ulceration | Uveitis | Vaginal discharge (non-infectious) | Vaginal mucositis | Vaginal stenosis/length | Pulmonary fibrosis (radiographic changes) | Rash: dermatitis associated with radiation - Radiation | Pain - Rectum | Rigors/chills | AST, SGOT (serum glutamic oxaloacetic transaminase) | ALT, SGPT (serum glutamic pyruvic transaminase) | Neuroendocrine: ADH secretion abnormality (e.g., SIADH or low ADH) | Salivary gland changes/saliva | Seizure | Neuropathy: cranial - CN I Smell | Supraventricular and nodal arrhythmia - Sinus bradycardia | Supraventricular and nodal arrhythmia - Sinus tachycardia | Mucositis/stomatitis (clinical exam) - Pharynx | Pain - Neuralgia/peripheral nerve | Rash: dermatitis associated with radiation - Chemoradiation | Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura or hemolytic uremic syndrome) | Urine color change | Supraventricular and nodal arrhythmia - Supraventricular arrhythmia NOS | Ventricular arrhythmia - Bigeminy | Ventricular arrhythmia - Ventricular arrhythmia NOS | Supraventricular and nodal arrhythmia - Atrial fibrillation | Intra-operative injury - Biliary tree NOS | Cheilitis | Conduction abnormality/Atrioventricular heart block - AV block-Second degree Mobitz Type I (Wenckebach) | Febrile neutropenia | Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10^9/L) | Fistula, GI - Pharynx | Hemolysis (e.g., immune hemolytic anemia, drug related hemolysis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Abdomen NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Appendix | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Artery | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Biliary tree | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Bronchus | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Cecum | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Cervix | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Colon | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Conjunctiva | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Cornea | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Dental-tooth | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Duodenum | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Esophagus | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Eye NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Ileum | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Jejunum | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Joint | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Kidney | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Larynx | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lens | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lip/perioral | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Liver | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lymphatic | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Mucosa | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Neck NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Nose | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Pancreas | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Paranasal | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Pelvis NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Penis | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Peristomal | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Pharynx | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Prostate | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Rectum | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Scrotum | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Sinus | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Spleen | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Stomach | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Trachea | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Ureter | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Urethra | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Uterus | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Vagina | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Vein | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Vulva | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Wound | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Bladder (urinary) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Catheter-related | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Fallopian tube | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lung (pneumonia) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Mediastinum NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Nerve-cranial | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Nerve-peripheral | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Peritoneal cavity | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Pleura (empyema) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Salivary gland | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Skin (cellulitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Small bowel NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Soft tissue NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Ungual (nails) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Upper airway NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Urinary tract NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Bone (osteomyelitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Brain (encephalitis, infectious) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Brain + Spinal cord (encephalomyelitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - External ear (otitis externa) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Foreign body (e.g., graft, implant, prosthesis, stent) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Gallbladder (cholecystitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Heart (endocarditis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Meninges (meningitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Middle ear (otitis media) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Muscle (infection myositis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Oral cavity-gums (gingivitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Spinal cord (myelitis) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Upper aerodigestive NOS | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Anal/perianal | Infection with normal ANC or Grade 1 or 2 neutrophils - Foreign body (e.g., graft, implant, prosthesis, stent) | Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Blood | Infection with normal ANC or Grade 1 or 2 neutrophils - Blood | Infection with unknown ANC - Blood | Stricture/stenosis (including anastomotic), GU - Bladder | Supraventricular and nodal arrhythmia - Supraventricular extrasystoles (premature atrial contractions; premature nodal/junctional contractions) | Leak (including anastomotic), GU - Bladder | Leak (including anastomotic), GU - Fallopian tube | Neuropathy: cranial - CN IX Motor-pharynx; Sensory-ear, pharynx, tongue | Cholesterol, serum-high (hypercholesteremia) | Cardiac ischemia/infarction | Urinary electrolyte wasting (e.g., Fanconi's syndrome, renal tubular acidosis)
Common Terminology Criteria for Adverse Events2201188v1Adverse Event GradeCommon Toxicity Criteria Adverse Event Reporting Gradea numeric code to describe the severity of an adverse event using the protocol-specified version defined for the Common Terminology Criteria for Adverse Events.5 | 0 | 1 | 2 | 4 | 3
Complete Remission2760856v1Was a cytogenetic complete remission achieved?Cytogenetic Analysis Complete Remission Confirmed IndicatorThe indicator that describes whether or not a cytogenetic complete remission was confirmed.Not Done | Unknown | Yes | No | Not Applicable
Consent Form656v4Date Informed Consent SignedInformed Consent Form Signed DateThe date on which the patient/participant/legal representative agreed to participation in a protocol, treatment, or other activity by signing an informed consent document. 
Contrast Agent3915791v1Confirmed patient with no allergy to contrast agent prior to administrationIV Contrast No Allergy Confirmation Prior Administer Yes No IndicatorA response of Yes or No to indicate that there was confirmation that the patient has no known allergies to contrast agent prior to injection of contrast.No | Yes
Course2732184v1CourseProtocol Course Number CountNumeric value assigned to identify a period of protocol activity; a course is comprised of multiple cycles of protocol-dictated activities. [Manually-curated] 
Cutaneous Melanoma3357639v1Clinical N StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for melanoma of the skin based on evidence obtained from clinical assessment parameters determined prior to treatment.N3 | N2c | N1 | N0 | NX
Cutaneous Melanoma3357641v1Pathologic N StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for melanoma of the skin based on evidence obtained from pathologic examination through completion of definitive surgery.N2b | N2a | N2 | N1b | N1a | N0 | N1 | N2c | NX | N3
Cutaneous Melanoma3357643v1Disease StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for melanoma of the skin.Stage unknown | IV | III | IIC | IIB | IIA | IB | IA | 0 | IIIC | IIIB | IIIA
Cutaneous Melanoma3357638v1Pathologic T StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary melanoma of the skin based on evidence obtained from pathologic examination through completion of definitive surgery.T1b | T1a | T1 | T0 | TX | T2 | T2a | T2b | T3 | T3a | T3b | T4 | T4a | T4b | Tis
Cutaneous Melanoma3357640v1Clinical M StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for melanoma of the skin based on evidence obtained from clinical assessment parameters determined prior to treatment.M1c | M1b | M1a | M0
Cutaneous Melanoma3357637v1Clinical T StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary melanoma of the skin based on evidence obtained from clinical assessment parameters determined prior to treatment.T1b | T1a | T1 | T0 | TX | T2 | T2a | T2b | T3 | T3a | T3b | T4 | T4a | T4b | Tis
Cutaneous Melanoma3357642v1Pathologic M StageCutaneous Melanoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for melanoma of the skin based on evidence obtained from pathologic examination through completion of definitive surgery.M1a | M1b | M1c
Date2193134v2DateDateA value that represents the time or period to which any event belongs. 
Date and Time2193274v2Date/TimeDateTimeThe value that represents the time or period to which any event belongs and the measured or measurable period during which an action, process, or condition exists or continues. 
Diagnostic, Therapeutic, or Research Equipment3914995v1Has the equipment used for this study been qualified by sponsor?Equipment Protocol Requirement Yes No Not Applicable IndicatorA response of yes/no/not applicable to indicate success in satisfying the sponsor's protocol requirement for an approved diagnostic, therapeutic, and/or research equipment.No | Yes | Not Applicable
Diagnostic, Therapeutic, or Research Equipment3915155v1Equipment Qualification DateEquipment Qualification Event DateThe date on which the diagnostic, therapeutic, and/or research equipment was approved by the sponsor as having met qualifications for study participation. 
Diagnostic, Therapeutic, or Research Equipment2413274v2.1Manufacturer's Model NameEquipment Manufacturer Model Name TextThe words that describe the style or design of an entity"s finished goods used to perform a diagnostic, therapeutic or research activity. 
Diagnostic, Therapeutic, or Research Equipment3914992v1Daily equipment QC run on date of study?Equipment Completed Daily Quality Control Yes No IndicatorA response of Yes or No to indicate if the daily quality assurance techniques and activities were performed on the diagnostic, therapeutic, and/or research equipment.No | Yes
Diagnostic, Therapeutic, or Research Equipment3902074v1Equipment IDEquipment Property IdentifierThe identifier of an approved diagnostic, therapeutic, and/or research equipment. 
Diagnostic, Therapeutic, or Research Equipment2681980v1.2Device Serial NumberEquipment Serial Number TextOne or more characters used to identify a manufacturer-provided serial number of an automated device that created the observations used for cancer-related research, diagnosis or therapy. 
Diagnostic, Therapeutic, or Research Equipment2866141v1Manufacturer NameEquipment Manufacturer Name TextThe words that describe an entity that produces finished goods used to perform a diagnostic, therapeutic or research activity. 
Diagnostic, Therapeutic, or Research Equipment2182481v1.2Station NameEquipment Station Name TextThe words that describe the location of supplies or apparatus used for research, diagnosis or therapy. 
Diagnostic, Therapeutic, or Research Equipment3914996v1Reason non-qualified equipment was used for this studyEquipment Protocol Requirement Not Qualified ReasonAn explanation why an approved diagnostic, therapeutic, and/or research equipment did not comply with the sponsor's requirements. 
Diagnostic, Therapeutic, or Research Equipment2413278v1.2Software Version(s)Equipment Software Version TextOne or more characters which describe a specific form or variant of data and/or instructions stored in the computer. 
Differentiated Thyroid Gland Carcinoma3461831v1Papillary of Follicular Disease Stage, 45 Years and OlderPapillary or Follicular (Differentiated) Thyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 45 Years and Older Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for papillary or follicular cancer (differentiated) in cases 45 years of age or older.Stage unknown | IVC | IVB | IVA | III | II | I
Differentiated Thyroid Gland Carcinoma3461830v1Papillary of Follicular Disease Stage, Under 45 YearsPapillary or Follicular (Differentiated) Thyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Under 45 Years Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for papillary or follicular cancer (differentiated) in cases under 45 years of age.Stage unknown | II | I
Digestive System Neuroendocrine Neoplasm4986350v1Pathologic N StageDuodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Digestive System Neuroendocrine Neoplasm4986325v1Clinical M StageDuodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Digestive System Neuroendocrine Neoplasm4986324v1Clinical N StageDuodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Digestive System Neuroendocrine Neoplasm4986326v1Pathologic T StageDuodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | TX
Digestive System Neuroendocrine Neoplasm4986323v1Clinical T StageDuodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | TX
Digestive System Neuroendocrine Neoplasm4986351v1Pathologic M StageDuodenum/Ampulla/Jejunum/Ileum Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the duodenum/ampulla/jejunum/ileum neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Disease or Disorder2190264v1Is gross disease unifocal or multifocal?Gross Disease Foci Statusthe focal status of gross disease.Unknown | Unifocal | Multifocal
Distance3123079v1Surgical margin distance (as determined by surgeon)Surgical Margin Distance Surgeon MeasurementThe numerical distance from the closest point of the lesion to the closest point of the surgical margin, as determined by surgeon. 
Dose2182728v2DoseAgent DoseThe amount that represents the dose of the agent. 
Eligibility Determination2960879v1Eligibility Determined DateEligibility Determination DateThe date on which the eligibility status was determined. 
Eligibility Determination2960890v1Reason patient not able to participate in trialPatient Trial Screening Ineligibility ReasonText term to signify the reason a patient is determined to not be a candidate or unable to participate in a clinical trialOther, specify | Insurance/financial issues | Other health issues | Logistical and/or transportation issues | Prior problems with protocol compliance | Did not meet Eligibility Criteria | Participant Decision | Investigator Decision
Eligibility Waiver2003855v3Was a waiver granted?Waiver IndicatorA yes/no/NA indicator to denote if a subject's enrollment/eligibility requirements were waived for a sponsor-approved reason.No | Yes | N/A
Eligibility Waiver2003389v3Waiver IDWaiver NumberThe numeric identifier for a sponosor-granted waiver. Not applicable for NCI sponsored studies. 
Eligibility Waiver2960875v1Reason for waiverEligibility Waiver Reason TextThe text that describes the reason why a participant who is not formally eligible is admitted to a study. 
Emission scan3916053v1Minutes post-injectionEmission Scan Post Radioactivity Acquisition Duration Minute NumberThe length or duration in minutes of the emission scan following the injection of radiotracer. 
Emission scan3916052v1Minutes post injection stop timeEmission Scan Post Radioactivity Stop TimeClock time in minutes when the emission scan ended following the injection of radiotracer. 
Emission scan3380276v1Emission scan start timeEmission Scan Start TimeThe emission scan start time recorded in the 24 hour format. Precision can be truncated by omitting the seconds or both the seconds and minutes (23:59 or 23). 
Emission scan3380277v1Emission scan stop timeEmission Scan Stop TimeThe emission scan start time recorded in the 24 hour format. Precision can be truncated by omitting the seconds or both the seconds and minutes (23:59 or 23). 
Emission scan3916058v1CT or MR Scan obtained with PetPET Emission Scan with CT or MRI Yes No Unknown IndicatorA response of yes, no, or unknown to indicate if a contrast-enhanced CT or MRI was obtained as part of the PET emission scan.No | Yes | Unknown
Emission scan2718366v1Emission acquisition mode:Emission Scan Acquisition Mode TypeA subdivision of a particular functioning condition of emitted or discharge from a sensing device used in the acquisition of data or an image.2 | 1 | Time of Flight
Emission scan3916051v1Minutes post injection start timeEmission Scan Post Radioactivity Start TimeClock time in minutes when the emission scan started following the injection of radiotracer. 
Endometrial Neoplasm3108377v2FIGO StageEndometrial Carcinoma FIGO 2009 StageThe extent of endometrial cancer in the body, based on staging criteria from the Federation of Gynecology and Obstetrics (FIGO).Stage IVB | Stage IVA | Stage IV | Stage IIIC2 | Stage IIIC1 | Stage IIIB | Stage IIIA | Stage III | Stage II | Stage IB | Stage IA | Stage I
Ethnic Group2200284v2CDC Ethnicity CodeCenters for Disease Control and Prevention Ethnicity Unique Identifier CodesThe unique identifier for reporting information about ethnicity based on the Centers for Disease Control and Prevention (CDC) categories. 
Ethnic Group2192217v2EthnicityEthnic Group Category TextThe text for reporting information about ethnicity based on the Office of Management and Budget (OMB) categories.Not Hispanic or Latino | Hispanic or Latino | Unknown | Not reported
Ethnic Group2192221v2Ethnicity, otherOther Ethnic Group Category TextThe text that describes an ethnic group not included in the Office of Management and Budget (OMB) list for reporting ethnicity data. 
Evaluation2004170v3Evaluation DateEvaluation DateThe date of the evaluation, procedure or visit that yielded data. 
Event2423305v1Description of a type of EventEvent Description TypeThe term that describes something that happens at a given place and time.Surgical Procedure | Observation | Encounter due to therapy | Administered substance | Admission | Discharge | Transfer | Order | Start | Stop | End | Result | Questionnaire completed | Consultation | Childhood | Diagnosis | Remission | Death | Progression | Randomization | Procedure | Diagnostic Imaging | Registration | Birth
Event2423385v1Date/Time of an eventEvent DateTimeThe particular year, month, day and/or time of a significant occurrence or happening. An expression of both date and time that the event has happened or will happen. [Explanatory comment: The preferred exchange format for DateTime is YYYYMMDDhhmmss.uuuu[+|-]ZZzz where YYYY is a Year of the Gregorian Calendar and may contain the integers 1 or 2 in the first position and the integers 0 to 9 in the remaining three positions, mm is a Month of the Gregorian Calendar represented by the values 00 to 12 beginning with January as 01, DD is a Day represented by the values 00 to 31, hh is a Hour with numbers between 00 and 23 (00 being midnight and 12 being noon), mm is a Minute with numbers between 00 and 59, ss is Seconds with numbers between 00 and 59, uuuu is optional Fractional Seconds with integers (0 to 9) in any position, and [+|-]ZZzz=optional difference in hours (ZZ - integers +14 to -13) and minutes (zz-values 00 to 59) from Coordinated Universal Time (UTC). A Full DateTime would contain all the elements, YYYYMMDDhhmmss. Partial DateTime may be filled from the left, e.g., YYYY, YYYYMM, YYYYMMDD, YYYYMMDDhh, YYYYMMDDhhmm, YYYYMMDDhhmmss, etc. This business rule for reporting Partial DateTime is in agreement with the HL7 guidelines for exchange of DateTime information. The display format for DateTime information is determined by programmatic requirements.] 
Excision3122572v1Resection typeSurgical Resection Procedure TypeThe name that describes the surgical resection procedure performed on an individual.Subtotal | Other | Optimal debulking | Gross total | SMV/PV patch | Extensive Subtotal | Suboptimal debulking | Suboptimal | Minor | Partial debulking | Segmental
Excision3122696v1Resection type other specifySurgical Resection Procedure Other Specify TextThe free-text field used to describe a surgical resection procedure that is different from existing. 
Family Member2690165v2Family Member RelationshipFamily Member Relationship TypeThe subgroup that describes the state of connectedness between members of the unit of society organized around kinship ties.Granddaughter | Grandson | Mother | Half Sister | Half Brother | Father | Refused | Don't Know | Grandparent | Parent | Child | Uncle | Nephew | Grand Nephew | Paternal Uncle | Maternal Grandparent | Paternal Grandparent | Aunt | Niece | Domestic Partner | Ward | Paternal Great Grandparent | Half Sibling | Grandfather | Grandchild | Spouse | Son-in-law | Brother-in-law | Daughter-in-law | Sister-in-law | Cousin | First Cousin | First Cousin Once Removed | Natural Son | Father-in-law | Mother-in-law | Maternal Great Grandparent | Paternal Aunt | Maternal Uncle | Maternal Aunt | Maternal Grandmother | Paternal Grandmother | Maternal Grandfather | Paternal Grandfather | Grand Niece | Natural Daughter | Adoptive Sister | Adoptive Father | Adoptive Mother | Adoptive Brother | Adopted Son | Adopted Daughter | Maternal Half Sister | Maternal Half Brother | Maternal Great Uncle | Maternal Great Aunt | Maternal First Cousin Once Removed | Maternal First Cousin | Legal Guardian | Great Grandchild | Grandmother | Full Sister | Full Brother | Foster Son | Foster Sister | Foster Mother | Foster Father | Foster Daughter | Foster Brother | Natural Grandparent | Natural Grandmother | Natural Grandfather | Natural Grandchild | Natural Father | Natural Child | Natural Brother | Stepson | Stepsister | Stepmother | Stepfather | Stepdaughter | Stepbrother | Natural Sister | Natural Sibling | Natural Parent | Natural Mother | Sibling | Paternal First Cousin Once Removed | Paternal First Cousin | Paternal Great Aunt | Paternal Half Brother | Paternal Half Sister | Paternal Great Uncle | Husband | Wife | Identical Twin Sister | Identical Twin Brother | Identical Twin Sibling | Fraternal Twin Sibling | Fraternal Twin Sister | Fraternal Twin Brother | Twin Sibling | Step Child | Step Sibling | Maternal Half Sibling | Paternal Half Sibling | Female Cousin | Male Cousin | Sister | Brother | Other | None | Daughter | Son
Form64166v3Date Form AmendedForm Amended Complete Datethe date the data on the form was last changed or revised. 
Form3437657v1UseConcomitant Medication Form Data Collection Use ReasonText explanation of the use of a concomitant medication data collection form based on intended application to a particular portion of therapy or more widely.Cumulative at end of therapy | Specific therapy cycle | During each protocol treatment administration
Gastric Neuroendocrine Neoplasm4986315v1Pathologic M StageStomach Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the gastric neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Gastric Neuroendocrine Neoplasm4986312v1Pathologic T StageStomach Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary gastric neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | Tis | TX
Gastric Neuroendocrine Neoplasm4986314v1Pathologic N StageStomach Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the gastric neuroendocrine tumor based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Gastric Neuroendocrine Neoplasm4986298v1Clinical N StageStomach Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the gastric neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Gastric Neuroendocrine Neoplasm4986311v1Clinical M StageStomach Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the gastric neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Gastric Neuroendocrine Tumor4986297v1Clinical T StageStomach Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary gastric neuroendocrine tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | Tis | TX
Gastrointestinal Stromal Tumor4983629v1Disease Stage - Gastric GISTGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Gastric GIST Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for gastric GIST, also to be used for omentum.IIIB | IB | IA | II | IIIA | IV | Stage unknown
Gastrointestinal Stromal Tumor4983626v1Pathologic N StageGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the gastrointestinal stromal tumor based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1
Gastrointestinal Stromal Tumor4983622v1Clinical T StageGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary gastrointestinal stromal tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | TX
Gastrointestinal Stromal Tumor4983625v1Pathologic T StageGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary gastrointestinal stromal tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | TX
Gastrointestinal Stromal Tumor4983624v1Clinical M StageGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the gastrointestinal stromal tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Gastrointestinal Stromal Tumor4983623v1Clinical N StageGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the gastrointestinal stromal tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1
Gastrointestinal Stromal Tumor4983688v1Disease Stage - Small Intestinal GISTGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Small Intestine Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for small intestine GIST, also to be used for esophagus, colorectal, mesentery, and peritoneum.I | II | IIIA | IIIB | IV | Stage unknown
Gastrointestinal Stromal Tumor4983627v1Pathologic M StageGastrointestinal Stromal Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the gastrointestinal stromal tumor based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Gene2322244v1GeneBank Accession NumberGene Genbank_Accession_Number_Property Genomic IdentifierA functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._Indicates the accession number for a Gene within the GenBank database.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier provided by GenBank, for a sequence record. [Explanatory comment: An accession number applies to the complete record and is usually a combination of a letter(s) and numbers, such as a single letter followed by five digits (e.g., U12345) or two letters followed by six digits (e.g., AF123456). Some accessions might be longer, depending on the type of sequence record] 
Gene2322247v1UniGene IdentifierGene UniGene Genomic IdentifierA functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._UniGene is an experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster contains sequences that represent a unique gene, as well as related information such as the tissue:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifiers for a gene cluster assigned by UniGene. [Explanatory comment: The Cluster IDs begin with the species identifier (e.g., Hs) followed by a period and then the cluster ID number. The cluster id is usually, but not always, stable from build to build. This definition has been reviewed by David Wheeler, PhD of the NCBI.] 
Gene2322243v1Gene EnsEMBL IdentifierGene Ensembl Genomic IdentifierA functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust. The Ensembl Genome Brow:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier assigned to a gene by EnsEMBL. It is used to uniquely identify a gene in the EnsEMBL system. [Explanatory comment: The format is ENSGxxxxxxxxxxx for humans. The one for mouse is ENSMUSGxxxxxxxxxxx. So the general format is ENS Species (except human) G ? xxxxxxxxxxx. There are always 11 digits in this identifier. There are some species that don't follow these rules. For instance, species such as Drosophila or Tetraodon were not annotated by Ensembl follow a different convention. This definition has been reviewed by Xose M. Fernandez and Bert Overduin representing the Ensembl Helpdesk.] 
Gene2322245v1GeneBank Nucleotide Sequence IdentifierGene Versioned Genbank Accession Number Genomic IdentifierA functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._control number:A Genbank accession number with an explicit version.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._A nucleotide sequence identification number that represents a single, specific sequence in the GenBank database. [Explanatory comment: This identification number uses the accession.version format implemented by GenBank/EMBL/DDBJ in February 1999. (The unique identifier for a sequence record. An accession number applies to the complete record and is usually a combination of a letter(s) and numbers, such as a single letter followed by five digits (e.g., U12345) or two letters followed by six digits (e.g., AF123456). Some accessions might be longer, depending on the type of sequence record.) If there is any change to the sequence data (even a single base), the version number will be increased, e.g., U12345.1 &#8594; U12345.2, but the accession portion will remain stable. The accession.version system of sequence identifiers runs parallel to the GI number system, i.e., when any change is made to a sequence, it receives a new GI number AND an increase to its version number. Whenever an individual searches an NCBI sequence database, only the most recent version of a record is retrieved. 
Gene2322246v1Entrez Gene IdentifierGene Entrez Gene Genomic IdentifierA functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule)._Entrez Gene is NCBI's database for gene-specific information. It focuses on the genomes that have been completely sequenced, that have an active research community to contribute gene-specific information, or that are scheduled for intense sequence analysi:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier assigned to a gene by the National Center for Biotechnology Information (NCBI). [Explanatory comment: The identifier that is assigned (GeneID) is an integer, and is species specific. In other words, the integer assigned to dystrophin in human is different from that in any other species. For genomes that had been represented in LocusLink, the GeneID is the same as the LocusID. The GeneID is reported in RefSeq records as a 'db_xref' (e.g. /db_xref="GeneID:856646", in GenBank format).] 
Gestational Trophoblastic Tumor3447653v1Disease StageGestational Trophoblastic Tumor American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T) and metastases (M) and by grouping cases with similar prognosis for gestational trophoblastic tumor.Stage unknown | I | IA | IB | II | IIA | IIB | III | IIIA | IIIB | IV | IVA | IVB
Gestational Trophoblastic Tumor3447650v1Pathologic T StageGestational Trophoblastic Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary gestational trophoblastic tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | TX
Hepatocellular Carcinoma3377212v1Pathologic T StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary hepatocellular carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.T4 | T3b | T3a | T2 | T1 | T0 | TX
Hepatocellular Carcinoma3377214v1Pathologic M StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the hepatocellular carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Hepatocellular Carcinoma3377213v1Pathologic N StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the hepatocellular carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.N1 | N0 | NX
Hepatocellular Carcinoma3377215v2Disease StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for hepatocellular carcinoma.I | II | IIIA | IIIB | IIIC | IVA | IVB | Stage unknown
Hodgkin Lymphoma2902443v1Modified Ann Arbor StageHodgkin's Lymphoma Modified Ann Arbor Staging System StageClassification of severity/extent of Hodgkins Disease (HD) lymphoma based on the modified Ann Arbor or Cotswold staging system, which categorizes HD into four stages based on anatomic lymph node group involvement.IV | III 2 | III 1 | IIIE | III | IIE | II | IE | I
Image2547763v2Image Acquisition Start TimeImage Acquisition Start DICOM TimeThe time when acquisition of data resulting in this image started, displayed in the format hhmmss.frac; where hh (00-23); minutes (00-59); seconds (00-59); frac=fractional part "000000"-"999999". The Acquisition Time (0008,0032) use the same time base as Series Time (0008,0031) for PET Series images. 
Image2614025v2Image LateralityImage Laterality CodeTextual codes to indicate the manifestations of one side of the body versus the other in an image.U | B | R | L
Image2659466v1Image Start TimeImage Start DICOM TimeThe time when image pixel data creation started, displayed in the format hhmmss.frac; where hh (00-23); minutes (00-59); seconds (00-59); frac=fractional part "000000"-"999999". Required if image is part of a series in which the images are temporally related. 
Image2717692v2Pixel Measures SequenceImage Pixel Measures Sequence DICOM Sequence of Items TextIdentifies the physical characteristics of the pixels of this frame. Only a single Item shall be permitted in this sequence. 
Image2659468v2Image Acquisition DateImage Acquisition DateThe date the acquisition of data that resulted in this image started. 
Image2672191v2Was imaging completed?Image Complete Yes No IndicatorA response of yes or no to indicate if an imaging event whether physical or electronic has been brought to a conclusion.Yes | No
Image2904496v1Kilovolt peak (kVp) SettingImage Kilovolt Peak Float 16 NumberA floating point decimal number measured in kilovolts to capture the peak accelerating voltage applied in an X-ray tube between the cathode and anode. 
Image2659464v2Image Start DateImage Start DateThe date the image pixel data creation started. Required if image is part of a series in which the images are temporally related. 
Image2976193v1Indicate the image quality:Image Quality CategoryIndicates a grouping for a biomedical image that is of acceptable quality, with no technical defect likely to impair using the image for diagnosis or for intended purposes.Not Adequate Quality | Adequate Quality | Exemplary Quality | Limited Quality
Image2182362v2SOP Class UIDImage Service-Object Pair Class Unique IdentifierUniquely identifies the union of a specific set of DIMSE Services and one related Information Object Definition (as specified by a Service Class Definition) which completely defines a precise context for communication of operations on such an object or notifications about its state. 
Image2182360v2SOP Instance UIDImage Service-Object Pair Instance Unique IdentifierUniquely identifies a concrete occurrence of an Information Object that is managed by a DICOM Application Entity and may be operated upon in a communication context defined by a specific set of DIMSE Services (on a network or interchange media). A SOP Instance is persistent beyond the context of its communication. 
Image Plane3113183v2Image Slice LocationImage Plane Slice Location Float or Fixed-point Millimeter NumberA string of characters representing either a fixed point number or a floating point number capturing the relative position and orientation of the image slice relative to the patient-based coordinate system expressed in number of millimeters. 
Image Plane3113185v2Slice ThicknessImage Plane Slice Thickness Float or Fixed-point Millimeter NumberA string of characters representing either a fixed point number or a floating point number capturing the nominal slice thickness relative to the patient-based coordinate system expressed in number of millimeters. 
Image Study2902332v1Image Study Start TimeImage Study Start DICOM TimeThe time when an image study started, displayed in the format hhmmss.frac; where hh (00-23); minutes (00-59); seconds (00-59); frac=fractional part "000000"-"999999". 
Image Study2902330v2Image Study Start DateImage Study Start DateThe date when an image study started. 
Image Study2847022v1Study Instance UIDImage Study Instance Unique IdentifierA globally unique set of characters which are not human readable used to identify, name, or characterize a radiographic technique used to evaluate a specific anatomic location for a specific purpose. 
Imaging Agent2718368v3PET imaging agent sourcePET Imaging Agent Source TypeCategories for representing the origin of a compound that enables or improves the visualization of body structures or functions for medical imaging such as the radioisotope form of glucose used in positron emission tomography (PET).Synthesized | Purchased | Obtained from outside supplier | Prepared in-house
Imaging Agent3165845v1Was imaging agent administered?Imaging Agent Administered Yes No IndicatorA response of yes or no to indicate if an imaging agent was used in the imaging study.No | Yes
Imaging Agent3165873v1Radiochemical purity test resultPET Imaging Agent Radiopharmaceutical Purity Test Result NumberA numeric value representing the quality of the Positron Emission Tomography (PET) study imaging agent purity test as it relates to compliance with USP standards. 
Imaging Agent3165839v1Method [of synthesis]PET Imaging Agent Manufactured Method TextText describing the series of actions used to synthesize a radioactive material used in Positron Emission Tomography (PET) imaging. 
Imaging Agent3165865v1Pyrogen test resultsPET Imaging Agent Pyrogen Test Result TypeCategories for indicting the success of the pyrogen quality testing.Passed | Failed | Not Done
Imaging Agent3165834v2Imaging Agent NamePET Imaging Agent Identifier NameOne or more characters used to identify, name, or characterize a compound that enables or improves the visualization of body structures or functions for medical imaging such as the radioactive form of glucose used in Positron Emission Tomography (PET).I -124 Iodide | Ga-68 DOTA-NOC | Ga-68 DOTATOC | Cu-64 ATSM | F-18 Fluorodopa | F-18 Fluorodihydrotestosterone (FDHT) | F-18 Fluoroestradiol (FES) | F-18 FMISO | F-18 FLT | F-18 FDG | F-18 Fluoride
Imaging Agent3930171v1Specific ActivityImaging Agent Radionuclide Specific Activity ValueA numerical quantity defined as the ratio of radioisotope activity to total mass of the element present, used as a measure of radio-purity for the radioactive imaging agent. 
Imaging Agent3836018v1Confirmation of fasting requirementsPerson Imaging Agent Fasting Drink Exercise Required Complete Yes No Unknown IndicatorResponse to indicate whether fasting requirements for food, water and exercise were met in preparation for the use of an imaging agent.No | Yes | Unknown
Informed Consent3775395v1Consented?Informed Consent Procedure Complete Yes No IndicatorResponse that indicates whether a participant has agreed to the information addressed in a specific type of informed consent.No | Yes
Informed Consent3775411v1Type of CorrespondencePatient Informed Consent Cancel Withdrawal Paperwork TypeTerm to describe the type of correspondence detailing a patient's withdrawal or cancellation of informed consent.Signed and dated letter from study participant | Clinic Note | Signed and dated letter from study participant's legal guardian/POA | Telephone Call from patient or legal guardian
Informed Consent3781754v1Type of correspondence commentsPatient Informed Consent Cancel Withdrawal Other Paperwork TextText to describe the type of correspondence detailing a patient's withdrawal or cancellation of informed consent that is different from the options provided. 
Informed Consent2988262v1Who Consented?Informed Consent Signed Legal Adult Role TypeThe description of the role of the person who signed the informed consent document.Legal Representative | Patient
Infusion Procedure2475888v1Flow RateInfusion Flow Rate NumberNumeric value to represent measurement of the continuous movement of an intravenous substance relative to time, expressed as a value in milliliters per minute. 
Ingredient2871652v1IngredientIngredient NameThe name that describes a compound, or is a component part of any combination or mixture; an element; a constituent. 
Institution2481533v1Institution prescribing treatmentTreating Institution Identifier CodeCode that uniquely identities the organization providing treatment for a person or study subject. 
Internal Radiation Therapy2220523v1Mesh WidthBrachytherapy Implant Width Measurementthe width of brachytherapy. 
Internal Radiation Therapy2004511v3Seed lossBrachytherapy Radioactive Seed Implant Dosing Unit Lost Ind-3the yes/no indicator whether the brachytherapy seed implant, a dosing unit in a form of an incapsulated radioactive material that constitutes an implantable pellet designed for brachytherapy, was lost or expelled.No | Yes | Unknown
Internal Radiation Therapy3029084v1Seed Loss DetailsBrachytherapy Radioactive Seed Loss TextThe free text field used to describe details relating to radioactive seed loss. 
Internal Radiation Therapy3123941v1Brachytherapy modality other, specifyBrachytherapy Delivery Technique Other Specify TextThe free-text field used to describe a brachytherapy modality that is different than the choices offered. 
Internal Radiation Therapy2201422v1Brachytherapy techniqueBrachytherapy Delivery Technique Typethe type of brachytherapy used.Other | Mesh seeds | Individual Seeds | Vaginal cylinder | Tandems | Mini ovoids | Manchester ovoid | Fletcher-suit | Needle(s) | Mesh | Double strand
Internal Radiation Therapy3029079v1Implant NumberBrachytherapy Implant Unique Identification NumberThe sequential number used as an identifer assigned to a brachytherapy implant. 
Internal Radiation Therapy3130379v1LengthBrachytherapy Implantation Length MeasurementThe measurement of implantation length (such as strand or mesh ) within a incision. 
Intervention or Procedure3028746v1Stop DateIntervention Occurrence End DateThe end date for the administration of the intervention. 
Intervention or Procedure3028744v1Start DateIntervention Occurrence Begin DateThe start date for the administration of the intervention. 
Intervention or Procedure3028750v1UnitIntervention Potency Unit of Measure for Unified Code for Units of Measure CodeA code system intended to include all units of measures being contemporarily used in interventions in international science, engineering, and business. Its purpose is to facilitate unambiguous electronic communication of quantities together with their units.h | [oz_av] | ng | ug | mol | mg/mL | 10^7{Cells}/kg | kU/L | [iU]/L | [iU] | L/min | mg/kg | mg/dL | mg/24.h | meq/L | meq/dL | meq/24.h | meq | 10^6 | 10^6{pfu} | m[iU]/m2 | m[iU] | ng/mL | {No Scre} | {Unknown} | U/m2 | 10^3 | mg/h | ug/h | meq/h | [RAD] | [gal_us] | {Seed} | {Unit} | 10^9{Cells}/kg | {Wafer} | J | mg/m2/h | [iU]/mg | U/g | ug/m2 | {Bottle} | 10^5{Cells}/kg | 10^6{Cells}/kg | {AUC} | {IV Bag} | mg/{inhalation} | [iU]/mg{alpha-Tocopherol} | [iU]{Vitamin A} | {RAE} | {RE} | {Session} | {Patch} | mL/h | mg/wk | {Measure} | kU/kg | keV | J/cm2 | [iU]/kg | {Inhalation} | g/m2 | eq | [drp] | {Dose} | {Course} | {Course} | {Cells} | {Capsule} | {Caplet} | u | {Application} | 10^9{pfu} | 10^8{pfu} | 10^7{pfu} | mg/m2 | ug/kg | ug/cm2 | uCi | M[RAD] | 10^6eV | mL/kg | [psi] | {pfu} | {packet} | osm | nm{light} | ng/L | ng/kg | mU | mosm | 10^6{VP} | MU | {VP} | U/kg | {Troche} | {TCID50} | [tsp_us] | {tbl} | [tbs_us] | {Suppository} | {Spray} | {puff} | % | {YU} | mg/m2/wk | mg/m2/24.h | ug/kg/24.h | ug/m2/h | mg/kg/d | g/d | ug/kg/wk | g/wk | kg | pg | uL | % | g | min | umol | cGy | Ci | dL | Gy | Hz | kHz | kPa | kU | L | mCi | MHz | mL | mmol | mV | nCi | nmol | Pa | mg | s | u[IU]/mL
Investigator3783691v1Investigator date signatureInvestigator Withdrawal by Subject Quality of Life Consent Knowledge Confirmation DateCalendar date Investigator acknowledges understanding of a study patient's decision to withdraw consent from the Quality of Life portion of a study. 
Investigator3783588v1Investigator AttestationInvestigator Withdrawal by Subject Quality of Life Consent Knowledge Confirmation Yes No IndicatorText term to signify confirmation of the Investigator's understanding of a study participant's decision to withdraw consent from participation in the Quality of Life portion of a study.No | Yes
Investigator2740424v1Treating Physician Or Participating Investigator NameTreating Physician Or Participating Investigator NameText name for an investigator or physician involved in a study (may be the registering physician or investigator and/or the treating physician for a study participant. [Manually-curated] 
Investigator3781763v1Investigator AttestationInvestigator Withdrawal by Subject Knowledge Confirmation Yes No IndicatorTerm to signify confirmation of the Investigator's understanding of the study participant's decision to withdraw informed consent.No | Yes
Investigator3783517v1Investigator AttestationInvestigator Withdrawal by Subject Biospecimen Collection Consent Knowledge Confirmation Yes No IndicatorText term to signify confirmation of the Investigator's understanding of a study participant's decision to withdraw consent from participation in biological specimen collection(s).No | Yes
Isotope2716600v1Time of injectionPET Isotope Injection Start TimeTime at which the imaging agent was injected: recorded in military time format, e.g. 1:00 pm = 1300 hrs. 
Isotope2714760v3Location of Injection SitePET Isotope Injection Anatomic Site CodeThe location where a syringe containing a substance (such as a radiopharmaceutical) used in a computerized image of the metabolic activity of body tissues entered the body.1 | 2 | 3 | 4 | 5 | 6 | 99 | 88
Isotope2716522v2Any radiotracer infiltration at injection site noted?PET Isotope Infiltration Infiltration TypeIndication that diffusion or accumulation in a tissue or cells of a substance (such as a radiopharmaceutical).None | Minor (<= 20% of dose) | Severe (> 20% of dose)
Isotope2714877v1Other Location of Injection SitePET Isotope Injection Other SpecifyText detailing anatomic site of injection other than indicated. 
Isotope3419986v1Net activity at the time of injectionPET Isotope Injection Time Dose Assay ValueThe quantity of a substance (such as a radioisotope) at the time of injection measured in milliCuries (mCi). 
Isotope3419980v1Net activity at time of assayPET Isotope Time Dose Assay ValueThe quantity of a substance (such as a radioisotope) drawn/extracted into a syringe measured in milliCuries (mCi). 
Isotope2732417v2Activity in full syringe before injectionPET Isotope Begin Dose Assay ValueThe quantity of a substance (such as a radioisotope) drawn/extracted into a syringe measured in milliCuries (mCi). 
Isotope2716772v1Residual Dose TimePET Isotope Residual Dose Assay TimeThe time a quantity of a substance (such as a radioisotope) remaining after a computerized image is recorded in military time format, e.g. 1:00 pm = 1300 hrs. 
Isotope2716598v1Time of dose assayPET Isotope Begin Dose Assay TimeTime at which dose assay was drawn: recorded in military time format, e.g. 1:00 pm = 1300 hrs. 
Isotope2716774v2Residual activity in syringe after injectionPET Isotope Residual Dose Assay Isotope ValueThe measured activity remaining in the syringe after injection of the radiopharmaceutical into the subject. Activity of radiotracer measured in milliCuries (mCi) 
Laboratory2183360v2Lab ValueLaboratory Test Result Numeric ValueNumeric result of the laboratory analysis expressed as a number of 12 digits total, with 5 after the decimal. 
Laboratory Finding3809152v1Laboratory Data SourceLaboratory Data Source TypeCategory describing the origin of a laboratory data result.Other | Sponsor Lab | Referral Lab | Central Lab
Laboratory Finding2002236v4Report DateLaboratory Finding Report Datethe date this form of laboratory findings was completed. 
Laboratory Procedure2003746v6Lab TestLaboratory Finding Test NameIdentifier name given to a test performed on body fluid(s) and tissues; test names are typically comprised of the analyte name, properties (%, Ratio, etc.), the type of body fluid tested, and any special instructions.Testosterone, Blood | Creatinine, Blood | Chromogranin A, Blood | HLA-DPB, Blood | Sequenced Based HLA-DR (DRB), Blood | Sequenced Based HLA-DR (DRB), Blood | Sequenced Based HLA-DR (DRB1), Blood | Sequenced Based HLA-DQB1, Blood | Sequenced Based HLA-C (CW), Blood | Sequenced Based HLA-B, Blood | HLA Antibody Screen, Blood       | Dopamine, Plasma | Norepinephrine, Plasma | Epinephrine, Plasma | Epstein Barr Virus (EBV), Heterophile, IgM, Serum | Paroxysmal Nocturnal Hemoglobinuria Flow | CD4+/CD25+/Foxp3+, #, Blood | Folate, Red Blood Cell | Globulin, Serum | Alanine Aminotransferase (ALT or SGPT), Serum | Anti-Pneumococcal Antibody Serotype 19A (57) Post-Vaccination, Serum | Creatine Kinase (CK), Serum | T Lymphocytes, #, Blood | Methemoglobin, %, Arterial Blood | 4-OHT Z Isomer, Tissue | 4-OHT E Isomer, Tissue | 4-OHT Z Isomer, Plasma | 4-OHT E Isomer, Plasma | HIV1, Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Nucleic Acid Testing (NAT), Donor, Serum | GMCSF, Serum | Glucose-6-Phosphate Dehydrogenase (G6PD), Blood | Pro Brain Natriuretic Peptide (BNP), Serum | Human Herpesvirus 6, PCR, Quantitative, Blood | CMV PCR Quantitative Log 10, Blood | EBV PCR Quantitative Log 10, Blood | Insulin, Fasting, Serum | Creatinine Clearance (CrCl), Cockcroft-Gault, Serum | 5-Hydroxyindoleacetic Acid (5-HIAA), Urine | Immature Granulocytes (IG), Absolute, Number, Blood | Immature Granulocytes (IG), %, Blood | HHV6B, PCR, Quantitative, CSF | HHV6, Log 10, PCR, Quantitative, Blood | CD11C, Blood | D-dimer, Plasma | Vitamin D 25-OH, D2+D3 Total, Serum | Procollagen 1, Intact N-terminal peptide (P1NP), Serum | Beta-Crosslaps, Serum | Osteocalcin, Serum | Anion Gap, Serum | IC50 (Half Maximal Inhibitory Concentration), Bone Marrow | IC50 (Half Maximal Inhibitory Concentration), Blood | Atypical Cells, Blood | Antistreptolysin O, Blood | Low Density Lipid (LDL)-High Density Lipid (HDL) Cholesterol Ratio, Serum | Thyroid Stimulating Hormone (TSH)-Free Thyroxine (T4) Ratio, Serum | Human Herpesvirus 6 (HHV6) Viral Load, DNA, Blood | Prolymphocytes, %, Bone Marrow | Neuron-Specific Enolase (NSE), Serum | Vasoactive Intestinal Peptide (VIP), Serum | Pancreatic Polypeptide, Serum | Glucagon, Serum | Gastrin, Serum | Creatine Phosphokinase (CPK), Serum | Cholesterol, Total, Fasting, Serum | MGMT Promoter Methylation, Blood | MGMT Promoter Methylation, Tissue | Glucose Tolerance Test (GTT), Serum | Bilirubin, Indirect, Serum | Hepatitis C Virus (HCV) Viral Load, Serum | Hepatitis Be Antigen, Serum | Anti-HCV Antibody, Serum | Anti-Hbe Antibody, Serum | Estimated GFR (eGFR), Serum | Erythropoietin, Serum | von Willebrand Activity, Blood | von Willebrand Antigen, Blood | Thrombomodulin, Blood | P-Selectin, Blood | Platelets, Blood | Absolute Neutrophil Count (ANC), Blood | White Blood Cells (WBC), #, Blood | Blood Urea Nitrogen (BUN), Serum | Amylase, Serum | Glucose, Serum | Prothrombin Time (PT), Blood | Partial Prothromboplastin Time (PTT), Blood | Aspartate Aminotransferase (AST or SGOT), Serum | Creatinine Clearance, 24 hour, Urine | Creatinine, Serum | Beta-2 Microglobulin, Serum | BCR-ABL Sensitivity, Blood | BCR-ABL P210 Assay, Blood | BCR-ABL/G6PDH Ratio, Blood | Basophils, %, Blood | Basophils, #, Blood | Neutrophil Bands, %, Blood | Neutrophil Bands, #, Blood | Bacteria, Microscopic, Spot Urine | Appearance, Urine | Appearance, Cerebrospinal Fluid | Antiadrenal Antibody, Serum | Antinuclear Antibody (ANA), Serum | Alpha 2 Globulin, Electrophoresis, Timed Urine | Alpha 2 Globulin, Protein Electrophoresis, Serum | Alpha 1 Globulin, Electrophoresis, Timed Urine | Alkaline Phosphatase, Serum | Albumin, Serum | Albumin, Electrophoresis, Timed Urine | Alpha-1 Fetoprotein, Serum | Adenovirus Antibody, Serum | Adrenocorticotropin, Serum | Acid Phosphatase (ACP), Serum | Antibody Screen, Serum | ABO Group, Rh Type, Blood | Varicella Zoster Virus (VZV) DNA, Cerebrospinal Fluid | White Blood Cells (WBC), Microscopy, Spot Urine | White Blood Cells (WBC), Other, % Blood | White Blood Cells (WBC), #, Cerebrospinal Fluid | Alpha 1 Globulin, Protein Electrophoresis, Serum | Calcium Oxalate Crystals, Urine | Casts, Spot Urine | Cardiolipin Antibody, IgM, Serum | Cardiolipin Antibody, IgG, Serum | Total Lung Capacity %, Respiratory System | Total Lung Capacity %, Predicted, Respiratory System | Cadaverine, Tissue | Cancer Antigen 27-29 (CA27-29), Serum | Carcinogenic Antigen 19-9 (CA19-9), Serum | Carcinogenic Antigen 15-3 (CA15-3), Serum | Carcinogenic Antigen 125 (CA125), Serum | B Lymphocytes, #, Blood | Diffuse Cytoplasmic Anti-Neutrophil Cytoplasmic Antibody, Serum | Calcium, Serum | Calcium, Ionized, Serum | Calcium, 24 hour, Urine | Calcitonin, Serum | Blood Urea Nitrogen (BUN)/Creatinine Ratio, Serum | Blasts, #, Blood | BK Virus, Polymerase Chain Reaction (PCR), #, Urine | BK Virus, Polymerase Chain Reaction (PCR), #, Blood | Bilirubin (Bile), Spot Urine | Bile (Biliary Obstruction), Spot Urine | Bicarbonate, Serum | Beta Choriogonadotropin (BHCG), or Pregnancy Test, Spot Urine | Beta Choriogonadotropin BHCG, or Pregnancy Test, Serum | Beta Globulin, Electrophoresis, Timed Urine | Beta Globulin, Protein Electrophoresis, Serum | CD22, #, Blood | CD22 Cells, Antibody, #, Blood | CD20, %, Blood | CD20, #, Blood | CD19 Cells, %, Blood | CD19 Cells, #, Blood | CD16 or CD56/CD3, %, Blood | CD16 or CD56/CD3, #, Blood | CD16 or CD56/CD3-, %, Blood | CD16 or CD56/CD3-, #, Blood | CD14, %, Peripheral Mononuclear Cells (PBMC), Blood | CD10 Cells, Blood | CD103 Cells, Blood | Cyclic Citrullinated Peptide (CCP), Antibody, Serum | CD3/7G7, %, Blood | CD3/7G7, #, Blood | CD3/CD4-/CD8-, %, Blood | CD3/CD4-/CD8-, #, Blood | CD3/CD30 Cells, %, Blood | CD3/CD30 Cells, #, Blood | CD3/CD25 Cells PE, %, Blood | CD3/CD25 Cells PE, #, Blood | CD38 Cells, #, Blood | CD2 Cells, %, Blood | CD25 Cells, %, Blood | CD25 Cells, #, Blood | CD25 Cells PE, %, Blood | CD25 Cells PE, #, Blood | CD4/CD25/CD69 Cells, %, Blood | CD4/CD25/CD69 Cells, #, Blood | CD4/CD25/CD62L Cells, %, Blood | CD4/CD25/CD62L Cells, #, Blood | CD4/CD62L-/CD45RA, %, Blood | CD4/CD62L-/CD45RA, #, Blood | CD4/CD62L/CD45RA, %, Blood | CD4/CD62L/CD45RA, #, Blood | CD4/CD45RA+CD45RO, %, Blood | CD4/CD45RA+CD45RO, #, Blood | CD45 Cells, #, Blood | CD3 Cells, %, Flow Cytometry, Blood | CD3 Cells, #, Blood | CD3/HLA-DR, %, Blood | CD3/HLA-DR, #, Blood | CD3/CD8/CD57, %, Blood | CD3/CD8/CD57 Cells, #, Blood | CD3/CD8/CD28, %, Blood | CD3/CD8/CD28 Cells, #, Blood | CD3/CD25 Cells, %, Blood | CD3/CD25 Cells, #, Blood | CD4 Cells to CD3 Cells, #, Blood | CD4/CD30 Cells, %, Blood | CD4/CD30 Cells, #, Blood | CD4/CD25 Cells, %, Blood | CD4/CD25 Cells, #, Blood | CD4/7G7 Cells, %, Blood | CD4/7G7 Cells, #, Blood | CD4/CD25 PE Cells, %, Blood | CD4/CD25 PE Cells, #, Blood | CD4/CD45RO, %, Blood | CD4/CD45RO, #, Blood | CD4/CD45RA, %, Blood | CD4/CD45RA, #, Blood | CD4 Cells to CD3 Cells, %, Blood | CD7 Cells, %, Blood | CD7 Cells, #, Blood | CD7-/CD25 PE Cells, %, Blood | CD7-/CD25 PE Cells, #, Blood | CD7/CD25 PE Cells, %, Blood | CD7/CD25 PE Cells, #, Blood | CD5 Cells, %, Blood | CD52 Cells, #, Blood | CD4 Cells, %, Flow Cytometry, Blood | CD4 Cells, #, Blood | CD4/HLA-DR, %, Blood | CD4/HLA-DR, #, Blood | CD4 Cells to CD8 Cells Ratio, Blood | CD4/CD62L, %, Blood | CD4/CD62L, #, Blood | Cholesterol, Serum | Cholesterol to High Density Lipids (HDL), Ratio, Serum | Cholestanol, Serum | Chloride, Serum | Chloride, 24 hour, Urine | CH50 Complement, Serum | Centromere, Antibody, Serum | Cell Count, Cerebrospinal Fluid | Cellularity, %, Bone Marrow | Carcinoembryonic Antigen (CEA), Serum | CD8 Cells, %, Flow Cytometry, Blood | CD8 Cells, #, Blood | CD8/HLA-DR, %, Blood | CD8/HLA-DR, #, Blood | CD8/CD62L, %, Blood | CD8/CD62L, #, Blood | CD8/CD57, %, Blood | CD8/CD57, #, Blood | CD8/CD45RO, %, Blood | CD8/CD45RO, #, Blood | CD8/CD45RA, %, Blood | CD8/CD45RA, #, Blood | CD8/CD3, %, Blood | CD8/CD3, #, Blood | CD8/CD25, %, Blood | CD8/CD25, #, Blood | CD8/CD62L-/CD45RA, %, Blood | CD8/CD62L-/CD45RA, #, Blood | CD8/CD62L/CD45RA, #, Blood | CD8/CD45RA+CD45RO, %, Blood | CD8/CD45RA+CD45RO, #, Blood | CD8/CD62L/CD45RA, %, Blood | CD8/CD25 PE, %, Blood | CD8/CD25 PE, #, Blood | Creatinine, Spot or Timed Sample, Urine | Carbon Monoxide Diffusing Capacity, Respiratory System | Cortisol, Blood | Complement, C4, Serum | Complement, C3, Serum | Color, Urine | Color, Cerebrospinal Fluid | Carboxyhemoglobin, Arterial Blood | Coarse Granular Casts, Spot Urine | CO2 (Carbon Dioxide), Exhaled Gas | Cytomegalovirus, DNA, Polymerase Chain Reaction, Cerebrospinal Fluid | Cytomegalovirus (CMV) Antigenemia, Blood | Cytomegalovirus (CMV) Antibody, IgM, Serum | Cytomegalovirus (CMV) Antibody, IgG, Serum | Diphtheriae Antibody, Serum | Diffusing Capacity % Predicted, Respiratory System | Diffusion Capacity, Respiratory System | Direct Antiglobulin Test (Coombs), Red Blood Cells | C Reactive Protein, High Sensitivity, Serum | C Reactive Protein, Serum | Cyclosporine, Blood | Clean Catch Culture, Urine | Culture, Stool | Culture, Sputum | Culture, Respiratory Virus, Nasopharynx | Culture, Cerebrospinal Fluid | Culture, Blood | C-Telopeptide, Serum | Crystrals, Spot Urine | Dako EGFR Pharmdx Immunohistochemical Labeling, Tissue | Epstein-Barr Virus (EBV), IgM , Serum | Epstein-Barr Virus (EBV), Nuclear Antibody, IgG, Serum | Epstein Barr Virus (EBV) Nuclear Antibody, Serum | Epstein-Barr Virus (EBV) Early Antigen, Serum | Epstein Barr Virus (EBV) Antibody, Serum | Double Strand DNA (DSDNA) Antibody, Serum | Dopamine, 24 hour, Urine | Double Negative T (DNT) Cells, %, Blood | Double Negative T (DNT) Cells, #, Blood | DNA-TCR B Chain, Blood | Diffusing Capacity to Alveolar Ventilation Ratio, Respiratory System | Diffusing Capacity to Alveolar Ventilation Ratio %, Respiratory System | Diffusion Capacity Carbon Monoxide (DL) Adjusted, Respiratory System | Diffusion Capacity Carbon Monoxide (DL) Adjusted, % Predicted, Respiratory System | Fibrin Degradation Products (FDP), Blood | Fluorescent Activated Cell Sorting (FACS) Lymphoid Cells, #, Blood | Expiratory Volume, Respiratory System | Estimated Creatinine Renal Clearance, Urine | Estradiol, Serum | Erythrocyte Sedimentation Rate (ESR), Blood | Expiratory Reserve Volume (ERV), Respiratory System | Expiratory Reserve Volume (ERV), % Predicted, Respiratory System | Epinephrine, 24 hour, Urine | Eosinophils, %, Blood | Eosinophils, #, Blood | Smith Extractable Nuclear Antibody, Serum | Extractable Nuclear Antigens (ENA) Screen, Blood | EGFR vXXI Immunohistochemical Labeling, Tissue | Volume expelled during midportion of expiration, Respiratory System | Volume expelled during midportion of expiration % Predicted, Respiratory System | Forced Expiratory Flow (FEF), during midportion of expiratory cycle, Pre, % Predicted, Respiratory System | Forced Expiratory Flow (FEF), during midportion of expiratory cycle, Pre, Respiratory System | Forced Expiratory Flow (FEF), during midportion of expiratory cycle, Post, % Change, Respiratory System | Forced Expiratory Flow (FEF), during midportion of expiratory cycle, Post, Respiratory System | Forced Expiratory Flow (FEF), during midportion of expiratory cycle, Post, % Predicted, Respiratory System | FEV1 to FVC Ratio, Respiratory System | FEV1 to FVC Predicted Ratio, Respiratory System | FEV1 to FVC Ratio, Pre, Respiratory System | FEV1 to FVC Ratio, Post, Respiratory System | Fetal Hemoglobin, Blood | Forced Expiratory Technique (FET), 100%, Pre, Respiratory System | Forced Expiratory Technique (FET), 100%, Post, Respiratory System | Ferritin, Serum | Forced Expiratory Volume 1 Second (FEV1), Post, % Change, Respiratory System | Functional Residual Capacity, Respiratory System | Functional Residual Capacity (FRC), % Predicted, Respiratory System | Folate, Serum | Fine Granular Casts, Spot Urine | Fibrinogen, Fibrometer, Platelet Poor Plasma | Fibrinogen, Auto, Platelet Poor Plasma | Fibrinogen, Blood | Forced Expiratory Volume 1 Second (FEV1) Slope, Respiratory System | Forced Expiratory Volume, Respiratory System | Forced Expiratory Volume 1 Second (FEV1), Pre, Respiratory System | Forced Expiratory Volume 1 Second (FEV1), Pre, % Predicted, Respiratory System | Forced Expiratory Volume % Predicted, Respiratory System | Forced Expiratory Volume 1 Second (FEV1), Post, Respiratory System | Forced Expiratory Volume 1 Second (FEV1), Post, % Predicted, Respiratory System | Glucose, Spot Urine | Glucose, Non-fasting, Serum | Glucose, Fasting, Serum | Glucose, CSF | Gamma Glutamyl Transferase (GGT), Serum | Glomerular Filtration Rate, Manual Calculation, Blood | Gamma Globulin, Electrophoresis, Timed Urine | Gamma Globulin, Protein Electrophoresis, Serum | Forced Vital Capacity (FVC), Respiratory System | Forced Vital Capacity (FVC), Pre, Respiratory System | Forced Vital Capacity (FVC), Pre, % Predicted, Respiratory System | Forced Vital Capacity (FVC) % Predicted, Respiratory System | Forced Vital Capacity (FVC), Post, Respiratory System | Forced Vital Capacity (FVC), Post, % Predicted, Respiratory System | Forced Vital Capacity (FVC), Post, % Change, Respiratory System | Hemoglobin (Hgb) A1C, Blood | Hepatitis C Antibody, Serum | Hepatitis A Virus Antibody (HAV), Total, Serum | Hepatitis A Virus Antibody (HAV), IgM, Serum | High Density Lipoprotein, Cholesterol, Serum | Hepatitis C Virus, RNA, Reverse Transcriptase (RT), Polymerase Chain Reaction (PCR), Serum | Hematocrit, %, Blood | Bicarbonate (HCO3), Arterial Blood | Human Choriogonadotropin (HCG), Serum | Hepatitis B Core Antibody, Serum | Hepatitis B Surface Antigen, Serum | Antibody to Hepatitis B surface antigen (HBSAb), Serum | Haptoglobin, Serum | Human Anti-Mouse Antibody, Blood | HLA-A24 Subtype Antigen | HLA-A03 Subtype Antigen, White Blood Cells | HLA-A3 Subtype Antigen | HLA-A2 Antigen, White Blood Cells | HIV Viral Load, Serum | HIV Viral Load, Cerebrospinal Fluid | Human Immunodeficiency Virus (HIV), 1-2 Antibody, Serum | Human Immunodeficiency Virus (HIV) 1, Western Blot, Serum | HIV1 Log Viral Load, Polymerase Chain Reaction (PCR), Plasma | HIV1 Log Viral Load, Polymerase Chain Reaction (PCR), Cerebrospinal Fluid | Human Immunodeficiency Virus (HIV) 1, Antibody, Western Blot, Serum | Histamine, Tissue | Human Growth Hormone (HGH), Serum | Hemoglobin, Spot Urine | Hemoglobin, Blood | HLA DR Antigen, White Blood Cells | HLA DRB Antigen, White Blood Cells | HLA DRB1 Antigen, White Blood Cells | HLA DQB1 Antigen, White Blood Cells | HLA Cw Antigen, White Blood Cells | HLA B Antigen, White Blood Cells | HLA A Antigen, White Blood Cells | IGF-1 (Human Growth Hormone), Blood | Immunoglobulin E (IgE), Serum | Immunoglobulin D (IgD), Serum | Immunoglobulin A (IgA), Serum | Inspiratory Capacity (IC), Respiratory System | Inspiratory Capacity (IC), % Predicted, Respiratory System | Hyaline Casts, Spot Urine | HTLV1/HTLV2 Antibody, Serum | Herpes Simplex Virus 2 (HSV2) IgG, Serum | Herpes Simplex Virus 1 (HSV1) IgG, Serum | Herpes Simplex Virus (HSV) 1/2, IgM, Serum | Helicobactor Pylori Antibody, IgG, Serum | Lamotrigine, Serum | Lupus Anticoagulant, Staclot, Platelet Poor Plasma | Lactate, Cerebrospinal Fluid | Ketones, Spot Urine | Iron, Serum | Iron Saturation, Ratio, Serum | Iodine, Free, 24 hour, Urine | Iodine, Concentration, 24 hour, Urine | Iodine, 24 hour, Urine | Insulin, Serum | International Normalized Ratio (INR), Prothrombin Time, Blood | Inhibin B, Blood | Inhibin A, Blood | Insulin-life Growth Factor Binding Protein 3, Serum | Immunoglobulin M (IgM), Serum | Immunoglobulin M (IgM), Immunoelectrophoresis, Spot Urine | Immunoglobulin G (IgG), Serum | Lymphocytes, %, Cerebrospinal Fluid | Lymphocytes, %, Blood | Lymphocytes, #, Blood | Atypical Lymphocytes, #, Blood | Abnormal Lymphocytes, %, Blood | Lupus Anticoagulant, Platelet Poor Plasma | Liver Kidney Microsomal Antibody, Serum | Lipase, Serum | Large Unstained Cells, %, Blood | Large Unstained Cells, #, Blood | Levetiracetam, Serum | Leukocyte Esterase, Spot Urine | Low Density Lipoproteins, Cholesterol, Serum | Lactate Dehydrogenase (LDH), Serum | Mucous, Spot Urine | Monocytes, %, Bone Marrow | Monocytes, %, Blood | Monocytes, #, Blood | Mitochondrial Antibody, Serum | MGMT (O6-methylguanine-DNA methyltransferase) Immunohistochemical Labeling, Tissue | Metanephrine, 24 hour, Urine | Metamyelocytes, %, Bone Marrow | Megakaryocytes, %, Bone Marrow | Mean Corpuscular Volume (MCV), Red Blood Cells | Mean Corpuscular Hemoglobin (MCH), Red Blood Cells | Mean Corpuscular Hemoglobin Concentration (MCHC), Red Blood Cells | Myelin Basic Protein, Cerebrospinal Fluid | Maximum Forced Expiratory Flow, Respiratory System | Forced Vital Capacity (Maximum), Respiratory System | Magnesium, Serum | Lymphocytes Variants, %, Blood | Lymphocytes, Variant, #, Blood | Lymphocytes, %, Bone Marrow | Neutrophils, %, Blood | Neutralizing Antibody LMB-2, Serum | Neutralizing Antibody BL22, Serum | Sodium/Potassium Ratio, Serum | N8 Acetylspermidine, Tissue | N1 Acetylspermine, Tissue | N1 Acetylspermidine, Tissue | FAB Marrow Rating, Bone Marrow | Myelocytes, %, Bone Marrow | Mullerian inhibiting substance, Serum | Parathyroid Hormone, Intact, Blood | PTEN Immunohistochemical Labeling, Tissue | Prostate Specific Antigen (PSA), Serum | Protein-Creatinine Ratio, Urine | Total Protein Electrophoresis, Serum | Protein, Qualitative, Urine | Protein excretion, 24 hour, Urine | Protein, CSF | Protein, 24 hour, Urine | Promyelocytes, %, Bone Marrow | Progesterone, Serum/Plasma | Prealbumin, Serum | Potassium, Serum | Potassium, 24 hour, Urine | Polymorphonuclear Cells (Polys), %, Blood | Polymorphonuclear Cells (Polys), #, Blood | Percent Oxygen (pO2), Arterial Blood | Platelet Mean Volume (PMV), Blood | Plasma Cells, %, Bone Marrow | pH, Spot Urine | pH, Arterial Blood | pH, Venous Blood | Phosphate (inorganic Phosphorus), Serum | Phenytoin, Serum | Prostaglandin E2, Tissue | Percent Carbon Dioxide (pCO2), Arterial Blood | Parietal Cell Antibody, Serum | pAKT Immunohistochemical Labeling, Tissue | Other Cell Count, Cerebrospinal Fluid | Osmolality, Serum | Osmolality, 24 hour, Urine | Nucleated Red Blood Cells (NRBC), #, Blood | Normetanephrine, 24 hour, Urine | Norepinephrine, 24 hour, Urine | Natural Killer T Cells, %, Blood | Natural Killer T Cells, #, Blood | Natural Killer (NK) Cells, %, Blood | Natural Killer (NK) Cells, #, Blood | Nitrite, Spot Urine | Rheumatoid Factor, Serum | Reticulocytes, %, Red Blood Cells | Reticulocytes, %, Bone Marrow | Renal Epithelial Cells, Spot Urine | Red Cell Distribution Width (RDW), Red Blood Cells | Red Blood Cells (RBC), #, Cerebrospinal Fluid | Red Blood Cells (RBC), #, Blood | Red Blood Cells (RBC), Microscopy, Spot Urine | Red Blood Cells (RBC), Microscopy, #, Spot Urine | Putrescine, Tissue | Squamous Epithelial Cells, Spot Urine | Spermine, Tissue | Spermidine, Tissue | Specific Gravity, Spot Urine | Specimen Collection Period, Urine | Sodium, Serum | Sodium, 24 hour, Urine | Sirolimus (Rapamycin), Blood | Residual Volume to Total Lung Capacity Ratio, Respiratory System | Rapid Plasma Reagin (RPR), Serum | Ribonucleoprotein Extractable Nuclear (RNP) Antibody, Serum | Thyroglobulin Antibody, Serum | Thyroperoxidase Antibody, Serum | Thrombin Time, Blood | Trefoil Factor 1, Tissue | Testosterone, Total, Serum | Thyroxine Binding Globulin (TBG), Serum | Tacrolimus, Blood | Thyroxine (T4), Serum | Thyroxine (T4), Free, Serum | Thyroxine (T4), Free, Dialysis, Serum | Triiodothyronine (T3), Serum | Triiodothyronine (T3), Free, Serum | Sjogren's Syndrome-A Extractable Antibody, Serum | Toxoplasmosa Gondii, Antibody, IgM, Serum | Vaccinia Culture, Spot Urine | Vaccinia Culture, Serum | Urobilinogen, Spot Urine | Urate (Uric Acid), Serum | Uric Acid (Urate), 24 hour, Urine | Troponin T, Blood | Triglycerides, Serum | Calcium, Ionized, Arterial Blood | Varicella Zoster Virus (VZV), IgG, Antibody, Serum | Varicella Zoster Virus (VZV) Antigen, Immunofluorescence, Skin | Volume Residual, Respiratory System | Respiratory Volume (RV), % Predicted, Respiratory System | Volume, Urine | Very Low Density Lipoprotein (VLDL) Cholesterol, Serum | Vitamin D, 25-Dihydroxy, Blood | Vitamin D, 1, 25-Dihydroxy, Blood | Vitamin B12, Serum | Vital Capacity (VC), Respiratory System | Vital Capacity (VC), % Predicted, Respiratory System | Valproate (Valproic Acid), Serum | Metanephrine, Unconjugated, 24 hour, Urine | Thyrotropin (Thyroid Stimulating Hormone or TSH), Serum | T Lymphocytes, %, Blood | T Lymphocyte Suppressor Cells , Blood | T Lymphocyte Helper Cells, Blood | Trypanosoma cruzi Antibody, IgG, Serum | Transitional Cells, Spot Urine | Transferrin, Serum | Total Protein, Serum | Bilirubin, Direct, Serum | Bilirubin, Total, Serum | Sjogren's Syndrome-B Extractable Antibody, Serum | Hepatitis C Virus, RNA, Quantitative, Copies/mL, Serum | Hepatitis C Virus, RNA, Quantitative, IU/mL, Serum | Anti-Interleukin 15 Antibody, Serum | Interleukin 2 s-Receptor-Alpha, Serum | Alkaline Phosphatase, Bone, Serum | Parathyroid (Parathyrin intact) Hormone, Serum | Adiponectin, Serum | Thyroid Stimulating Immunoglobulins (TSI), Serum | Follicle Stimulating Hormone (FSH), Serum | Luteinizing Hormone (LH), Serum | Cortisol, Serum | Immunofixation Electrophoresis, Serum | Albumin-Creatinine Ratio, Urine | Short Tandem Repeat Chimerism, Dual Cord, %, Whole Blood | Short Tandem Repeat Chimerism, Clusters of Differentiation 3 (CD3), %, Whole Blood | Short Tandem Repeat Chimerism, Clusters of Differentiation 19 (CD19), %, Whole Blood | Short Tandem Repeat Chimerism, Clusters of Differentiation 14 (CD14), %, Whole Blood | Nonseparated Short Tandem Repeat Chimerism, %, Bone Marrow | Nonseparated Short Tandem Repeat Chimerism, %, Whole Blood | Short Tandem Repeat Chimerism, %, White Blood Cells | Short Tandem Repeat Chimerism, %, Other Source | Short Tandem Repeat Chimerism, Natural Killers, %, Whole Blood | Short Tandem Repeat Chimerism, Multiple Donor, %, Whole Blood | Short Tandem Repeat Chimerism, Multiple Donor, %, White Blood Cells | Short Tandem Repeat Chimerism, Multiple Donor, %, Other Source | Short Tandem Repeat Chimerism, Multiple Donor, %, Bone Marrow | Short Tandem Repeat Chimerism, MonoMac, %, Whole Blood | Bisphenol, Serum/Plasma | Tamoxifen, Serum/Plasma | Endoxifen, Serum/Plasma | 4 Hydroxytestosterone (4-OH), Serum/Plasma | Bisphenol, Tissue | Estradiol, Tissue | Tamoxifen, Tissue | 4 Hydroxytestosterone (4-OH), Tissue | Endoxifen, Tissue | Anti-Saccharomyces cerevisiae Antibodies (ASCA), IgA, Serum | Anti-Saccharomyces cerevisiae Antibodies (ASCA), IgG, Serum | C-Peptide, Serum | Leptin, Serum | Methotrexate, Serum | QuantiFERON-TB Gold (QFT), Blood | Activated Partial Thromboplastin Time (APTT) | Hepatitis B Viral Load (HBV), DNA, Blood | Hepatitis B Core (HBC) Antibody, IgM, Serum | Toxoplasmosa Gondii, Antibody, IgG, Serum | Epstein-Barr Virus (EBV), DNA, #, Polymerase Chain Reaction (PCR), Blood | Cytomegalovirus (CMV), Polymerase Chain Reaction (PCR), Blood | Cortisol 3, Serum | Cortisol 2, Serum | Cortisol 1, Serum | Monoclonal Protein, Electrophoresis, Urine | Monoclonal Protein, Electrophoresis, Serum | Prolactin, Serum | Cortisol, 24 hour, Urine | Blasts, %, Blood | Copper, Serum | Ammonia, Serum | Aldolase, Serum | Occult Blood (Guaiac), Stool | Normoblasts, %, Bone Marrow | Pronormoblasts, %, Bone Marrow | Polymorphic Basophils, %, Bone Marrow | Polymorphic Eosinophils, %, Bone Marrow | Polymorphic Neutrophils, %, Bone Marrow | Basophilic Myelocytes, %, Bone Marrow | Eosinophilic Myelocytes, %, Bone Marrow | Neutrophilic Myelocytes, %, Bone Marrow | Myeloblasts, %, Bone Marrow | 5'-Nucleotidase, Serum | Interferon, Serum | Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Blood | T lymphocyte Cytotoxic Cells (CTL), Blood | T Lymphocytes, Delayed Hypersensitivity Testing (DTH), Blood | Urea Nitrogen, 24 hour, Urine | Gamma Globulin, %, 24 hour, Urine | Beta Globulin, %, 24 hour, Urine | Alpha 2 Globulin, %, 24 hour, Urine | Alpha 1 Globulin, %, 24 hour, Urine | Protein-Albumin Ratio, Urine | Oxalate, 24 hour, Urine | Clotting Time, Blood | Clot Retraction, Blood | Bleeding Time, Patient, Blood | Pulmonary (Lung) Compliance, Respiratory System | Tidal Volume, Respiratory System | Oxygen Saturation, Arterial Blood | Total Iron Binding Capacity, Serum | Calcium, Corrected, Serum | Lambda Light Chain, Immunoelectrophoresis, Urine | Kappa Light Chain, Immunoelectrophoresis, Urine | Polyclonal Protein, Immunoelectrophoresis, Urine | Monoclonal Protein, Immunoelectrophoresis, Urine | Immunoglobulin G, Immunoelectrophoresis, Urine | Immunoglobulin E, Immunoelectrophoresis, Urine | Immunoglobulin D, Immunoelectrophoresis, Urine | Immunoglobulin A, Immunoelectrophoresis, Urine | Bence Jones Protein, Electrophoresis, Serum | Lambda Light Chain, Electrophoresis, Serum | Kappa Light Chain, Electrophoresis, Serum | Polyclonal Protein, Electrophoresis, Serum | Anti-Pneumococcal Antibody Serotype 4 (4) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 33F (70) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 3 (3) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 23F (23) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 22F (22) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 20(20) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 2 (2) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 19F (19) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 19A (57) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 18C (56) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 17F (17) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 15B (54) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 14 (14) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 12F (12) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 11A (43) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 10A (34) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 1 (1) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 9V (68) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 9N (9) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 8 (8) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 7F (51) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 6B (26) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 5 (5) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 4 (4) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 33F (70) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 3 (3) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 23F (23) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 22F (22) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 20 (20) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 2 (2) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 19F (19) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 18C (56) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 17F (17) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 15B (54) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 14 (14) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 12F (12) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 11A (43) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 10A (34) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 1 (1) Post-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 9V (68) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 9N (9) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 8 (8) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 7F (51) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 6B (26) Pre-Vaccination, Serum | Anti-Pneumococcal Antibody Serotype 5 (5) Pre-Vaccination, Serum | Atypical Lymphocytes, %, Blood | Hepatitis A Virus Antibody (HAV), IgA, Serum | Hepatitis A Virus Antibody (HAV), IgG, Serum | Beta-2 Microglobulin, Urine | Chromogranin A, Serum | Thyroglobulin, Serum | Pheresis Bag, #, Platelet | Pheresis Bag, #, WBC | Nucleated Cells, Total, Blood | Glucose, Quantitative, 24 hour, Urine | Epidermal Growth Factor Receptor (EGFR) Mutation, Tissue | Cytokeratin Fragments 21-1, Serum | Chromosome 9p21 Expression, %, Blood | Chromosome 17 Expression, %, Blood | Chromosome 7 Expression, %, Blood | Chromosome 3 Expression, %, Blood | BRAF Gene Mutation V600E, Tissue | Anaplastic Lymphoma Kinase (ALK) Gene Arrangement, Tissue | HER2/neu (Human Epidermal Growth Factor Receptor), FISH, Tissue | HER2/neu (Human Epidermal Growth Factor Receptor), IHC, Tissue | HER2/neu (Human Epidermal Growth Factor Receptor), Serum | Human Epididymis Protein 4 (HE4), Serum | Progesterone Receptor (PR), Serum | Estrogen Receptor (ER), Serum | Plasminogen Activator Inhibitor (PAI-1), Tissue | Urokinase Plasminogen Activator (uPA), Serum | Urokinase Plasminogen Activator (uPA), Tissue | Nuclear Matrix Protein 22 (NMP22), Urine | KRAS Gene Mutation, Tissue | KIT (CD117) Gene Mutation, Tissue | 5 Protein Signature (Ova1), Serum | 21 Gene Signature (Oncotype DX), Tissue | 21 Gene Signature (Oncotype DX), #, Tissue | 70 Gene Signature (Mammaprint), Tissue | Plasminogen Activator Inhibitor (PAI-1), Serum
Laboratory Procedure2003580v3TimeLab Collection TimeThe time when a sample for a lab test was collected. 
Laboratory Test Result2841229v1Abnormal FlagTest Result Reference Object Range Flag IndicatorAn indicator that can be set or unset in order to signal whether the result lies outside the boundaries of the reference range.Yes | No
Laboratory Test Result2841221v1Reference Range Lower Limit Numeric ValueTest Result Low Test Reference Range NumberThe number that represents the reported low limit of the test reference range. 
Laboratory Test Result3241064v1Lab ValueLaboratory Test Result Character ValueCharacter result of a laboratory analysis expressed as text. 
Laboratory Test Result2841212v1Reference Range Upper Limit Numeric ValueTest Result High Test Reference Range NumberThe number that represents the reported upper limit of the test reference range. 
Laboratory Test Result2787947v1Lab Test Unit of Measure UCUM CodesLaboratory Test Result Unit of Measure Unified Code for Units of Measure CodeThe code that represents the unit of measure for the laboratory test result.g/L | mg/mL | mmol/L | {CAE}Unit | 10^9{Cells}/L | /uL | 10^9{Cells} | 10^8{Cells} | 10^7{Cells}/kg | 10^6{Cells}/uL | 10^6{Cells} | 10^3{Cells}/uL | 10^12{Cells}/L | /100{WBC} | %/100{WBC} | g/24.h | {Enzyme}U/mL | {Enzyme}U/dL | {Enzyme}U | aL | {Copies} | {Cells}/uL | [GPL'U] | g/uL | g/dL | kU/L | [iU]/mL | [iU]/m2 | [iU]/L | [iU] | {Index Value} | [HPF] | L/s | L/min | mg/L | mg/kg | mg/dL | mg/24.h | meq/L | meq/kg | meq/dL | meq/24.h | meq | ug/{Specimen} | ug/mL | ug/L | ug/dL | ug/24.h | LPF | 10^6/uL | 10^6 | 10^6{pfu} | uU/mL | umol/dL | umol/24.h | u[iU]/mL | mg/mL/min | m[iU]/mL | m[iU]/m2 | m[iU] | mm/h | mL/min/mm[Hg]/L | mL/min/mm[Hg] | mL/min/1.73.m2 {BSA} | mL/min | nmol/mg{Protein} | ng/mL | ng/dL | {NA} | 10^6U/mL | [MPL'U] | mosmol/kg | mmol/min/kPa/L | mmol/24.h | mm[Hg] | pg{PEG2}/mg{Protein} | pg/mL | pg/dL | nmol/mL | {No Scre} | mU/mL | {Unknown} | U/uL | U/mL | U/m2 | U/L | U/24.h | U | {Titer} | {Threshold} | 10^3/mm2 | 10^3/uL | 10^3 | {RNA copies}/mL | ng/mL/h | 10^5{Cells}/kg | 10^6{Cells}/kg | % | fmole | ukatal/L | pg | uL | g | nm | mL/min/kg | L | mL | mmol | nmol | mg | ng/mL{DDU} | 10^8{Cells}/kg | 10^3{Cells}/mL | {Cells}/mL | h | s | mL/s | umol/L | fL | nmol/L | pmol/L
Leukemia58208v3Rai Stage ClassificationCLL Leukemia RAI Stagestage of chronic lymphocytic leukemia according to the Rai stage classification.Stage 0 | Stage I | Stage II | Stage III | Stage IV
Limited2004106v3Dose-Limiting Toxicity?Dose Limiting Toxicity IndIndication (Y or N) of an Adverse event considered to be a dose-limiting toxicityY | N
Lymphoma2902417v1Ann Arbor StageLymphoma Ann Arbor Staging System StageThe classification of severity/extent of lymphoma (Hodgkins and Non-Hodgkins) based on the Ann Arbor staging system which categorizes lymphoma into four stages based on anatomic lymph nodal group involvement.IVB | IIIB | IIB | IB | IA | IE | IIA | IIE | IIIA | IIIE | IIIE,S | IIIS | IVA
Meddra System Organ Class2943864v1MedDRA System Organ Class (SOC)MedDRA System Organ Class Term NameText term to represent the highest level of a terminology distinguished by anatomical or physiological system, etiology, or purpose, and referencing an international medical terminology (Medical Dictionary for Regulatory Activities) version 12.0, designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle.Congenital, familial and genetic disorders | Cardiac disorders | Blood and lymphatic system disorders | Infections and infestations | Immune system disorders | Hepatobiliary disorders | General disorders and administration site conditions | Gastrointestinal disorders | Eye disorders | Endocrine disorders | Ear and labyrinth disorders | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Musculoskeletal and connective tissue disorders | Metabolism and nutrition disorders | Investigations | Injury, poisoning and procedural complications | Vascular disorders | Surgical and medical procedures | Social circumstances | Skin and subcutaneous tissue disorders | Respiratory, thoracic and mediastinal disorders | Reproductive system and breast disorders | Renal and urinary disorders | Psychiatric disorders | Pregnancy, puerperium and perinatal conditions | Nervous system disorders
Medical2003874v3Medical History DescriptionMedical History DescriptionBrief description of major medical and surgical events that occurred during the patient's lifetime. 
Medical Examination3134023v1Reason imaging was not completedImage Exam Not Completed ReasonProvide reason imaging exam was not initiated, performed or completed.Participant death | Participant withdrew | Equipment failure/error | Medical reason | Participant refusal | Scheduling problem | Other | Unknown
Medical Examination3134024v1Other reason imaging was not completedImage Exam Not Completed Reason Other SpecifyA textual reason not listed describing why the imaging exam was not initiated, performed or completed. 
Medical Examination3134842v1Medical reason imaging was not completedImage Exam Not Completed Medical ReasonA medical reason the imaging exam was not initiated, performed or completed.Claustrophobia | Injection complication | Progressive disease | Abnormal laboratory level | Adverse Event | Other
Medication2179986v1Is the patient taking any concomitant medicationsConcomitant Medication Use Ind-3the yes/no/unknown indicator to ask if a patient is taking any medication that is not part of protocol treatment (including medication prescribed for other medical conditions).No | Yes | Unknown
Messenger RNA2322249v1GeneBank Full Sequence IdentifierMessenger RNA Genbank_Accession_Number_Property Genomic IdentifierMessenger RNA. A class of RNA molecules that contain protein-coding information in their nucleotide sequence and can be translated into the amino acid sequence of a protein. Bacterial mRNAs are generally primary transcripts in that they do not require po_Indicates the accession number for a Gene within the GenBank database.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier for an entire sequence record when the record is submitted to GenBank. [Explanatory comment: An accession number applies to the complete record and is usually a combination of a letter(s) and numbers, such as a single letter followed by five digits (e.g., U12345) or two letters followed by six digits (e.g., AF123456). Some accessions might be longer, depending on the type of sequence record] 
Messenger RNA2322251v1Messenger RNA RefSeq IdentifierMessenger RNA RefSeq Genomic IdentifierMessenger RNA. A class of RNA molecules that contain protein-coding information in their nucleotide sequence and can be translated into the amino acid sequence of a protein. Bacterial mRNAs are generally primary transcripts in that they do not require po_The Reference Sequence (RefSeq) collection aims to provide a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, transcript (RNA), and protein products, for major research organisms. RefSeq standards serve as the basis for me:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier for a Messenger RNA sequence (actually the cDNA sequences constructed from mRNA) assigned in the RefSeq data collection. [Explanatory comment: RefSeq accession numbers can be distinguished from GenBank accessions by their prefix distinct format of [2 characters|underbar]. The NM_123456 (6 digits) format is used for mature RNA (mRNA) protein-coding transcripts.] 
Messenger RNA2322248v1EnsEMBL IdentifierMessenger RNA Ensembl Genomic IdentifierMessenger RNA. A class of RNA molecules that contain protein-coding information in their nucleotide sequence and can be translated into the amino acid sequence of a protein. Bacterial mRNAs are generally primary transcripts in that they do not require po_Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust. The Ensembl Genome Brow:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier assigned to a transcript by EnsEMBL. It is used to uniquely identify a gene transcript in the EnsEMBL system. [Explanatory comment: The format is ENSTxxxxxxxxxxx for humans. The one for mouse is ENSMUSTxxxxxxxxxxx. So the general format is ENS Species (except human) T ? xxxxxxxxxxx. There are always 11 digits in this identifier.There are some species that don't follow these rules. For instance, species such as Drosophila or Tetraodon were not annotated by Ensembl follow a different convention. This definition has been reviewed by Xose M. Fernandez and Bert Overduin representing the Ensembl Helpdesk.] 
Messenger RNA2322250v1GeneBank Nucleotide Sequence NumberMessenger RNA Accession Number Versioned Genbank Accession Number Genomic IdentifierMessenger RNA. A class of RNA molecules that contain protein-coding information in their nucleotide sequence and can be translated into the amino acid sequence of a protein. Bacterial mRNAs are generally primary transcripts in that they do not require po_control number:A Genbank accession number with an explicit version.:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._A nucleotide sequence identification number that represents a single, specific sequence in the GenBank database. [Explanatory comment: This identification number uses the accession.version format implemented by GenBank/EMBL/DDBJ in February 1999. (The unique identifier for a sequence record. An accession number applies to the complete record and is usually a combination of a letter(s) and numbers, such as a single letter followed by five digits (e.g., U12345) or two letters followed by six digits (e.g., AF123456). Some accessions might be longer, depending on the type of sequence record.) If there is any change to the sequence data (even a single base), the version number will be increased, e.g., U12345.1 8594; U12345.2, but the accession portion will remain stable. The accession.version system of sequence identifiers runs parallel to the GI number system, i.e., when any change is made to a sequence, it receives a new GI number AND an increase to its version number. Whenever an individual searches an NCBI sequence database, only the most recent version of a record is retrieved.] 
Name2590797v1Organism Additional NameOrganism Additional Name Value Additional Name TextAny individual living thing.:Added; extra; further.:The words or language units by which a thing is known._The information contained in a data field._Added; extra. (from American Heritage Dictionary)_The words or language units by which a thing is known._Text; the words of something written. 
Name2590796v1Organism Additional Name SourceOrganism Additional Name Source Additional Name Source TextAny individual living thing.:Added; extra; further.:The words or language units by which a thing is known._Where something is available._Added; extra. (from American Heritage Dictionary)_The words or language units by which a thing is known._Source; where something is available._Text; the words of something written. 
Name2590798v1Organism Additional Name CommentOrganism Additional Name Comment Additional Name Comment TextAny individual living thing.:Added; extra; further.:The words or language units by which a thing is known._A written explanation or criticism or illustration that is added to a book or other textual material._Added; extra. (from American Heritage Dictionary)_The words or language units by which a thing is known.._A written explanation, observation or criticism added to textual material._Text; the words of something written. 
Neoplasm3451636v1Disease StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for cancer of the vagina.Stage unknown | 0 | I | II | III | IVA | IVB
Neoplasm3437198v1Pathologic N StageOvarian Cancer and Primary Peritoneal Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the ovarian and primary peritoneal carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Neoplasm3225684v1FIGO StageGynecologic Tumor Grouping Cervical Endometrial FIGO 2009 StageThe extent of a cervical or endometrial cancer within the body, especially whether the disease has spread from the original site to other parts of the body, as described by the International Federation of Gynecology and Obstetrics (FIGO) stages.Stage IVB | Stage IVA | Stage IV | Stage IIIC2 | Stage IIIC1 | Stage IIIC | Stage IIIB | Stage IIIA | Stage III | Stage IIB | Stage IIA | Stage II | Stage IC | Stage IB2 | Stage IB1 | Stage IB | Stage IA2 | Stage IA1 | Stage IA | Stage I | Stage 0 | Stage IIA1 | Stage IIA2
Neoplasm3371445v1Pathologic M StageThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the thyroid tumor based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3444617v1Clinical N StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the uterine carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | N2 | NX
Neoplasm3377209v1Clinical T StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary hepatocellular carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T4 | T3b | T3a | T2 | T1 | T0 | TX
Neoplasm3361903v1Disease StageBladder Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for urinary bladder cancer.Stage unknown | IV | III | II | 0is | 0a | I
Neoplasm3357526v1Pathologic T StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary colon and rectal cancer based on evidence obtained from pathologic examination through completion of definitive surgery.T4b | T4a | T3 | Tis | T0 | TX | T1 | T2
Neoplasm3451635v1Pathologic M StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the cancer of the vagina based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3419407v1Disease StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for breast carcinoma.Stage unknown | IV | IIIC | IIIB | IIIA | IIB | IIA | IB | IA | 0
Neoplasm3448030v1Clinical M StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the carcinoma of the vulva based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3114074v1StageGynecologic Tumor Grouping FIGO 1988 Endometrial Carcinoma Stagethe extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body according to the International Federation of Gynecology and Obstetrics Gynecologic (FIGO) 1988 staging system for endometrial carcinoma.IVB | IVA | IV | IIIC | IIIB | IIIA | III | IIB | IIA | II | IC | IB | IA | I
Neoplasm3444618v1Pathologic N StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the uterine carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | N2 | NX
Neoplasm3357525v1Clinical T StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary colon and rectal cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.T4b | T4a | T3 | Tis | T0 | TX | T1 | T2
Neoplasm3437185v1Clinical T StageOvarian Cancer and Primary Peritoneal Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary ovarian and peritoneal carcinoma carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T1 | T1a | T1b | T1c | T2 | T2a | T2b | T2c | T3a | T3b | T3c | TX | T0 | T3
Neoplasm3447422v1Clinical M StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the fallopian tube carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3447364v1Clinical T StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary fallopian tube carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T1a | T1b | T1c | T2 | T2a | T2b | T2c | T3 | T3a | T3b | T3c | Tis | TX
Neoplasm3361880v2Pathologic T StageBladder Cancer American Joint Committee On Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary urinary bladder cancer based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | pT2a | pT2b | T3 | pT3a | pT3b | T4 | T4a | Ta | Tis | TX | T4b
Neoplasm3474989v1FIGO StageGynecologic Vaginal Tumor Federation of Gynecology and Obstetrics (FIGO) 2009 StageAnatomic extent of the primary carcinoma of the vagina based on surgical pathologic examination.IVB | IVA | I | II | III
Neoplasm3448026v1Clinical T StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary carcinoma of the vulva based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1a | T1b | T2 | T3 | Tis | TX
Neoplasm3447421v1Pathologic N StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the fallopian tube carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Neoplasm3452496v1Pathologic N StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the exocrine and endocrine pancreatic cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Neoplasm3447652v2Pathologic M StageGestational Trophoblastic Tumor American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the gestational trophoblastic tumor based on evidence obtained from pathologic examination through completion of definitive surgery.M1 | M1a | M1b
Neoplasm3371435v1Clinical T StageThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary thyroid tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T4b | T4a | T3 | T2 | T1b | T1a | T1 | T0 | TX
Neoplasm3655869v1Pathologic N StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the breast carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.pN0 | pN0(i+) | pN0(i-) | pN0(mol+) | pN0(mol-) | pN1 | pN1a | pN1b | pN1c | pN1mi | pN2 | pN2a | pN2b | pN3 | pN3a | pN3b | pN3c | pNX
Neoplasm3451628v1Pathologic T StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary cancer of the vagina based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | Tis | TX
Neoplasm3436561v1Clinical N StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the prostate carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N1 | N0 | NX
Neoplasm3436565v1Pathologic M StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the prostate carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1 | M1a | M1b | M1c
Neoplasm3451634v1Clinical M StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the cancer of the vagina based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3745015v1Pathologic N StageLung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the lung carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.N3 | N2 | N1 | N0 | NX
Neoplasm3444619v1Clinical M StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the uterine carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3431313v1Disease StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for cervical cancer.0 | I | II | III | Stage unknown | IVB | IVA | IIIB | IIIA | IIB | IIA2 | IIA1 | IIA | IB2 | IB1 | IB | IA2 | IA1 | IA
Neoplasm3116943v1StageGynecologic Tumor Grouping FIGO 2009 Cervical Carcinoma Stagethe extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body according to the International Federation of Gynecology and Obstetrics Gynecologic (FIGO) 2009 staging system for cervical cancer.IVB | IVA | IV | IIIB | IIIA | III | IIB | IIA2 | IIA1 | IIA | II | IB2 | IB1 | IB | IA2 | IA1 | IA | I
Neoplasm3447420v1Clinical N StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the fallopian tube carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Neoplasm3371436v1Clinical T Stage, AnaplasticThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Anaplastic Clinical Tumor T StageExtent of the primary thyroid anaplastic tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T4b | T4a
Neoplasm3915162v1Disease StageNasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for nasopharyngeal cancer.Stage unknown | IVC | IVA | IVB | II | 0 | I | III
Neoplasm3436562v1Clinical M StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the prostate carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M1c | M1b | M1a | M1 | M0
Neoplasm3361879v1Clinical M StageBladder Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the urinary bladder cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3431311v1Pathologic N StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the cervical cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Neoplasm3448031v1Pathologic M StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the carcinoma of the vulva based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3451631v1Clinical N StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the cancer of the vagina based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Neoplasm3915161v1Pathologic M StageNasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the nasopharyngeal cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3444200v1Pathologic M StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the gastric cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3436556v1Clinical T StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary prostate carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T4 | T3b | T3a | T3 | T2c | T2b | T2a | T2 | T1c | T1b | T1a | T1 | T0 | TX
Neoplasm3447648v1Clinical T StageGestational Trophoblastic Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary gestational trophoblastic tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | TX
Neoplasm3474988v1FIGO StageGynecologic Uterine Sarcoma Tumor Federation of Gynecology and Obstetrics Gynecologic (FIGO) 2009 StageAnatomic extent of the primary uterine sarcoma based on surgical pathologic examination.I | IA | IB | IC | II | IIA | IIB | III | IIIA | IIIC | IV
Neoplasm3371443v1Pathologic T Stage, AnaplasticThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Anaplastic Pathologic Tumor T StageExtent of the primary thyroid anaplastic tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T4b | T4a
Neoplasm3444616v1Pathologic T StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary uterine carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T1a | T1b | T2 | T3a | T3b | T4 | Tis | TX
Neoplasm3474985v2FIGO StageGynecologic Gestational Trophoblastic Tumor Federation of Gynecology and Obstetrics (FIGO) 2009 StageAnatomic extent of the primary trophoblastic disease based on surgical pathologic examination.I | II | III | IV
Neoplasm3915160v1Pathologic N StageNasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the nasopharyngeal cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N3b | N3a | N0 | N1 | N2 | N3 | NX
Neoplasm3377210v1Clinical N StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the hepatocellular carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N1 | N0 | NX
Neoplasm3474990v1FIGO StageGynecologic Vulvar Tumor Federation of Gynecology and Obstetrics (FIGO) 2009 StageAnatomic extent of the primary carcinoma of the vulva based on surgical pathologic examination.IVB | IVA | IA | IB | II | III
Neoplasm3371440v1Clinical N StageThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the thyroid tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.N1b | N1a | N1 | N0 | NX
Neoplasm3915157v1Clinical N StageNasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the nasopharyngeal cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N3b | N3a | N0 | N1 | N2 | N3 | NX
Neoplasm3452507v2Disease StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for exocrine and endocrine pancreatic cancer.0 | IA | IB | IIA | IIB | III | IV | Stage unknown
Neoplasm3437196v1Pathologic T StageOvarian Cancer and Primary Peritoneal Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary ovarian and peritoneal carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.T1 | T1a | T1b | T1c | T2 | T2a | T2b | T2c | T3a | T3b | T3c | TX | T0 | T3
Neoplasm3448027v1Pathologic T StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary carcinoma of the vulva based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1a | T1b | T2 | T3 | Tis | TX
Neoplasm3444137v1Clinical T StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary gastric cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.TX | T4b | T4a | T4 | T3 | T2 | T1b | T1a | T1 | Tis | T0
Neoplasm3745014v1Pathologic T StageLung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary lung carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.TX | T4 | T3 | T2b | T2a | T2 | T1b | T1a | T1 | T0 | Tis
Neoplasm3452491v1Pathologic T StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary exocrine and endocrine pancreatic cancer based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | Tis | TX
Neoplasm3745012v1Clinical N StageLung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the lung carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N3 | N2 | N1 | N0 | NX
Neoplasm3437197v1Clinical N StageOvarian Cancer and Primary Peritoneal Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the ovarian and primary peritoneal carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Neoplasm3436564v2Pathologic N StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the prostate carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.pN0 | pN1 | NX
Neoplasm3444615v1Clinical T StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary uterine carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T1a | T1b | T2 | T3a | T3b | T4 | Tis | TX
Neoplasm3745011v1Clinical T StageLung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary lung carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.TX | T4 | T3 | T2b | T2a | T2 | T1b | T1a | T1 | T0 | Tis
Neoplasm3371444v1Pathologic N StageThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the thyroid tumor based on evidence obtained from pathologic examination through completion of definitive surgery.N1b | N1a | N1 | N0 | NX
Neoplasm3357527v1Clinical N StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the colon and rectal cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N2b | N2a | N2 | N1c | N1b | N1a | N1 | N0 | NX
Neoplasm3474987v1FIGO StageGynecologic Ovarian Tumor Federation of Gynecology and Obstetrics (FIGO) 2009 StageAnatomic extent of the primary carcinoma of the ovary based on surgical pathologic examination.IV | I | IA | IB | IC | II | IIA | IIB | IIC | III | IIIA | IIIB | IIIC
Neoplasm3447467v1Disease StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for fallopian tube carcinoma.Stage unknown | 0 | I | IA | IB | IC | II | IIA | IIB | IIC | III | IIIA | IIIB | IIIC | IV
Neoplasm3419391v1Clinical M StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the breast carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M1 | cM0(i+) | M0
Neoplasm3444156v1Clinical N StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the gastric cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N3 | N3b | N3a | N1 | NX | N0 | N2
Neoplasm3452492v1Clinical N StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the exocrine and endocrine pancreatic cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | NX
Neoplasm3419389v2Clinical N StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the breast carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.N3c | N3b | N3a | N3 | N2b | N2a | N2 | N1 | N0 | NX
Neoplasm3444170v1Clinical M StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the gastric cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3419387v1Clinical T StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary breast carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.T4 | T4d | T4c | T4b | T4a | T3 | T2 | T1c | T1b | T1a | T1mi | T1 | Tis (Paget's) | Tis (LCIS) | Tis (DCIS) | Tis | T0 | TX
Neoplasm3361877v1Clinical N StageBladder Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the urinary bladder cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | N2 | N3 | NX
Neoplasm3447365v1Pathologic T StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary fallopian tube carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T1a | T1b | T1c | T2 | T2a | T2b | T2c | T3 | T3a | T3b | T3c | Tis | TX
Neoplasm3915158v1Clinical M StageNasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the nasopharyngeal cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3357530v1Pathologic M StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the colon and rectal cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1b | M1a | M1
Neoplasm3431309v1Clinical M StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the cervical cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3474983v1FIGO StageGynecologic Fallopian Tube Tumor Federation of Gynecology and Obstetrics (FIGO) 2009 StageAnatomic extent of the primary fallopian tube carcinoma based on surgical pathologic examination.IV | I | IA | IB | IC | II | IIA | IIB | IIC | III | IIIA | IIIB | IIIC
Neoplasm3357531v1Disease StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for colon and rectal cancer.Stage unknown | IVB | IVA | IIIC | IIIB | IIIA | IIC | IIB | IIA | 0 | I
Neoplasm3357528v1Pathologic N StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the colon and rectal cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N2b | N2a | N2 | N1c | N1b | N1a | N1 | N0 | NX
Neoplasm3444138v1Pathologic T StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary gastric cancer based on evidence obtained from pathologic examination through completion of definitive surgery.TX | T4b | T4a | T4 | T3 | T2 | T1b | T1a | T1 | Tis | T0
Neoplasm3452505v1Clinical M StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the exocrine and endocrine pancreatic cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3448028v1Clinical N StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the carcinoma of the vulva based on evidence obtained from clinical assessment parameters determined prior to treatment.N0 | N1 | N1a | N1b | N2 | N2a | N2b | N2c | N3 | NX
Neoplasm3452490v1Clinical T StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary exocrine and endocrine pancreatic cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | Tis | TX
Neoplasm3436563v2Pathologic T StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary prostate carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.pT2 | pT2a | pT2b | pT2c | pT3 | pT3a | pT3b | pT4 | T0 | TX
Neoplasm3444217v1Disease StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for gastric cancer.Stage unknown | 0 | IA | IB | IIA | IIB | IIIA | IIIB | IIIC | IV
Neoplasm3666854v1Clinical T StageBladder Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary urinary bladder cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | T4a | Ta | Tis | TX | T4b
Neoplasm3431307v1Clinical T StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary cervical cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.T1a | T4 | T3b | T3a | T3 | T2b | T2a2 | T2a1 | T2a | T2 | T1b2 | T1b1 | T1b | T1a2 | T1a1 | T1 | T0 | Tis | TX
Neoplasm3448032v1Disease StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for carcinoma of the vulva.Stage unknown | 0 | I | IA | IB | II | IIIA | IIIB | IIIC | IVA | IVB
Neoplasm3437199v1Clinical M StageOvarian Cancer and Primary Peritoneal Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the ovarian and primary peritoneal carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3361883v1Pathologic N StageBladder Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the urinary bladder cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | N2 | N3 | NX
Neoplasm3357529v1Clinical M StageColorectal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the colon and rectal cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.M1b | M1a | M1 | M0
Neoplasm3444620v1Pathologic M StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the uterine carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3915159v1Pathologic T StageNasopharyngeal Cancer American Joint Committee On Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary nasopharyngeal cancer based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T2 | T3 | T4 | Tis | TX
Neoplasm3745016v1Pathologic M StageLung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the lung carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1b | M1a | M1
Neoplasm3431310v1Pathologic T StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary cervical cancer based on evidence obtained from pathologic examination through completion of definitive surgery.T0 | T1 | T1a | T1b | T2 | T2a | T2b | T3 | T3a | T3b | T4 | Tis | TX | T1a2 | T1a1 | T1b1 | T1b2 | T2a1 | T2a2
Neoplasm3452506v1Pathologic M StagePancreatic Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the exocrine and endocrine pancreatic cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3431312v1Pathologic M StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the cervical cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3745013v1Clinical M StageLung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the lung carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1
Neoplasm3915156v1Clinical T StageNasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary nasopharyngeal cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | Tis | TX
Neoplasm3447466v1Pathologic M StageFallopian Tube Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the fallopian tube carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3451633v1Pathologic N StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the cancer of the vagina based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | NX
Neoplasm3444621v1Disease StageUterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for uterine carcinoma.Stage unknown | 0 | I | IA | IB | II | III | IIIA | IIIB | IIIC1 | IIIC2 | IVA | IVB
Neoplasm3431308v1Clinical N StageCervical Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Regional Lymph Node N StageExtent of the regional lymph node involvement for the cervical cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.N1 | N0 | NX
Neoplasm3437200v1Pathologic M StageOvarian Cancer and Primary Peritoneal Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the ovarian and primary peritoneal carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3451626v1Clinical T StageVaginal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Tumor T StageExtent of the primary cancer of the vagina based on evidence obtained from clinical assessment parameters determined prior to treatment.T0 | T1 | T2 | T3 | T4 | Tis | TX
Neoplasm3371442v1Pathologic T StageThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary thyroid tumor based on evidence obtained from pathologic examination through completion of definitive surgery.T4b | T4a | T3 | T2 | T1b | T1a | T1 | T0 | TX
Neoplasm3371441v1Clinical M StageThyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the thyroid tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.M1 | M0
Neoplasm3123069v1Tumor size longest diameter (as determined by surgeon)Longest Tumor Surgeon Diameter MeasurementThe longest diameter for a tumor/lesion as determined by surgeon. 
Neoplasm3361884v1Pathologic M StageBladder Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the urinary bladder cancer based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neoplasm3448029v1Pathologic N StageVulvar Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the carcinoma of the vulva based on evidence obtained from pathologic examination through completion of definitive surgery.N0 | N1 | N1a | N1b | N2 | N2a | N2b | N2c | N3 | NX
Neoplasm3419393v1Pathologic T StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Tumor T StageExtent of the primary breast carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.T4 | T4d | T4c | T4b | T4a | T3 | T2 | T1c | T1b | T1a | T1mi | T1 | Tis (Paget's) | Tis (LCIS) | Tis (DCIS) | Tis | T0 | TX
Neoplasm3377211v1Clinical M StageLiver Cancer American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the hepatocellular carcinoma based on evidence obtained from clinical assessment parameters determined prior to treatment.M1 | M0
Neoplasm3444155v1Pathologic N StageGastric Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Regional Lymph Node N StageExtent of the regional lymph node involvement for the gastric cancer based on evidence obtained from pathologic examination through completion of definitive surgery.N3 | N3b | N3a | N1 | NX | N0 | N2
Neoplasm3447651v2Clinical M StageGestational Trophoblastic Tumor American Joint Committee on Cancer (AJCC) Edition 7 Clinical Distant Metastasis M StageExtent of the distant metastasis for the gestational trophoblastic tumor based on evidence obtained from clinical assessment parameters determined prior to treatment.M0 | M1 | M1a | M1b
Neoplasm3419406v1Pathologic M StageBreast Cancer American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M StageExtent of the distant metastasis for the breast carcinoma based on evidence obtained from pathologic examination through completion of definitive surgery.M1
Neuroendocrine Neoplasm4986358v1Disease StageDigestive System Neuroendocrine Tumor American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for digestive system neuroendocrine tumor.IIIB | IIIA | I | 0 | IIA | IIB | IV | Stage unknown
Non-Small Cell Lung Carcinoma3745017v1Disease StageNon-Small Cell Lung Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for non-small cell lung carcinoma.Stage unknown | IV | IIIB | IIIA | IIB | IIA | IB | IA | 0 | Occult
Notification3782616v1If yes, Date amended datePatient Notification Treating Site Consent Amended DateCalendar date on which a participant notified the treating site of a change in their specimen consent. 
Off Treatment23v3Off Treatment DateOff Treatment Datethe date of completion, progression, death, or decision to discontinue therapy. 
Off Treatment2453219v1Reason Treatment EndedOff-treatment Codethe CDUS codes for the rationale for cessation of the clinical trial intervention. (CDUS Exchange)01 | 02 | 03 | 05 | 12 | 13 | 06 | 07 | 10 | 11 | 04 | 08 | 98
Off Treatment2956870v1Off Treatment Other, SpecifyOff Treatment Reason SpecifyThe free text field to specify a reason or event that caused a participant to be removed from a clinical protocol. 
Organism2342465v2Organism NCBI Taxonomy IdentiferOrganism National Center for Biotechnology Information Taxonomy Identifier National Center for Biotechnology Information Taxonomy IdentifierA living thing, such as an animal, a plant, a bacterium, or a fungus._Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease. (http://www.ncbi.nlm.nih.gov/):The theories and techniques of naming, describing, and classifying organisms, and the study of the relationships of taxa. (from On-line Medical Dictionary):One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information - all for the better understanding of molecular processes affecting human health and disease. (http://www.ncbi.nlm.nih.gov/)_The theories and techniques of naming, describing, and classifying organisms, and the study of the relationships of taxa. (from On-line Medical Dictionary)_One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing. 
Organism2223784v4Organism Scientific NameOrganism Scientific_Name Scientific Name TextA living thing, such as an animal, a plant, a bacterium, or a fungus._The name applied to a plant, animal, or other organism, according to the Codes of Nomenclature, consisting of a Genus and species._The name applied to a plant, animal, or other organism, according to the Codes of Nomenclature, consisting of a Genus and species._Text; the words of something written. 
Organism2590793v1Organism Taxonomy RankOrganism Taxonomy Rank Taxon Rank NameA living thing, such as an animal, a plant, a bacterium, or a fungus._The theories and techniques of naming, describing, and classifying organisms, and the study of the relationships of taxa.:A relative status as compared to others within a group._A group or category, at any level, in a system for classifying plants or animals. (On-line Medical Dictionary)_A relative status as compared to others within a group._The words or language units by which a thing is known.Family | Genus | Infraclass | Infraorder | Kingdom | Order | Phylum | Species | Subclass | Subfamily | Suborder | Subphylum | Class | No Rank | Forma | Parvorder | Species Group | Species Subgroup | Subgenus | Subspecies | Subkingdom | Tribe | Subtribe | Superclass | Superfamily | Superkingdom | Superorder | Superphylum | Variety
Organism2223787v4Organism Common NameOrganism Common Name Common Name TextA living thing, such as an animal, a plant, a bacterium, or a fungus._Widely known or encountered.:The words or language units by which a thing is known._Widely known or encountered._The words or language units by which a thing is known._Text; the words of something written. 
Organizational Unit2517552v1Organization Email AddressOrganizational Unit Email Address TextThe string of characters that represents an electronic mail address of an organizational unit. 
Ovarian Carcinoma3437201v1Disease StageOvarian Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for ovarian carcinoma.IB | II | IIA | IIB | IIC | III | IIIA | IIIB | IIIC | IV | Stage unknown | I | IA | IC
Partial2183073v1Year DateYear DateThe value that represents a period of 365 or 366 days in a Gregorian calendar. 
Partial2183070v1Day DateDay DateThe value that represents a division of time equal to the time elapsed between one midnight to the next. 
Partial2193252v2HourHour TimeThe time value that represents a period of time measured in twenty-fourths of a mean solar. 
Partial2193265v2SecondSecond TimeA time value that represents a period of time measured in sixtieths of a minute. 
Partial2193261v2MinuteMinute TimeA time value that represents a period of time measured in sixtieths of an hour. 
Partial2183066v1Month DateMonth DateThe code that represents one of the parts of the year into which a calendar year is divided.01 | 02 | 03 | 04 | 05 | 06 | 07 | 08 | 09 | 10 | 11 | 12 | 00
Participant2822790v1What was the prior study participant identifier?Participant Prior Clinical Study IdentifierThe unique numeric or alphanumeric identification that was assigned to a participant from a previous study. 
Participant2746468v1Participant Local IdentifierHealthcare Facility Participant IdentifierThe unique numeric or alphanumeric designation assigned by a healthcare facility used to link to the participant's medical record. 
Participant2746466v1Was the participant on a prior study with this group?Participant Prior Clinical Study Participation Ind-3The yes/no/unknown indicator that asks whether the participant was on a prior protocol with this group.Unknown | Yes | No
Participant2974066v1Consent TypeParticipant Informed Consent TypeAn identifier specifying the type of consent document reviewed and/or approved, referencing a clinical study, specimen collection, or other research activity of which the candidate participant has been informed of the relevant medical facts and the risks involved.Other | Correlative | Standard of Care | PK | Quality of Life | Donor | Record Release | Tissue Bank | Study Participation | Biomarker | Screening | Medical Imaging
Participant2746541v1Enrollment DateParticipant Enrollment DateThe date the Participant is accepted into the study. The study site may also be notified of the treatment arm and Study Participant Identifier on this date. 
Participant2988215v1Consent Type SpecifyParticipant Informed Consent Difference SpecifyText field that captures the specific type of consent when multiple consents of the same type are used on a study. 
Participant2974196v1Consent LanguageParticipant Consent Language CodeThe three letter code that represents the language in which the informed consent was provided. 
Pathologist64320v3Reviewing PathologistReviewing Pathologist Namename of reviewing pathologist. 
Patient2423393v1The calculation of age based on the equation of Date of Event-Date of Birth.Derived Person Age ValueThe length of time that one has existed in completed years, months and days at the time of the event. [Explanatory Comment 1: Age is calculated as the Event Date - Person Birth Date. The transfer format of Years, Months and Days (YYY.MM.DD) includes values for year between 0 and 999, for month between 0 and 11, and for day between 0 and 30. Explanatory Comment 2: The majority of external standards does not represent, transmit, or store the concept of Age. An algorithm is included to provide guidance for the computation of age value.] 
Patient3613171v1Specimen withdrawal of consent approvedPatient Specimen Institutional Review Board Approval Consent Withdrawn Yes No Indicatorthe yes/no indicator related to an acceptance as satisfactory by an authoritative body (internal review board) of the patient's withdrawal (when the permission to do something is rescinded or withdrawn) of consent for specimen (a preparation of tissue or bodily fluid taken for examination or diagnosis) research activities.No | Yes
Patient3475327v1Date study participant rescinded consent withdrawalPatient Cancel Withdraw Consent DateThe date of the annulment of the ceasing of a patient's consent. 
Patient2199780v1Withdrawn consent datePatient Withdraw Consent Datethe date the patient withdrew consent. 
Patient2552398v1Was patient hospitalized for toxicity?Patient Toxicity Hospitalization IndicatorText indicator to signify that a patient/participant's hospitalization was due to toxicity or side effects from an agent or other cause.Yes | No
Patient2001039v4Participant InitialsPatient Initials Namethe initial letters of the first, middle, and last names of the patient or participant registered on the clinical trial. 
Patient3521329v1Consent Withdrawal for specimen(s)Patient Specimen Consent Withdrawn Yes No Indicatorthe yes/no indicator that asks whether patient consent was withdrawn for specimen research activities.No | Yes
Patient1925v2.31Participant Subgroup CodePatient Subgroup Codethe subgroup (stratum) is a unique patient characteristic that will be utilized to uniformly group patients for separate analysis or treatment. Each subgroup should have a unique code for identification. The investigator will provide a code (up tp 10 characters) for each subgroup with the Protocol Submission Checklist. 
Patient2171v4Date of RegistrationPatient Registration Datethe date the patient was enrolled on the protocol. 
Patient2960892v1Specify reason not eligiblePatient Ineligibility Other Specify TextThe free text field that describes another response when other is chosen from a list of values for why the patient is ineligible to participate in the study. 
Patient2465308v1Intergroup Participant IdentifierPatient Multiple Clinical Trials Cooperative Group Identifier Numbera numeric sequent used to uniquely identify an individual participating in an intergroup clinical protocol. 
Patient2201880v1Finding DescriptionPatient Abnormal Physical Examination Specifythe free text field to specify the abnormal physical examination or systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual's health assessment. 
Patient3783558v1Reason for withdrawal from Quality of Life portion of studyPatient Quality of Life Consent Withdrawn ReasonText term to capture an explanation a participant withdrew from the Quality of Life (QOL) portion of a study.Other | I am not comfortable with the questions being asked | No reason given | The questionnaires are too time consuming
Patient2179659v2Medical History DatePatient Relevant Medical History DateThe date a medical history was taken. 
Patient3521331v1Consent Withdrawal for QOL companionPatient Companion Study Quality of Life Consent Withdrawn Yes No Indicatorthe yes/no indicator that asks whether patient consent was withdrawn for a quality of life companion study.No | Yes
Patient3783574v1Reason for withdrawal from Quality of Life portion of study, OtherPatient Quality of Life Consent Withdrawn Consent Other Reason TextText that describes the reason a participant withdrew from the Qualify of Life portion of a study that is different from the options presented. 
Patient2201750v1Overall Physical Exam PerformedPatient Physical Examination Ind-2the yes/no indicator whether a physical examination has been performed.No | Yes
Patient3783584v1Date Witness confirmed study participant withdrew consentWitness Confirmation Patient Withdraw Quality of Life Consent DateCalendar date a witness confirms that a participant notified the treating site of the desire to withdraw consent from the Quality of Life portion of a study. 
Patient3613143v1Date of amended consentPatient Amended Consent Datethe date related to the patient's altered formally of consent. 
Patient1235v4Is the participant eligible for inclusion on this studyPatient Eligibility Indicatorthe yes/no/unknown indicator that asks the investigator to stipulate whether the patient is eligible for inclusion on this protocol.No | Yes | Unknown
Patient2182072v1Randomization DatePatient Randomization DateDate of a process used in therapeutic trials or other research endeavors for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. 
Patient2003301v4Study Participant IdentifierPatient IdentifierThe unique numeric or alphanumeric identification assigned to a participant in a clinical trial or research study. 
Performance Status2003315v4.2Performance Status (Zubrod)Zubrod Performance Status ScoreThe functional level of the patient based on the Zubrod performance scale.0 | 1 | 2 | 3 | 4
Performance Status2179787v2Public Eating RatingDietary Performance Status Assessment Location Scalethe assessment of the location and social eating habits of a cancer patient/participant using a published validated scale by List, Ritter-Sterr and Lansky.0 | 100 | 25 | 50 | 75
Performance Status2180158v1.1Performance Status (Lansky)Lansky Performance Status ScoreNumeric score representing performance status of a subject under 12 years of age according to the Lansky scale.90 | 80 | 70 | 60 | 50 | 40 | 30 | 20 | 10 | 0 | 100
Performance Status2179791v2Understandability of Speech RatingSpeech Performance Status Assessment Comprehension Scalethe assessment of the understandability of speaking ability of a cancer patient/participant using a published validated scale by List, Ritter-Sterr and Lansky.0 | 100 | 25 | 50 | 75
Performance Status2199894v1Objective assessmentCardiac Performance Status Assessment Objective Response Scalethe objective assessment scale of the New York Heart Association cardiac assessment.A | B | C | D
Performance Status2003853v4.2Performance Status (Karnofsky)Karnofsky Performance Status ScoreScore from the Karnofsky Performance status scale, representing the functional capabilities of a person.0 | 50 | 40 | 30 | 20 | 10 | 100 | 90 | 80 | 70 | 60
Performance Status88v5.1Performance Status (ECOG)Performance Status Assessment Eastern Cooperative Oncology Group Scalethe ECOG functional performance status of the patient/participant.1 | 2 | 3 | 4 | 5 | 0
Performance Status2179784v2Normalcy of Diet RatingDiet Performance Status Assessment Intake Scalethe assessment of the variety and content of the diet of a cancer patient/participant using a published validated scale by List, Ritter-Sterr and Lansky.0 | 100 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90
Performance Status2181292v1.1New York Heart Association ClassificationCardiac Performance Status Assessment Function Scalethe cardiac function assessment scale as described by the New York Heart Association.Unknown | Class I | Class II | Class III | Class IV
Performing Laboratory2841282v1Performing Laboratory NamePerforming Laboratory Name TextThe name of the laboratory that actually performed a test and that is also therefore the source of the data. 
Person653v6BSAPerson Body Surface Area Valuethe calculated numerical quantity that represents the 2-dimensional extent of the body surface relating height to weight. 
Person2006410v3Body Mass Index (BMI)Person Body Mass Index ValueA calculated numerical quantity that represents an individual's weight to height ratio. [Manually-curated] 
Person2179643v4HeightPerson Height ValueThe number that describes the vertical distance of an individual. 
Person2179689v4WeightPerson Weight ValueThe number that describes the vertical force exerted by the mass of an individual as a result of gravity. 
Person2222323v1Person Full Formatted NameDerived Person Full Formatted NameA formatted means of uniquely identifying an individual derived from multiple naming elements. 
Person2227048v1Person Sex PhenotypePerson Sex Phenotype Text TypeText designations that identify phenotypic person sex . Sex is described as the assemblage of physical properties or qualities by which male is distinguished from female. [Explanatory Comment 1: Identification is based upon observation/phenotype.] [Explanatory Comment 2: Phenotype is the outward appearance of the individual. It is the product of interactions between genes and between the genotype and the environment.]Unknown | Unspecified | Intersex | Male Phenotype | Female Phenotype | Male-to-Female Transsexual Phenotype | Female-to-Male Transsexual Phenotype
Person2176v5Fax NumberResponsible Person Fax Numberthe telephone number to reach a fax machine for the person who documented the information on the case report form. 
Person2630200v1Weight unit of measurePerson Weight Unit of Measure Unified Code for Units of Measure CodeThe Unified Code for Units of Measure symbols that represent a determinate amount or quantity used as the standard of measurement for the vertical force exerted by the mass of an individual as a result of gravity.[oz_av] | [lb_av] | kg | g
Person2435955v1Rank of language used by a personPerson Language Preference Rank TypeThe terms that describe the relative status or position of a person's means of communication. [EXPLANATORY COMMENT: The use of this data element should allow for multiple instances of primary language to accommodate those persons who are fluent in multiple languages and consequently do not prefer speaking/writing any single language.]Secondary | Primary
Person2665353v1Abbreviations for US Military Rank Name PrefixPerson United States Military Rank Name Prefix Abbreviation TextThe abbreviation that represents the rank for personnel in the United States uniformed services as an affix occurring at or before the beginning of an individual's name. [Explanatory comment: Includes all U.S. armed services and Public Health Service Commisioned Corps.] 
Person2674076v2Education LevelPerson Education Level TypeA subdivision of the demographic parameter indicating the grade or highest level of education attained by a human being.Bachelor Degree | Associate Degree | Academic Doctorate Degree | Master's Degree | Professional Doctorate Degree | VoTech Program | Kindergarten | Preschool | 1st Grade | 2nd Grade | 3rd Grade | 4th Grade | 5th Grade | 6th Grade | 7th Grade | 8th Grade | 9th Grade | 10th Grade | 11th Grade | 12th Grade No Diploma | High School Graduate | General Equivalency Diploma | No Formal Schooling | Refused | Some College, No Degree | Don't Know
Person62587v4Street AddressPerson Address Namethe address or postal information for a person. 
Person2433964v2Person Reported AgePerson Reported Age ValueAn individual's description in completed years of their elapsed time since birth. 
Person2179590v2Middle Name or InitialPerson Middle NameA means of identifying an individual by using a word or group of words indicating a person's middle name. 
Person2201713v2Role or AffiliationPerson Affiliation Role Text TypeThe text that describes the distinguishable characteristics of the action or activity assigned to or required or expected of a person in a formal association with a group or organization.Principal Investigator | Funded Principal Investigator | Maintainer | Developer | Oncology Nurse | Medical Oncologist | Primary care physician | Gastroenterologist | Surgical Oncologist | Physician Assistant | Nurse Practitioner | PCP | Infusion Nurse | Clinical Nurse Specialist | Site Coordinator | Radiation Oncologist | Project Coordinator | Referring Pathologist | Regulatory Coordinator | Representative Investigator | Research Clinician | Research Nurse | Registrar | Surgeon | Research Pathologist | Reviewing Radiologist | Site Representative Investigator | Sponsor/Medical Expert | Statistician | Study Chairperson | Study Coordinator | Community Educator | Guardian | Laboratory Director | Laboratory Technologist | Lead Drug Monitor | Legal Representative of the Sponsor | Neuropathologist | Pharmaceutical Liaison | Pharmacologist | Physicist | Population Member | Practitioner Assigned | Protocol Author | Sponsor | Treating Physician | Admitting Physician | Attending Physician | Audiologist | Bronchoscopist | Central Reviewer | Clinical Coordinator | Co-Investigator | Consulting Physician | Coordinating Investigator | Evaluator | Practitioner | Translator | Participant | Interpreter | Interviewer | Health Care Provider | Grant Principal Investigator | Letter of Intent Review Chair | Mail Contact | Medical Physicist | Reviewing Pathologist | Sponsor Medical Expert | Subject Recruiter | Submitting Pathologist | Abstractor | Contact Person | Nurse | Patient | Pharmacist | Physician | Referring Physician | Social Worker | Data Manager | Investigator | Associate | Agent Expert | Mail Contact (Mgr) | Protocol Chair at an Organization | Employee | Site Investigator | Checklist Completer | Checklist Supervisor | Primary Shipping Designee | Program Director | Drug Company Contact | Protocol Specialist | Shipping Designee | Branch Chief | Participant Chief | Head of Division | Address Module Coordinator | Registration Coordinator | CDU Web Contact | Agent Inspector | CEP Member | Adverse Event Coordinator | Account Administrator | AdEERS Contact | ABS Coordinator | Group Coordinator | Division Head | Primary CDUS Contact | Secondary CDUS Contact | Grant Investigator | PMB Drug Company Contact | Principal Investigator (MGR) | Mail to contact | Clinical Research Associate | Concept Review Chair | Co-Project Officer | Contract Officer | Grant Specialist | Medical Monitor | Program Specialist | Project Officer | Protocol Chair | Protocol Lead Investigator | Protocol Review Chair | Review Liaison | Review Specialist | Scientific Monitor | Site Leader | Study Chair | Contract Principal Investigator
Person2464437v1Person Religion CodePerson Religion Designation CodeThe code that represent the self-reported identification of a personal or institutionalized systems of belief and reverence for a supernatural power regarded as creator and governor of the universe. 
Person2262142v1Person Name TypePerson Name TypeA name type that describes a non-current person name.Married | Culture | Birth | Alternative | Publications
Person2538920v1Height unit of measurePerson Height Unit of Measure Unified Code for Units of Measure CodeThe Unified Code for Units of Measure symbols that represent a determinate amount or quantity used as the standard of measurement for the vertical size of an individual person.m | [in_i] | [ft_i] | cm
Person2517550v1Person Email AddressPerson Email Address TextThe string of characters that represents the electronic mail address of a person. 
Person2661012v3CRA fax numberClinical Research Associate Person Fax Numberthe facsimile number, a telecommunications technology used to transfer copies of documents using devices operating over the telephone network, of the contact the person who is employed by a study sponsor or by a contract research organization (CRO), operates independently from the clinical study site and functions as a monitor, and/or auditor, and/or a project director within a particular trial or institution. 
Person2663165v1Person Name Prefix Abbreviation TextPerson Name Prefix Abbreviation TextThe abbreviation that represents an affix occurring at or before the beginning of an individual's name.Prof. | Br. | Mrs. | Ms. | Sr. | Dr. | Miss | Mr. | Fr. | Rev. | Bish. | Ch. | R.
Person2220102v2Social Security NumberPerson Social Security NumberA person's 9-digit social security number, a unique identifier assigned by the United States Social Security Administration. 
Person2435968v1ISO 639-2 Language CodePerson Language CodeA three character system of symbols and rules that represents the name of a means of communication used by a person. 
Person2435944v1Communication methodPerson Communication Method TypeThe terms that describe the means of a process or procedure for the exchange of information between people by speech, signals or writing.Spoken Language | Written Language | Sign Language
Person2644401v1Body TemperaturePerson Vital Signs Temperature Physical Examination ValueThe numeric value of a person's body temperature. 
Person2175v3Phone NumberResponsible Person Phone Numberthe telephone number to use to contact the person who documented the information on the case report form. 
Person2668490v1CertificationPerson Certification Suffix Abbreviation TextThe abbreviation that represents the affix occurring at the end of a name for a designation earned that indicates that the person has specific knowledge, skills, or abilities determined by a certifying body.CNM | CCRA | CCNS | CANP | APRN | AOCNS | AOCNP | AONC | ANP | ACNP | DIP | CTRN | CVN | CRN | CPON | CPNP | CPN | CNS | CNP | SEC | PCCN | PA-C | OCN | HS | GNP | FNP | PN | MDA | EMTP | EMT | CRNA | CER
Person2943243v1Person Census Tract Code at EnrollmentPerson Enrollment Address United States Integer::2000 Census Tract CodeThe 2000 United States Census Bureau"s Area Classifications code that describes the census tract of a person"s residence at time of enrollment into a clinical trial. 
Person3913255v1Temperature RoutePerson Vital Signs Temperature Route TypeTerm to describe the path taken to measure a person's temperature.Axillary | Rectal | Dermal | Oral | Tympanic (Ear) | Nasopharyngeal
Person2200602v3Sex of PersonSelf Reported Person Sex Text TypeThe text that describes the assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female within a person. [Explanatory Comment: Identification of sex is usually based upon self-report and may come from a form, questionnaire, interview, etc.]Unknown | Unspecified | Male, Self-Report | Female, Self-Report | Intersex | Male-to-Female Transsexual | Female-to-Male Transsexual
Person2668458v1Clinical LicensePerson Clinical License Suffix Abbreviation TextThe abbreviation that represents the affix occurring at the end of a name for an official or legal permission relating to the examination and treatment of patients.NP | PA | RPH | RNP | RMA | RD | LCSW | FPNP | RN | LPN
Person2188083v2Marital StatusPerson Marital Status CategoryText term to describe a self-reported demographic parameter indicating a person's current conjugal status.Divorced | Married | Never Married | Domestic Partnership | Widowed | Separated
Person2179589v2Given NamePerson Given/First NameA word or group of words indicating a person's first (personal or given) name; the name that precedes the surname. Synonym = Given Name. 
Person2661003v1CRA phone numberClinical Research Associate Person Telephone Numberthe telephone number of the person who is employed by a study sponsor or by a contract research organization (CRO), operates independently from the clinical study site and functions as a monitor, and/or auditor, and/or a project director within a particular trial or institution. 
Person2865130v1Payment MethodPerson Healthcare Payer TypeText term for an entity, organization, government, corporation, health plan sponsor, or any other financial agent who pays a healthcare provider for the healthcare service rendered to a person or reimburses the cost of the healthcare service.Private Insurance | Medicaid | Medicaid and Medicare | Military Sponsored (Including CHAMPUS & TriCare) | Veterans Sponsored | No Means of Payment (No Insurance) | Medicare | Medicare and Private Insurance | Self-Pay (No Insurance) | Managed Care/Medicare | State Supplemental Health Insurance | Military or Veterans Sponsored, NOS | Other | Unknown
Person793v5.1Patient's Date of BirthPerson Birth Datethe month, day and year on which the person was born 
Person2637455v1Methods to Calculate BSAPerson Body Surface Area Method Text TypeThe words that describe the means by which a result is obtained for a measure of the 2-dimensional extent of the body surface.Boyd | Canine | DuBois | Feline | Gehan and George | Haycock | Linear Regression | Mosteller | Nomogram | Rabbit | Mouse | Rat | Guinea Pig
Person2222470v1Person Sex GenotypePerson Sex Genotype Text TypeThe textual representation of the sex of a person based upon genotyping. Genotyping is the genetic constitution of the individual; the characterization of the genes. [Explanatory Comment 1: Identification is based upon genotyping.] [Explanatory Comment 2: Genotyping is the genetic constitution of the individual; the characterization of the genes.]XXX | Klinefelter's Syndrome | Mosaic including XXXXY | Penta X syndrome | XXXY syndrome | XXYY syndrome | XX Genotype | XY Genotype
Person2200604v3Gender of a PersonPerson Gender Text TypeText designations that identify gender. Gender is described as the assemblage of properties that distinguish people on the basis of their societal roles. [Explanatory Comment 1: Identification of gender is based upon self-report and may come from a form, questionnaire, interview, etc.]Female | Male | Unknown | Unspecified
Person2006475v2Person Name SuffixIndividual Genealogy Suffix CodeText term to represent an individual's position in a family lineage or pedigree.Jr. | Sr. | II | III | IV | I
Person2956267v1Temperature Unit of Measure UCUM CodePerson Temperature Unified Code for Units of Measure CodeThe Unified Code for Units of Measure symbols that represent a determinate amount or quantity used as the standard of measurement for the property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat an individual person.CEL | [degF]
Person2681552v1Educational AttainmentPerson Education Level Summary TypeThe subdivision that summarizes the highest level of education attained by a person.Master's Degree | Bachelor's Degree | Doctoral degree or professional degree | Grade School | Graduate or professional degree | High school graduate (including equivalency) | Some college or associate degree | No formal education | Not high school graduate
Person2681952v1Training and Education SuffixPerson Training and Education Suffix Abbreviation TextThe abbreviation that represents the affix occurring at the end of a name for theory and hands on experience taught to a human being. [Explanatory comment: The Value Domain used for this Data Element combines the values from Public IDs 2668458 (Person Clinical License Suffix Abbreivation Text), 2668478 (Person Academic Degree Suffix Abbreviation Text), and 2668490 (Person Certification Suffix Abbreviation Text); one or more values can be entered in any order.]MD | NP | PA | CNM | DO | DMD | DED | DD | DC | DBA | BT | BSW | BSL | BS | BSN | BN | BFA | BEd | BEng | BE | BBA | BA | AS | AE | ABA | AAS | AA | PharmD | RPH | RNP | RMA | RD | LCSW | FPNP | CCRA | CCNS | CANP | APRN | AOCNS | AOCNP | AONC | ANP | ACNP | MSN | MSL | MPA | MME | MFA | MEE | MEd | ME | MDI | MCE | MA | LLM | JD | EdD | DSW | ThD | ScD | PhE | MT | MSW | AM | DIP | CTRN | CVN | CRN | CPON | CPNP | CPN | CNS | CNP | SEC | PCCN | PA-C | OCN | HS | GNP | FNP | AB | CCRP | CCRN | CCRC | CNA | CMA | CM | CFNP | CFRN | CEN | PN | MDA | EMTP | EMT | CRNA | CER | OD | ND | MS | MPH | MHSA | MBA | DrPH | DPM | DDS | DVM | PhD | RN | LPN
Person2179591v2Family NamePerson Family/Last NameA means of identifying an individual by using a word or group of words indicating a person's last (family) name. Synonym = Last Name, Surname. 
Person2644399v1Respiratory RatePerson Vital Signs Respiratory Rate Physical Examination ValueThe numeric value of a person's respiratory rate (the rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute). 
Person2436200v1Place where language is used.Person Language Location Use TypeThe terms that describe the places in which a language is used by a person.School | Worksite | Clinic | Home | Hospital
Person2956248v1Ideal WeightPerson Ideal Body Weight ValueThe numeric value that captures the optimal weight the patient/participant is expected to weigh based on criteria including height, gender, age and body type. 
Person2668478v1Academic DegreePerson Academic Degree Suffix Abbreviation TextThe abbreviation that represents the affix occurring at the end of a name for an award conferred by a college, university, or other postsecondary education institution as official recognition for the successful completion of a program of studies.MD | DO | DMD | DED | DD | DC | DBA | BT | BSW | BSL | BS | BSN | BN | BFA | BEd | BEng | BE | BBA | BA | AS | AE | ABA | AB | AAS | AA | PharmD | MSN | MSL | MS | MPH | MPA | MME | MFA | MEE | MEd | ME | MDI | MCE | MA | LLM | JD | EdD | DSW | ThD | ScD | PhE | MT | MSW | AM | OD | ND | MS | MPH | MHSA | MBA | DrPH | DPM | DDS | DVM | PhD
Personal Medical History3198806v1Medical History Assessment IndicatorPatient Personal Medical History Assessment IndicatorText term to signify whether a person's medical history was assessed/gathered by a caregiver.Yes | No
Personal Medical History2736881v1OngoingPersonal Medical History Ongoing IndicatorThe indicator used to represent continuation of a medical event or symptom experienced by a person.No | Yes | N/A
Physical Examination3192455v1Finding ResultPhysical Examination Finding TypeText descriptor of the overall results result of a physical examination category.Not Examined | Abnormal | Normal
Physical Examination3192450v1Body SystemPhysical Examination Criteria CategoryCategory or grouping used in the systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual's health assessment.Other | Pelvis | Neck | Dermatologic | Breasts | Abdomen | Cardiovascular | Endocrine/Metabolic | Gastrointestinal | Genitourinary | HEENT | Musculoskeletal | Neurologic | Respiratory | Hematopoietic/Lymph Node(s)
Physician62749v3Treating physicianTreating Physician Namethe name of the physician treating a person for specific medical conditions/problems. 
Planning Target Volume3733563v1Percent of PTV receiving > 95% of dosePlanning Target Volume Greater Than 95 Percent Dose Exposure Percent ValueNumeric value to describe the percentage of the planning target volume (PTV) of tissue exposed to more than 95% of a radiotherapy dose. 
Planning Target Volume3733557v1CTVClinical Planning Target Volume Dose Percentage ValueNumeric value to describe the clinical target volume (CTV), the traditional estimate of the volume of tissue to be treated with radiotherapy using generic bony landmarks as surrogates. 
Planning Target Volume3733567v1Percent of PTV receiving > 107% of dosePlanning Target Volume Greater Than 107 Percent Dose Exposure Percent ValueNumeric value to describe the percentage of the planning target volume (PTV) of tissue exposed to more than 107% of a radiotherapy dose. 
Plasma Cell Myeloma2689280v4What was the International Staging System for Myeloma Stage?Plasma Cell Myeloma International Staging System for Myeloma StageA description of the severity of myeloma disease based on the International Myeloma Working Group.1 (beta2-mic < 3.5, S. albumin >= 3.5) | Unknown | 2 (beta2-mic 3.5 - < 5.5, S. albumin-) | 3 (beta2-mic >= 5.5; S. albumin-)
Plasma Cell Myeloma2181363v1Durie-Salmon StageMyeloma Diagnosis Stagethe description of the severity of multiple myeloma disease in a patient classifying disease based on standard criteria defined by Durie-Salmon.Unknown | II - Fitting neither Stage I or Stage III | I - ALL of the following must be present | III - one of the following must be present
Position2008432v2Participant PositionParticipant Position TypeThe arrangement or orientation of a participant's body at a point in time.Prone | Semiprone | Sitting | Standing | Supine | Upright | Unknown
Positron Emission Tomography2714892v1Blood glucose before injection of imaging agentPET Blood Glucose Prior To Injection ValueRecord blood glucose value measured before administration of imaging agent. 
Positron Emission Tomography2714890v1Duration of patient fasting pre-PET imagingPrior To PET Fasting Hour DurationA numerical quantity to represent the period of time during which the individual has abstained from food before an imaging event measured as a whole number in the range of 0 to 24. 
Positron Emission Tomography2716520v2Patient voided immediately pre-imaging?PET Urination Prior Imaging Agent Ind-3A response (yes/no/unknown) which indicates if the person/patient voided prior to injection of an imaging agent [e.g. FDG] and imaging.Unknown | Yes | No
Positron Emission Tomography3162383v1PET Blood GlucosePET Blood Glucose Measurement Military TimeThe amount of a simple sugar found in the blood at a specific time during a PET imaging event recorded in military time format, e.g. 1:00 pm = 1300 hrs. 
Positron Emission Tomography2717650v2Was Foley catheter in place for scan?PET Foley Catheter Placed Ind-3A response (yes/no/unknown) which indicates if the Foley catheter was in place for the scan.Unknown | Yes | No
Positron Emission Tomography3163084v1PET emission scan typePET Emissions Scan TypeA response to indicate the type of PET emissions scan performedStatic | Dynamic | Whole Body
Positron Emission Tomography2717652v2Patient voided immediately post-imaging?PET Urination Post Imaging Agent Ind-3A response (yes/no/unknown) which indicates if the person/patient voided post injection of an imaging agent [e.g. FDG] and imaging.Unknown | Yes | No
Postoperative3123041v1Date of first postop flatusFirst Postoperative Flatus DateThe date of first postoperative gas or air in the gastrointestinal tract. 
Postoperative3122716v1Date of first postop bowel movementFirst Postoperative Bowel Movement DateThe date of the first postoperative bowel movement. 
Professional Organization or Group2413168v1Tax IDTax Organization Identifier NumberThe number representing the information related to the unique tax identifier of an organization. 
Professional Organization or Group2413117v2Organization's Role/AffiliationOrganization Role Affiliation Text TypeThe text that describes the distinguishable characteristics of a formal association between entities.Lead Organization | Participating Organization | Employer | guarantor | procurement | subscriber | research center | university | correctional institute | pharmacy distribution center | drug company | Clinical Resource Contractor | CRO | patient advocacy group | Contact | Health Maintenance Organization | Healthcare Facility | Institution | Lead | Provider | Referring | Reporting | Cancer Research Network | Repository | Regulatory Affairs | Hospital | Laboratory | Insurance
Professional Organization or Group2152v3Organization NameOrganization NameThe formal name of the organization. 
Professional Organization or Group2407007v1Organization ID numberOrganization Identifier Numberthe unique CTEP-assigned ID number of an organization. 
Prostate Carcinoma2902378v1Jewett StageProstate Carcinoma Whitmore-Jewett System StageCategorization of patients with prostate cancer using the Whitmore-Jewett staging system to describe the extent of their disease.D | C2 | C1 | C | B2 | B1 | BIN | B | A2 | A1 | A
Prostate Carcinoma3436566v1Disease StageProstate Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group StageStage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for prostate carcinoma.Stage unknown | IV | III | IIB | IIA | I
Protein2322253v1Protein RefSeq IdentifierProtein RefSeq Genomic IdentifierProteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._The Reference Sequence (RefSeq) collection aims to provide a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, transcript (RNA), and protein products, for major research organisms. RefSeq standards serve as the basis for me:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier for a Protein sequence assigned in the RefSeq data collection. [Explanatory comment: RefSeq accession numbers can be distinguished from GenBank accessions by their prefix distinct format of [2 characters|underbar]. The NP_123456 (6 digits) format is used for Protein products; primarily full-length precursor products but may include some partial proteins and mature peptide products.] 
Protein2322252v1Peptide Ensembl IdentifierProtein Ensembl Genomic IdentifierProteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._Ensembl is a joint project between EMBL-EBI and the Sanger Institute to develop a software system which produces and maintains automatic annotation on selected eukaryotic genomes. Ensembl is primarily funded by the Wellcome Trust. The Ensembl Genome Brow:One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier assigned to a peptide by EnsEMBL. It is used to uniquely identify a peptide in the EnsEMBL system. [Explanatory comment: The format is ENSPxxxxxxxxxxx for humans. The one for mouse is ENSMUSPxxxxxxxxxxx. So the general format is ENS Species (except human) P ? xxxxxxxxxxx. There are always 11 digits in this identifier. There are some species that don't follow these rules. For instance, species such as Drosophila or Tetraodon were not annotated by Ensembl follow a different convention. This definition has been reviewed by Xose M. Fernandez and Bert Overduin representing the Ensembl Helpdesk.] 
Protein2322254v1UniProt Primary Accession NumberProtein UniProtKB Primary Accession Number Genomic IdentifierProteins are a group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence._The UniProt Knowledgebase (UniProtKB), a product of the UniProt consortium, provides a central database of protein sequences with accurate, consistent, rich sequence and functional annotation. The UniProt Knowledgebase consists of two sections: Swiss-Prot - a section containing manually-annotated records with information extracted from literature and curator-evaluated computational analysis, and TrEMBL - a section with computationally analyzed records that await full manual annotation._Occurring first in time or sequence; original; of greatest rank or importance or value._A control number unique to an object, used to identify it among the other objects in a collection._One or more characters and/or numbers that are used to identify, name, or characterize the nature, properties, or contents of genomic sequences, mRNA transcripts, protein products, or other class of entities that occurs throughout the genome._The unique identifier for a protein sequence assigned by the Universal Protein Resource Knowledge Base. [Explanatory comment: Accession numbers consist of 6 alphanumerical characters in the following format: 1 [O,P,Q], 2 [0-9], 3 [A-Z, 0-9], 4 [A-Z, 0-9], 5 [A-Z, 0-9], 6 [0-9]. For example, P99999 is the accession ID for human Cytochrome c. Some other examples of valid accession numbers are as follows: P12345, Q1AAA9, O456A1 and P4A123.] 
Protocol Deviation2740412v2Protocol Deviation CategoryProtocol Deviation CategoryCategorization of the type of protocol deviation that occurred. Protocol Deviation CategoryOther, specify | Concomitant Medications | Study Procedures | Treatment | Informed Consent | Eligibility waiver | Eligibility not checked | Data Integrity Compromised
Protocol Deviation2435009v1.1Protocol Deviation Notification DateProtocol Deviation Notification DateDate on which the local study team and/or site PI became aware of the deviation. Study team members may include co-investigators, research nurses, study coordinators, CRAs, CRCs, co-investigators, or data managers at a site. [Manually-curated] 
Protocol Deviation2434998v1Protocol Deviation Occurrence DateProtocol Deviation Occurrence DateThe date on which the protocol deviation occurred. 
Protocol Deviation2740401v1Protocol Deviation Severity TypeProtocol Deviation Severity TypeA categorization to indicate a level of severity for a protocol deviation. [Manually-curated]Moderate | Major | Minor
Protocol Deviation2435038v1Protocol Deviation DescriptionProtocol Deviation Description TextA textual description of the protocol deviation which includes reasons and contributing factors. 
Protocol Deviation2435042v1.2Protocol Deviation Action TextProtocol Deviation Action TextThe free text field used to describe the corrective actions initiated by the site to address a specific deviation (i.e. patient's care) and/or prevent its recurrence. 
Protocol Deviation2740419v1Protocol Deviation Other Category Descriptive TextProtocol Deviation Other Category Descriptive TextText deviation description that is provided when a category of 'other' is selected. [Manually-curated] 
Protocol Treatment Arm2454528v1Treatment ArmProtocol Arm Assignment TextText term to capture protocol arm(s) available as described in a protocol for subject assignment at the time of eligibility completion and enrollment. Assignment occurs when there is more than one form of intervention or activity available to subjects enrolled in a trial. 
Pulse2186214v1Pulse OxPulse Oximetry ValueInteger value expressed as a whole number to represent the percentage of oxygen in the blood measured through cutaneous assessment. 
Pulse2767073v1PulsePulse Rate Measurement ValueNumeric value to represent the measurement of the heart rate, which is the number of contractions (heart beats) expressed in "beats per minute" (bpm). [Manually-curated] 
Race2200286v1CDC Race CodeCenters for Disease Control and Prevention Race Unique Identifier CodeThe unique identifer code for reporting information about race based on the Center for Disease Control and Prevention (CDC) categories. 
Race2192199v1RaceRace Category TextThe text for reporting information about race based on the Office of Management and Budget (OMB) categories.American Indian or Alaska Native | Asian | White | Black or African American | Not Reported | Unknown | Native Hawaiian or other Pacific Islander
Race2192205v1Race, Other SpecifyOther Race Category TextThe text that describes a race not included in the Office of Management and Budget (OMB) list for reporting race data. 
Radiation Therapy61465v3Total Number of FractionsRadiation Therapy Total Fractions Countthe quantity of total radiation therapy fractions. 
Radiation Therapy2003339v3Radiation TypeRadiation Therapy TypeType of radiation therapy being used.Limited Radiation | Radiation, NOS | Extensive Radiation
Radiation Therapy2178527v2Was RT interrupted for more than one week?Radiation Therapy Interruption Ind-2the yes/no indicator to determine if radiation therapy has been interrupted.No | Yes
Radiation Therapy2195477v1Other, specifyRadiation Therapy Type Other SpecifyA text field to describe of a method of radiation treatment administered to a patient. 
Radiation Therapy3733536v1PTVRadiation Therapy Target Volume Administered Planning Percentage ValueNumeric value to represent the planned targeted volume (PTV) of tissues included in a patient's radiation therapy treatment. 
Radiation Therapy3028890v1Radiation Therapy TypeRadiation Therapy Administered TypeThe type of radiation therapy given to a patient/participant.Stereotactic Radiosurgery | Other specify | Brachytherapy LDR | Brachytherapy HDR | IMRT | 3D Conformal | 2D Conventional | Stereotactic Body RT | Proton Beam
Radiation Therapy3028896v1Radiation Therapy ModalityRadiation Therapy Modality TypeText term to represent a radiation therapy (RT) source.Mixed | Electron | Photon | Neutron | Alpha | Proton | Carbon
Radiation Therapy2374v3Specify reasonRadiation Therapy Interruption Texta text field to provide an explanation for breaks in radiation treatment schedule.